

Author Index

- Abbasi F, 534A
 Abraham M, 330A
 Abrams M, 509A
 Abu-Shakra S, 307A, 332A, 348A
 Achim CL, 559
 Achiron A, 972A
 Adams M, 532A
 Adams S, 548A
 Adeyinka A, 463
 Adle-Biassette H, 269
 Adler JE, 309A
 Adornato B, 317A
 Afshani E, 546A
 Agid Y, 299A, 954
 Agius MA, 338A
 Aguglia U, 389
 Ahlskog JE, 329A
 Ahmad A, 293A
 Ahmad AK, 293A
 Ahmed MS, 293A
 Ahmed S, 282A
 Aicardi J, 687
 AIDS Clinical Trials Group, 347A
 Akiyama K, 331A
 Aksamit AJ Jr, 346A
 Alam J, 313A
 Albensi BC, 503A
 Albert E, 723
 Albin RL, 835
 Alemany M, 505A
 Alemayehu S, 296A
 Alexander GE, 324A, 510A
 Alexander M, 972A
 Alexandrov AV, 319A
 Alexandrova NA, 319A
 Alexeev V, 326A
 Alexianu ME, 327A
 Alfonso I, 687
 Alford M, 653
 Alger JR, 328A
 Algra A, 929
 Alhalabi M, 307A, 332A
 Alinauskas K, 312A
 Allen F, 502A
 Allen J, 518A, 532A, 553A
 Allen PS, 331A
 Allen RJ, 85
 Allen W, 521A
 Allos BM, 348A
 Alroy J, 499A, 534A
 ALS/North American Myotrophin Study Group, 335A, 971A
 Alsop DC, 618
 Altman A, 531A
 Amaducci L, 124, 292A, 314A, 323A, 325A, 340A
 Ambrosino M, 504A
 Aminoff MJ, 484
 Andermann AA, 537A
 Andermann F, 951
 Anderson AE, 525A
 Anderson CA, 127
 Ando M, 335A, 336A
 Ando Y, 335A
 Andrew M, 532A
 Antel JP, 312A, 901
 Apfel SC, 310A, 315A, 317A
 Appel SH, 327A
 Arai H, 649
 Archelos JJ, 186
 Archila R, 687
 Arezzo JC, 315A
 Arief AL, 696
 Ariyan C, 533A
 Arnold DL, 901
 Arnoldus EPJ, 697
 Aron AM, 535A
 Aronin P, 551A
 Aronky K, 532A
 Arwert F, 301A
 Asbury AK, 336A
 Ascher C, 513A
 Ashby P, 330A
 Ashwal S, 551A, 552A
 Askanas V, 282A, 705
 Asselin J, 502A
 Atkinson EJ, 345A
 Atlas D, 330A
 Auburger G, 299A
 Auerbach SA, 797
 Auld K, 552A
 Aurora TK, 322A
 Auses MGEM, 450
 Autilio-Gambetti L, 21
 Averbuch-Heller L, 972A
 Avishai-Elimer S, 526A
 Avison MJ, 194
 Awaad Y, 549A, 550A
 Axelrod FB, 335A
 Ayus JC, 696
 Azizi SA, 311A
 Baba E, 347A
 Back SA, 502A
 Backstrom JW, 527A
 Baer R, 335A
 Bagiella E, 287A, 290A
 Baiyewu O, 463
 Bakay RAE, 296A, 298A
 Baker M, 335A
 Balabanov R, 348A
 Baldwin RM, 589
 Bale JF Jr, 556A
 Balish M, 285A
 Ballal N, 550A
 Ballerini C, 314A
 Balmaceda C, 202
 Bandele AN, 503A, 523A
 Banet GA, 320A, 321A
 Bänffer JRJ, 170
 Bankiewicz KS, 316A
 Banks DL, 537A
 Bansil S, 341A
 Bär PR, 674
 Barak Y, 972A
 Baram TZ, 506A, 510A, 526A, 556A
 Barbour R, 643
 Barker PB, 318A
 Barks JDE, 501A, 538A
 Barnes PD, 519A, 524A
 Barnes PRJ, 681
 Baron M, 298A
 Barone FC, 322A
 Barry E, 296A
 Barton NW, 547A
 Barzilai A, 328A
 Bass D, 526A
 Bass NE, 527A
 Basser P, 284A
 Bastian AJ, 881
 Batjer H, 58
 Battistini S, 292A
 Bauer G, 210
 Bauer L, 512A
 Baumgardner TL, 509A, 515A
 Baumgart S, 511A, 540A
 Baumgartner WA, 317A
 Baumhefner RW, 315A
 Bawle EV, 543A
 Baxter D, 512A
 Beal MF, 357
 Bécache E, 520A
 Beck-Mannagetta G, 210
 Beckett LA, 325A
 Beekly D, 325A
 Beggarly ME, 537A
 Behar KL, 295A, 533A
 Beierwaltes P, 549A, 550A
 Belden D, 294A
 Bell J, 269
 Bella IR, 338A
 Bellance R, 454
 Belman AL, 349A, 513A
 Benbadis S, 520A
 Bennett RL, 141
 Benstead T, 303A
 Berek K, 210
 Berg M, 506A
 Bergey G, 296A
 Beric A, 332A
 Berk J, 345A
 Berkovic SF, 633, 951
 Berlitz P, 288A, 321A
 Bernard C, 513A
 Bernath O, 307A
 Berry-Kravis E, 499A
 Bertini E, 500A, 544A
 Bertolino A, 328A
 Bettinardi A, 340A
 Bhambhani K, 551A
 Bhardwaj A, 308A
 Bhatia S, 542A
 Bialer M, 352A
 Bianchi A, 210
 Bicknese AR, 499A
 Bierbrauer K, 541A
 Bird TD, 2, 141, 678, 965, 967, 970
 Bix GJ, 499A
 Bjork RJ, 245
 Black IB, 446
 Black W, 515A
 Blair R, 337A
 Blankenburg M, 739
 Blue ME, 531A
 Blumenthal BI, 555A
 Boatman D, 514A
 Boccone L, 316A
 Boden-Albala B, 322A
 Bodensteiner JB, 516A
 Boer M, 450
 Bohan TP, 505A, 556A
 Bolan EA, 503A, 523A, 524A
 Bolton CF, 303A, 307A
 Bonilla E, 541A
 Bonthius DJ, 501A
 Borland K, 300A
 Borlongan CV, 379
 Borowicz LM, 317A
 Boustany R-MN, 525A
 Boyett J, 343A, 518A
 Boylan KB, 333A, 367
 Bracco L, 292A, 325A
 Bradley EL, 625
 Bradley WG, 971A
 Brady RO, 547A
 Brahe C, 500A
 Brahic M, 454
 Branca D, 389
 Brandel JP, 299A
 Brannigan TH III, 288A, 334A
 Brault JM, 331A
 Braverman N, 554A
 Breakefield XO, 499A
 Bredeken DE, 839
 Bredt DS, 504A
 Breen FC, 287A
 Brew BJ, 563
 Brey RL, 119
 Brice A, 299A
 Brill V, 303A
 Brill C, 538A
 Bristol L, 295A
 Brod SA, 341A
 Bromberg JEC, 929

July issue, pp 1-136; August issue, pp 137-352; September issue, pp 353-558; October issue, pp 559-700; November issue, pp 701-834; December issue, pp 835-1024.

Author Index

- Abbasi F, 534A
 Abraham M, 330A
 Abrams M, 509A
 Abu-Shakra S, 307A, 332A, 348A
 Achim CL, 559
 Achiron A, 972A
 Adams M, 532A
 Adams S, 548A
 Adeyinka A, 463
 Adle-Biassette H, 269
 Adler JE, 309A
 Adornato B, 317A
 Afshani E, 546A
 Agid Y, 299A, 954
 Agius MA, 338A
 Aguglia U, 389
 Ahlskog JE, 329A
 Ahmad A, 293A
 Ahmad AK, 293A
 Ahmed MS, 293A
 Ahmed S, 282A
 Aicardi J, 687
 AIDS Clinical Trials Group, 347A
 Akiyama K, 331A
 Aksamit AJ Jr, 346A
 Alam J, 313A
 Albensi BC, 503A
 Albert E, 723
 Albin RL, 835
 Alemany M, 505A
 Alemayehu S, 296A
 Alexander GE, 324A, 510A
 Alexander M, 972A
 Alexandrov AV, 319A
 Alexandrova NA, 319A
 Alexeev V, 326A
 Alexianu ME, 327A
 Alfonso I, 687
 Alford M, 653
 Alger JR, 328A
 Algra A, 929
 Alhalabi M, 307A, 332A
 Alinauskas K, 312A
 Allen F, 502A
 Allen J, 518A, 532A, 553A
 Allen PS, 331A
 Allen RJ, 85
 Allen W, 521A
 Allos BM, 348A
 Alroy J, 499A, 534A
 ALS/North American Myotrophin Study Group, 335A, 971A
 Alsop DC, 618
 Altman A, 531A
 Amaducci L, 124, 292A, 314A, 323A, 325A, 340A
 Ambrosino M, 504A
 Aminoff MJ, 484
 Andermann AA, 537A
 Andermann F, 951
 Anderson AE, 525A
 Anderson CA, 127
 Ando M, 335A, 336A
 Ando Y, 335A
 Andrew M, 532A
 Antel JP, 312A, 901
 Apfel SC, 310A, 315A, 317A
 Appel SH, 327A
 Arai H, 649
 Archelos JJ, 186
 Archila R, 687
 Arezzo JC, 315A
 Arief AL, 696
 Ariyan C, 533A
 Arnold DL, 901
 Arnoldus EPJ, 697
 Aron AM, 535A
 Aronin P, 551A
 Aronky K, 532A
 Arwert F, 301A
 Asbury AK, 336A
 Ascher C, 513A
 Ashby P, 330A
 Ashwal S, 551A, 552A
 Askanas V, 282A, 705
 Asselin J, 502A
 Atkinson EJ, 345A
 Atlas D, 330A
 Auburger G, 299A
 Auerbach SA, 797
 Auld K, 552A
 Aurora TK, 322A
 Ausems MGEM, 450
 Autilio-Gambetti L, 21
 Averbuch-Heller L, 972A
 Avishai-Elimer S, 526A
 Avison MJ, 194
 Awaad Y, 549A, 550A
 Axelrod FB, 335A
 Ayus JC, 696
 Azizi SA, 311A
 Baba E, 347A
 Back SA, 502A
 Backstrom JW, 527A
 Baer R, 335A
 Bagiella E, 287A, 290A
 Baiyewu O, 463
 Bakay RAE, 296A, 298A
 Baker M, 335A
 Balabanov R, 348A
 Baldwin RM, 589
 Bale JF Jr, 556A
 Balish M, 285A
 Ballal N, 550A
 Ballerini C, 314A
 Balmaceda C, 202
 Bandele AN, 503A, 523A
 Banet GA, 320A, 321A
 Bänffer JRJ, 170
 Bankiewicz KS, 316A
 Banks DL, 537A
 Bansil S, 341A
 Bär PR, 674
 Barak Y, 972A
 Baram TZ, 506A, 510A, 526A, 556A
 Barbour R, 643
 Barker PB, 318A
 Barks JDE, 501A, 538A
 Barnes PD, 519A, 524A
 Barnes PRJ, 681
 Baron M, 298A
 Barone FC, 322A
 Barry E, 296A
 Barton NW, 547A
 Barzilai A, 328A
 Bass D, 526A
 Bass NE, 527A
 Basser P, 284A
 Bastian AJ, 881
 Batjer H, 58
 Battistini S, 292A
 Bauer G, 210
 Bauer L, 512A
 Baumgardner TL, 509A, 515A
 Baumgart S, 511A, 540A
 Baumgartner WA, 317A
 Baumhefner RW, 315A
 Bawle EV, 543A
 Baxter D, 512A
 Beal MF, 357
 Bécache E, 520A
 Beck-Mannagetta G, 210
 Beckett LA, 325A
 Beekly D, 325A
 Beggarly ME, 537A
 Behar KL, 295A, 533A
 Beierwaltes P, 549A, 550A
 Belden D, 294A
 Bell J, 269
 Bella IR, 338A
 Bellance R, 454
 Belman AL, 349A, 513A
 Benbadis S, 520A
 Bennett RL, 141
 Benstead T, 303A
 Berek K, 210
 Berg M, 506A
 Bergey G, 296A
 Beric A, 332A
 Berk J, 345A
 Berkovic SF, 633, 951
 Berlitz P, 288A, 321A
 Bernard C, 513A
 Bernath O, 307A
 Berry-Kravis E, 499A
 Bertini E, 500A, 544A
 Bertolino A, 328A
 Bettinardi A, 340A
 Bhambhani K, 551A
 Bhardwaj A, 308A
 Bhatia S, 542A
 Bialer M, 352A
 Bianchi A, 210
 Bicknese AR, 499A
 Bierbrauer K, 541A
 Bird TD, 2, 141, 678, 965, 967, 970
 Bix GJ, 499A
 Bjork RJ, 245
 Black IB, 446
 Black W, 515A
 Blair R, 337A
 Blankenburg M, 739
 Blue ME, 531A
 Blumenthal BI, 555A
 Boatman D, 514A
 Boccone L, 316A
 Boden-Albala B, 322A
 Bodensteiner JB, 516A
 Boer M, 450
 Bohan TP, 505A, 556A
 Bolan EA, 503A, 523A, 524A
 Bolton CF, 303A, 307A
 Bonilla E, 541A
 Bonthius DJ, 501A
 Borland K, 300A
 Borlongan CV, 379
 Borowicz LM, 317A
 Boustany R-MN, 525A
 Boyett J, 343A, 518A
 Boylan KB, 333A, 367
 Bracco L, 292A, 325A
 Bradley EL, 625
 Bradley WG, 971A
 Brady RO, 547A
 Brahe C, 500A
 Brahic M, 454
 Branca D, 389
 Brandel JP, 299A
 Brannigan TH III, 288A, 334A
 Brault JM, 331A
 Braverman N, 554A
 Breakefield XO, 499A
 Bredeken DE, 839
 Bredt DS, 504A
 Breen FC, 287A
 Brew BJ, 563
 Brey RL, 119
 Brice A, 299A
 Brill V, 303A
 Brill C, 538A
 Bristol L, 295A
 Brod SA, 341A
 Bromberg JEC, 929

July issue, pp 1-136; August issue, pp 137-352; September issue, pp 353-558; October issue, pp 559-700; November issue, pp 701-834; December issue, pp 835-1024.

- Brooks BR, 294A
Brooks DJ, 965
Brooks WM, 291A
Brosnan C, 315A
Brown MD, 163
Brown P, 245
Brown RH Jr, 460
Brown SE, 301A
Broyles S, 548A
Bruce D, 528A
Brück W, 788
Bruehl C, 414
Brumback RA, 521A
Brusilow W, 307A
Brutocao D, 536A
Bryan WW, 336A
Buchholz D, 289A
Buchman AS, 328A
Budka H, 337A
Buettner VL, 343A
Buist NRM, 921
Buncher CR, 522A
Burbridge B, 288A
Burch CM, 320A, 321A
Burgard S, 625
Burger P, 546A
Burgess CE, 532A
Bürk K, 299A
Burke GJ, 511A
Burke J, 525A
Burlina A, 544A
Burn DJ, 965
Burton EE, 335A
Burton L, 317A
Bushenbark K, 771
Butler IJ, 525A, 557A
Buzby JC, 348A
Byers PH, 960
Byskosh P, 340A
- Cairncross JG, 344A
Callahan A, 284A
Calne D, 379
Cameron DE, 317A
Camfield CS, 536A
Camfield PR, 536A
Campani D, 292A, 325A
Campbell G, 328A
Campbell KP, 353
Campi A, 749
Canady AI, 542A
Candido J, 305A
Cañizales E, 687
Carango P, 514A, 610
Cardellach F, 273
Carey J, 119
Cargan AL, 522A
Carlson KM, 538A
Carroll J, 288A, 523A
Carson BS, 514A
Carstens G III, 58
Carter TA, 500A
Cartier L, 454
Casademont J, 273
Cascino TL, 343A
Caselli RJ, 291A
Casey R, 286A
- Castellani R, 21
Castle V, 342A
Castora FJ, 532A
Caviness VS Jr, 509A, 529A
Cervenáková I, 245, 267
Cesaro P, 269, 580
Chabriet H, 231
Chad DA, 338A
Chalk C, 303A
Chamberlain MC, 344A, 517A
Chandler DA, 541A
Chang L, 643
Chang Y-J, 321A
Chaoudhri AN, 293A
Charles PD, 299A
Charney DS, 589
Chatkupt S, 541A
Chatterjee A, 326A
Chaudhry V, 317A, 337A, 539A
Chaudhuri R, 331A
Chavin JM, 336A
Chbihi T, 429
Chen F-J, 973A
Chen J, 286A
Chen LS, 556A
Chen R, 307A, 546A
Chen SG, 21
Chen X, 282A, 653
Cherington M, 347A
Cherqui D, 269
Chez MG, 544A
Chi S-I, 307A
Chmura TA, 298A
Choi DW, 307A
Choi S, 304A, 333A
Chopp M, 935
Chou SM, 293A
Chugani DC, 542A, 543A
Chugani HT, 510A, 542A, 543A, 550A, 551A
Chui H, 797
Ciurlionis R, 499A
Clark C, 643
Clark CM, 649
Clark GD, 499A
Clark HB, 237
Clark KR, 546A
Clarke V, 797
Clash KE, 503A
CNTF ALS Study Group, 336A
Cody JD, 520A
Cohen BH, 518A, 527A, 529A
Cohen ME, 546A
Cohen SR, 286A
Colao R, 389
Cole D, 552A
Colli M, 509A
Colom LV, 327A
Comella CL, 328A
Comi AM, 527A
Comi G, 749
Commissiong J, 317A
- Comu S, 545A
Connell F, 535A
Connolly AC, 514A
Connolly AM, 505A
Connolly M, 506A
Connolly S, 916
Conry JA, 505A, 534A, 535A
Contreras PC, 315A, 317A
Cook SD, 339A, 341A
Cookfair D, 313A
Coplin WM, 965
Cornblath DR, 317A, 336A, 337A, 350A
Cortazzo M, 517A
Cortelli P, 21
Coscoy L, 454
Costigan DA, 303A
Coulter DA, 893
Counihan TJ, 349A
Coyle PK, 284A, 312A, 345A, 349A, 513A, 560
Cozzens JW, 501A
Cramer SC, 342A
Craven D, 349A
Crawford TO, 538A, 539A
Créange A, 269
Crissé S, 323A
Cronin K, 563
Cullen K, 329A
Cummings P, 536A
Cummins J, 520A
Cupler EJ, 302A, 306A
Cupples LA, 797
Curtis R, 532A
Cusmai R, 500A
Cutting L, 515A
Czlonkowska A, 723
- Daamen M, 329A
Dabbagh O, 550A
Dabby R, 330A
Dafni U, 347A
Dagogo-Jack S, 599
Dahwan V, 511A
Dalakas MC, 218, 267, 302A, 306A, 307A, 333A
Dale J, 284A
Dalmau J, 102, 341A, 345A
Dambrosia JM, 504A
Damian M, 332A
Dani A, 324A, 510A
Danion A, 520A
Darby DG, 295A
DaRossa R, 553A
Das K, 500A
da Silva E, 510A, 551A
Dattwyler RJ, 349A
Dautenhahn LR, 555A
Davenport C, 274
Davidson B, 501A
Davidson E, 283A
Davies C, 521A
Davis RG, 524A
Davis TL, 299A
- Day M, 322A, 323A
DCN/SMA Group, 522A
Dean C, 670
DeAngelis LM, 51, 202, 344A
Debruyn CS, 610
DeCarli C, 296A
DeChadaravian JP, 540A, 541A
De Cristofaro MTR, 292A
Defer G, 580
De Fries JC, 509A
De Gasperi R, 292A, 340A
Degos J-D, 269, 580, 954
DeKosky A, 520A
DeKosky ST, 282A, 967
Delaney E, 667
de l'Aune W, 131
Delgado MR, 528A
DeLong GR, 519A
DeLong MR, 296A, 298A
DeLorenzo RJ, 505A
Deluca P, 522A
Demirkiran M, 571
Dempsey DA, 502A
Dence CS, 599
Denckla MB, 509A, 515A, 516A
Deng HX, 282A
Deng Z, 312A
Dennis S, 315A
Desai S, 511A, 540A
Desmond DW, 285A, 287A, 290A
De Stefano N, 901
DeTeresa R, 653
DeTorres C, 554A
Detre JA, 618
Determan DK, 532A
Deuschl G, 862
deVeber G, 532A
Devinsky O, 670
De Vivo DC, 468, 522A, 523A, 541A, 545A
Dewey RB Jr, 329A
Dharmarajan S, 520A
Dhib-Jalbut S, 315A, 339A
Diabetes Control and Complications Trial Research Group, 869
Dialdetti R, 330A
Diamond BE, 522A
Di Chiro G, 547A
Dickey C, 973A
Di Donato S, 544A
Diederich N, 300A
Dietz V, 965
DiMario FJ Jr, 512A
DiMauro S, 468, 541A, 705
Dinner DS, 529A
Dionisi-Vici C, 544A
Dippel DWJ, 832
Dixon J, 163
Doblars D, 283A
Dobos J, 522A
Dogali M, 332A

- Dokianais SG, 537A
D'Ollhaberriague L, 322A, 331A
Donahue B, 553A
Donaldson J, 543A
Donfield S, 556A
Donis-Keller H, 538A
Donovan D, 297A
Dooley JM, 536A
Dore-Duffy P, 348A
Dormia C, 310A
Dorndorf W, 332A
Doscher C, 284A, 312A
Dowling PC, 339A, 341A
Drachman DA, 290A, 291A
Drane WB, 514A
Driscoll SM, 505A
D'Souza S, 312A
Duara R, 797
Dubeau F, 951
Dubnick M, 326A
Duchowny M, 687
Duffner PK, 527A, 546A
Duffy J, 323A
Duggan D, 333A, 367
Duncan CC, 521A
Dunham B, 512A
du Plessis AJ, 519A
DuPont BR, 520A
Dutch Study Group on Down's Syndrome and Ageing, 225
Duvoisin RC, 355
Duvoux C, 269
Dybdal N, 30
Dyck PJ, 317A, 335A
Dykes-Hoberg M, 295A
Dzenko KA, 551A
- Earley C, 289A
Ebers G, 973A
Ebelen F, 329A
Ebner R, 825
Edelbrock C, 532A
Edelman RR, 290A, 295A
Edgar DM, 317A
Edge P, 508A
Edland SD, 325A
Eduard G, 305A
Edwin D, 351A, 547A
Efird JT, 342A
Ehrenkranz RA, 521A
Eidelberg D, 332A, 511A
Einberg KR, 306A
Eisenberger MA, 337A
El-Azzouni H, 350A
Elfont RM, 405
Ellison GW, 339A
Elmqvist JK, 339A
Engel AG, 484, 705
Engel WK, 282A, 333A
Epstein F, 553A
Epstein LG, 551A
Epstein M, 329A
Erenberg G, 529A
Espinosa JA, 951
- Esteban-Santillan C, 324A
Esterlitz J, 771
Evans DA, 325A
Evenhuis HM, 225
Ewart M, 347A
- Faerber EN, 524A
Fairclough RH, 338A
Falcini M, 292A, 325A
Falkous G, 691
Farrell K, 506A
Farrer LA, 797
Faught E, 396
Faustman DL, 147
Fawcett PRW, 916
Fazilat S, 296A, 534A
Fazilat S, 296A
Fazzini E, 332A
Feasby TE, 303A
Fedor H, 755
Feeser B, 289A
Feldman EL, 342A
Felice K, 335A, 971A
Fénelon G, 580
Fenton M, 300A
Ferlini A, 231
Fernández-Solà J, 273
Ferrell RE, 282A
Ferrer I, 554A
Ferriero DM, 136, 502A, 504A, 542A
Festoff BW, 971A
Feuchtwang IB, 552A
Feuerstein G, 322A
Fielder TJ, 85
Filipek PA, 509A
Filippi M, 749
Filley CM, 127, 509A
Filloux FM, 503A
Finberg JPM, 316A, 317A
Finck S, 520A
FineSmith RB, 504A
Fink F, 310A
Fink ME, 288A
Finlay J, 343A, 533A
Fiori MG, 231
Fischer AQ, 553A
Fischer J, 313A
Fisher M, 287A
Fisher PG, 517A
Fisher W, 283A
Fishman RA, 484
Flamini JR, 534A
Flanagan SD, 797
Flanigan K, 350A
Flavahan NA, 318A
Flax J, 92
Fleiss JL, 522A
Fletcher G, 346A
Flick JA, 540A
Flores L, 555A
Foley CM, 524A, 531A, 540A, 541A
Fonda C, 325A
Fontaine A, 580
Forleo P, 124, 323A
- Forsyth P, 344A
Forte L, 531A
Fortner CA, 505A
Fox PT, 520A
Foxon R, 274
Francis G, 901
Frangione B, 324A
Frank Y, 511A
Franz DN, 546A
Fraser PE, 972A
Frederiksen JL, 943
Freeman JM, 514A
Freeman TB, 379
Freij WW, 348A
Freilich RJ, 51
French JA, 618
Freo U, 324A, 510A
Freund LS, 731
Frey A, 283A
Friedman H, 546A
Friedman JH, 329A
Frisk CS, 343A
Frouin V, 580
Frye VH, 528A
Fryer A, 85
Fujii N, 349A
Fukuyama H, 349A
Funanage VL, 514A, 610
Furey ML, 324A, 510A
Furuya H, 349A
Fussell B, 589
Futrell N, 973A
- Gage FH, 289A
Gahl WA, 921
Gahring LC, 283A
Gaillard WD, 505A, 534A, 535A
Gajdusek DC, 245, 326A
Galaburda AM, 509A
Galasko D, 643
Gallard E, 218
Gama CH, 367
Gama Sosa MA, 340A
Gambetti P, 21, 269
Gan X-D, 502A
Gancher ST, 330A
Gandy S, 698
Gao W-Q, 30
Garavaglia B, 544A
Garcia Alvarez MB, 545A
Gardner J, 289A
Gardner TJ, 317A
Garg BP, 556A
Garlepp MJ, 957
Garrison L, 336A
Garvey MA, 530A, 535A
Gass A, 286A, 319A
Gates J, 670
Gaudino EA, 284A, 345A
Gauger LL, 379, 771
Gawel M, 335A, 971A
Gay CT, 520A
Gayan J, 509A
Gaynor JJ, 202
Gearing M, 131
Geisler MW, 284A, 345A
- Gelbard HA, 551A
Gelinias D, 335A, 971A
Geller E, 296A
Gény C, 580
Geocadin R, 297A
George MS, 284A
Gestri D, 340A
Geyer JR, 517A
Ghaemi M, 825
Ghidoni PD, 520A
Giannini C, 346A
Gibbons VP, 548A
Gibbs CJ Jr, 245
Giegerich G, 311A
Gilbert JR, 290A, 537A
Gill JS, 308A
Gilles EE, 526A
Gilles FH, 525A
Gilley DW, 325A
Gilliam TC, 500A
Gilman S, 176
Gilmartin RC, 523A
Ginsberg SD, 308A
Giuliani M, 545A
Glantz L, 341A
Glantz M, 341A
Glaspy JA, 342A
Glass JD, 755
Glauser SC, 543A
Glauser TA, 543A, 544A
Glazer J, 520A
Gleeson JG, 519A, 548A
Gluck JT, 202
Godaux E, 437
Godbold JH, 289A
Goetz CG, 298A, 299A, 300A, 331A
Golabek A, 324A
Golbe LI, 355
Gold R, 311A, 313A
Goldberg MP, 307A
Goldberg T, 334A
Goldfarb LG, 267, 307A, 326A
Goldman M, 289A
Goldsbrough MA, 317A
Goldsmith J, 556A
Goldstein DS, 316A, 921
Goldstein GW, 345A, 405
Goldwein JW, 517A, 518A
Gomez CR, 320A, 321A
Gomez RM, 346A
Gomez-Isla T, 254, 285A
Gonzalez AG, 555A
Good WV, 542A
Goodkin DE, 313A, 319A, 349A, 832
Goodman AD, 338A
Goodwin M, 505A
Goplen G, 350A
Gordin S, 328A
Gordon KE, 536A
Gorson KC, 302A, 337A
Gotman J, 512A
Gottesman RD, 512A
Gottfried M, 285A
Gould R, 511A

- Gowdagere S, 306A
 Grady C, 324A, 510A
 Graf WD, 536A
 Graham JR, 163
 Graham SH, 286A
 Gran B, 340A
 Granger C, 313A
 Grant S, 341A
 Gratacòs M, 554A
 Grau JM, 218, 273
 Graus F, 341A
 Gray F, 269
 Graziani LJ, 511A, 540A
 Greatorex JS, 519A
 Greebe P, 929
 Green R, 643
 Green RC, 797
 Greenberg SM, 254, 285A
 Greenlaw R, 731
 Greenlee JE, 283A
 Greenlee R, 58
 Greenstein RM, 512A
 Gregson NA, 809
 Greiwe M, 305A
 Grekova MC, 312A
 Grether JC, 504A
 Griebel R, 350A
 Griesz M, 297A
 Griffin DE, 405
 Griffin JW, 282A, 302A, 304A, 333A, 336A, 350A
 Griggs RC, 273, 705
 Gringlas MB, 511A, 540A
 Grisold W, 337A
 Groccia ME, 291A
 Gropman A, 530A
 Gross LA, 304A
 Gross-Tsur V, 508A
 Grossman M, 541A
 Grover WD, 524A, 531A, 540A, 541A
 Growdon JH, 797
 Gruner JA, 315A
 Gu Q, 320A, 322A
 Guillen S, 555A
 Gulcher J, 972A
 Gureje O, 463
 Gusella J, 554A
 Gutekunst C-A, 298A
 Haas RH, 163
 Haavik J, 343A
 Haddad GG, 521A, 533A
 Hagan P, 501A
 Hahn AF, 303A, 307A
 Hahn JS, 526A
 Haines JL, 319A, 797
 Hajnal BL, 542A
 Hales MA, 318A
 Hall KS, 463
 Hall WA, 237
 Hall ZW, 832
 Hallett M, 4, 139, 284A, 328A, 862, 910
 Haltia M, 245
 Hamed LM, 515A
 Handler M, 301A
 Hanefeld F, 788
 Hankins L, 557A
 Hanley DF, 308A
 Hanna BD, 536A
 Hansen L, 653
 Hanson RA, 506A
 Hantraye P, 580
 Hara A, 335A, 336A
 Hardies LJ, 520A
 Hariharan S, 530A
 Harper CR, 521A
 Harrell LE, 326A
 Harris C, 396
 Harris JB, 916
 Harrison MB, 300A
 Hartung H-P, 186, 311A, 313A
 Hashimoto T, 296A, 298A, 544A
 Hastings AE, 313A
 Hatta J, 296A
 Hauer P, 304A
 Hauser RA, 379, 771
 Hauser SL, 319A, 702
 Havstad S, 119
 Hawken MB, 38
 Haxby J, 510A
 Haycock JW, 260
 Hayes MT, 302A
 Hays AP, 303A, 334A
 Hazenberg MPH, 170
 He X, 282A
 Heberlein I, 300A
 Hedley-Whyte ET, 525A
 Hefti F, 30
 Heide W, 739
 Heidenreich F, 186
 Heikkinen E, 319A
 Heiman-Patterson TD, 336A, 337A
 Heiss W-D, 825
 Hellström I, 342A
 Hellström KE, 342A
 Helton E, 505A
 Henderson L, 38
 Hendrie HC, 463
 Hennerici MG, 286A, 319A
 Hentati A, 282A, 293A
 Hentges F, 300A
 Herbert J, 340A
 Herholz K, 825
 Hermann-Liu AC, 517A
 Herndon R, 313A
 Herndon RC, 520A
 Herrera P, 555A
 Hersch SM, 298A
 Herzog AG, 305A
 Hess DC, 288A
 Hetherington H, 396
 Hicks BA, 472
 Higuchi S, 649
 Hildebrand J, 437
 Hildmann T, 210
 Hilger Ch, 300A
 Hill A, 544A
 Hilt D, 315A
 Hilz MJ, 335A
 Hinshaw DB Jr, 551A, 552A
 Hinton DR, 342A
 Hise J, 58
 Hlustik P, 284A
 Ho TW, 336A, 346A, 350A
 Hoang KBN, 514A, 515A
 Hoard R, 345A
 Hobdell E, 541A
 Hochman A, 328A
 Hodder J, 331A
 Hodes ME, 295A
 Hoffer PB, 589
 Hoffman EP, 333A, 367
 Hofman K, 509A, 554A
 Hogan T, 350A
 Hohlfield R, 723
 Hohmann CF, 500A
 Hokanson J, 335A
 Holler E, 723
 Holmes CS, 921
 Holmes GL, 507A, 513A
 Holmes JL, 509A
 Holshouser BA, 551A, 552A
 Holt DA, 379
 Holtzman D, 504A
 Hook MA, 299A
 Hoople NE, 291A
 Hopkins LC, 303A
 Hornykiewicz O, 260
 Horowitz DR, 289A
 Horowitz M, 58, 546A
 Horsfield MA, 749
 Horton EJ, 506A
 Horwich MS, 698
 Horwitz B, 324A, 510A
 Hosseini H, 954
 Hove MT, 515A
 Howell RA, 633
 Hsieh S-T, 304A, 333A, 350A
 Hubble J, 301A, 771
 Huber S, 723
 Hudson LD, 348A
 Hughes RAC, 809
 Hui SL, 463
 Hung W-Y, 282A, 293A
 Hurko O, 527A, 538A
 Hurler-Jensen A, 320A
 Hurley CK, 313A
 Hurst DL, 517A
 Husain AM, 524A, 541A
 Husar W, 341A
 Hutchinson M, 817
 Hyman BT, 254, 285A, 460
 Hyman SE, 508A
 Iadecola C, 286A
 Iannaccone ST, 522A
 Ichord RN, 539A
 IFNB MS Study Group, 314A
 Ihara Y, 421
 Ikeda K, 306A
 Ikeda T, 155
 Ikoma K, 284A
 Illa I, 218
 Ilonen J, 465
 Inaba A, 327A
 Ince PG, 691
 Incorpora G, 524A
 Innis RB, 589
 Inoue M, 304A
 Intenzo C, 540A
 Intravenous Valproate Study Team, 670
 Invernizzi F, 544A
 Ippel EF, 450
 Irigoyen C, 555A
 Ironside J, 245
 Isaacson SH, 267
 Isabel I, 305A
 Ishihara T, 305A
 Ishiwa S, 503A, 539A
 Isidre F, 305A
 Israel JJ, 500A
 Ito Y, 421
 Ives JR, 295A
 Iwamori M, 338A
 Iwasaki Y, 306A
 Iyer S, 283A
 Jack CR Jr, 324A
 Jacobs BC, 170
 Jacobs L, 313A
 Jacobson DM, 318A
 Jacobson SA, 502A
 Jacquy J, 437
 Jamieson DG, 287A
 Jankovic J, 299A, 571
 Janss AJ, 549A
 Janssen I, 510A
 Janz D, 210
 Javed M, 817
 Javidan M, 763
 Jellinger K, 331A
 Jennekens FGI, 450
 Jeny R, 580
 Ji T, 501A
 Jiang H, 315A
 Jiang N, 935
 Jimi T, 304A
 Johns DR, 282A
 Johnson C, 289A
 Johnson D, 522A
 Johnson JH Jr, 530A
 Johnson K, 315A
 Johnson KP, 971A, 973A
 Johnson MI, 507A
 Johnson P, 297A, 546A
 Johnson-Wood K, 643
 Johnston MV, 503A, 530A, 531A, 539A
 Johnston P, 345A
 Jones L, 633
 Jordan BD, 698
 Jørgensen HS, 45, 659
 Joseph R, 309A
 Joullian AL, 285A

- Juarez C, 218
 Jubelt B, 293A
 Jun AS, 163
 Junck L, 176
 Juneja T, 293A
 Jung S, 311A

 Kachelhofer RD, 625
 Kaczmarek W, 535A
 Kahlon S, 552A
 Kaji R, 155, 837
 Kakulas BA, 966
 Kaler SG, 921
 Kamboh MI, 282A, 967
 Kamholz J, 429
 Kamrin AL, 531A
 Kanazawa I, 314A, 338A
 Kandt RS, 537A
 Kane KJ, 291A, 325A
 Kaneoke Y, 296A, 298A
 Kanik AB, 698
 Kanner R, 297A
 Kanthan R, 350A, 351A
 Kaplan A, 529A
 Kaplan PW, 346A, 351A
 Kapur J, 893
 Kargman DE, 320A, 322A
 Karp C, 527A
 Karpati G, 274, 705
 Katayama M, 155
 Katoh S, 305A
 Katrina-Craig U, 324A
 Kattapong VJ, 291A
 Katz P, 312A
 Katzen H, 301A
 Katzman R, 653
 Kaufman A, 163
 Kaufman DM, 535A
 Kaufmann WE, 500A
 Kawamura J, 305A
 Kawanishi K, 15
 Kawashiro T, 305A
 Kaye CI, 520A
 Kaye EM, 499A, 534A
 KcKhann GM, 317A
 Keipes M, 300A
 Keller G, 30
 Keller GM, 516A
 Kelley-Geraghty DC, 293A
 Kelley K, 534A
 Kelley RI, 538A, 539A
 Kelly B, 291A
 Kelly ER, 531A
 Kemp GJ, 681
 Kennard C, 38
 Kennedy DN, 509A
 Kenney K, 245
 Kessler DB, 288A
 Kessler JA, 287A, 309A, 310A, 315A, 317A, 320A, 825
 Khan A, 504A
 Khan AS, 552A
 Khan KA, 288A, 320A
 Khan M, 341A
 Khan OA, 339A
 Kholodenko D, 643

 Kida E, 535A, 536A
 Kim SU, 309A, 314A
 Kim T-W, 446
 Kim Y, 163
 Kimmel DW, 343A
 Kimmel SC, 292A
 Kimura J, 155, 837
 King DW, 511A
 King M, 951
 King P, 283A
 Kinkel RP, 547A
 Kinoshita M, 306A
 Kinsman SL, 530A
 Kira J-i, 347A
 Kirk CJ, 547A
 Kirsch JE, 194
 Kish SJ, 260
 Kitagawa Y, 331A
 Kittner S, 289A
 Klauber MR, 653
 Kleiman M, 531A
 Klein SK, 532A
 Kleinschmidt-DeMasters BK, 127
 Klockgether T, 299A, 329A
 Klörzsch C, 288A, 321A
 Kluin KJ, 176
 Knapp AG, 547A
 Knöll A, 343A
 Kobayashi T, 306A, 347A, 349A
 Koehler RC, 308A
 Koenigsberger D, 523A
 Koenigsberger MR, 541A
 Koeppe RA, 176
 Koffman B, 333A
 Koh S, 510A, 534A, 556A
 Kohara N, 155
 Kohler F, 541A
 Kokkinos J, 119
 Kokmen E, 324A, 326A
 Koller WC, 301A, 771
 Kollros PR, 538A, 540A
 Kolodgie M, 505A
 Kolodny EH, 292A, 332A, 335A, 340A
 Komai K, 293A
 Komolafe O, 463
 Kömpf D, 305A, 739
 König S, 505A
 Kononova S, 326A
 Koontz D, 163
 Koopman W, 307A
 Koopmans RA, 314A
 Kopin IJ, 316A
 Kopitnik T, 58
 Kordower JH, 379
 Kornberg AJ, 514A
 Kornetsky C, 332A
 Kosalko J, 520A
 Kosofsky BE, 508A
 Kostrzema B, 119
 Kotagal P, 512A, 520A, 529A
 Kotagal S, 548A
 Koth C, 516A

 Kottamasu S, 542A
 Koyanagi Y, 347A
 Kramer E, 533A
 Kranz-Eble P, 545A
 Kratz R, 335A, 971A
 Krendel DA, 303A
 Kretzschmar HA, 788
 Krewson C, 294A
 Kris M, 341A
 Krischer J, 546A
 Krol G, 51
 Kroos MA, 450
 Krumholz A, 296A
 Krupp LB, 284A, 312A, 345A, 349A
 Kuban KCK, 548A
 Kubori T, 155
 Kumar A, 537A
 Kun L, 546A
 Kuncel RW, 73, 282A, 539A
 Kunkel LM, 333A, 367, 500A
 Kurland LT, 324A
 Kurz A, 797
 Kuseliasukas C, 321A
 Kusunoki S, 338A
 Küther G, 328A
 Kuzniecky R, 396

 La Bella V, 327A
 LaBuda M, 527A
 Lagenaur C, 520A
 Lahad A, 678
 Lai EC, 299A, 335A, 971A
 Laing B, 957
 Lal B, 345A
 Laloo DG, 916
 Lalowski M, 324A
 Lamensdorf I, 316A
 Lammers G, 288A
 Lammers GJ, 697
 Lamoureux D, 295A
 Lancaster JL, 520A
 Lancman ME, 296A
 Landry SH, 525A
 Lane RJM, 38
 Lane SC, 525A
 Lanfermann H, 825
 Lang AE, 330A, 684
 Lang JE, 509A
 Lange DJ, 303A, 334A, 335A, 971A
 Lappi DA, 310A, 327A
 Larson KB, 599
 Lassmann H, 788
 Laterra J, 345A
 Latorraca S, 124, 323A
 Latov N, 303A
 Lavi E, 287A
 Layton BA, 625
 Layzer RB, 136, 701
 Le TT, 556A
 Leach RJ, 520A
 Leake BD, 339A
 Leber SM, 538A
 Lederman RJ, 298A

 Lee DA, 304A
 Lee V, 549A
 Lee VM-Y, 649
 Lee Y, 314A
 Lefly D, 509A
 Legido A, 524A, 531A, 540A, 541A
 Lehman K, 335A
 Leigh RJ, 972A
 Lennon VA, 340A
 Lennox G, 274
 Leon-Monzon M, 267
 Leppik I, 670
 Lerner M, 547A
 Lesaux J, 973A
 Levey AI, 73, 298A
 Levin BE, 301A
 Levine JL, 499A
 Levine SR, 119, 322A, 323A
 Leviton A, 525A
 Levy-Lahad E, 678
 Levy R, 317A
 Lewis DW, 532A
 Leys K, 714
 Li C-Y, 302A, 336A, 350A
 Li DKB, 314A
 Li F, 147
 Li S, 315A
 Libenson MH, 534A
 Lichtenfeld P, 306A
 Lieberburg I, 643
 Lieberman P, 329A
 Lilienfeld D, 771
 Lin H-C, 315A
 Lin W-M, 333A
 Linan MJ, 147
 Lincoln R, 319A
 Lindholm KM, 301A
 Lindquist C, 329A
 Lippa CF, 290A, 972A
 Lipton R, 529A
 Lipton SA, 347A
 Lischner HW, 531A
 Little B, 245
 Litvan I, 299A, 331A
 Liu L, 350A
 Liu X, 348A
 Liu Z, 507A, 513A
 Livermore JL, 499A
 Ljunggren A, 333A, 367
 Llana J, 320A
 Lloyd R, 346A
 Lo W, 546A
 Locke KW, 287A
 Loegering MB, 507A
 Loes DJ, 351A, 547A
 Login IS, 300A
 Logtenberg T, 674
 Lohman M, 176
 Loop B, 520A
 Löschmann P-A, 329A
 Losseff NA, 294A
 Lothman EW, 501A
 Louis DN, 342A
 Lozano A, 330A
 Lu D, 511A

- Ludolph AC, 310A, 328A
Luft BJ, 349A
Lugaresi E, 21
Lunkes O, 326A
Lynch T, 301A
Lynn H, 556A
- Mabie PC, 309A, 310A
Macapinlac HA, 344A
Macaya A, 554A
MacCollin M, 554A
Macdonald DR, 344A
Macerlaine D, 817
MacEwan L, 973A
MacGregor D, 532A
Machida N, 649
Mack KJ, 552A
Macko C, 282A, 302A
Macko R, 289A
Macpherson TA, 537A
Madigan MC, 483
Madri JA, 502, 521A
Madsen HO, 943
Maeda N, 290A
Maeder MA, 556A
Maguire-Zeiss KA, 852
Mahmood R, 351A
Maiese K, 316A
Maisog J, 324A
Majamaa K, 319A
Majnemer A, 528A
Makary MA, 538A
Makuch R, 521A
Malapira T, 771
Malik MM, 320A
Malkin MG, 344A
Malkoff MD, 320A, 321A
Maller A, 557A
Mammi S, 749
Manca A, 231
Mancuso AA, 515A
Manetto V, 21
Manfredi G, 292A, 325A
Manganaro F, 327A
Mangeshkumar V, 337A
Mangin J-F, 580
Mangone C, 331A
Mangot D, 324A, 510A
Manley GT, 102
Mano Y, 15
Manor O, 508A
Mantle D, 691, 916
Manto M, 437
Manzione D, 334A
Maraganore DM, 329A
Marek KL, 589
Marescaux Ch, 520A
Maria BL, 514A, 515A
Markesberry WR, 194
Markham J, 599
Markopoulou K, 373
Marks D, 763
Marks HG, 514A, 541A, 610
Marmur R, 309A
Marsden CD, 965
Marson D, 326A
- Martin LJ, 73, 308A
Martin R, 137
Martin WRW, 331A
Martinie D, 527A
Maruta Y, 343A
Masliah E, 653
Mason G, 396
Mason WP, 341A
Mass MK, 342A
Massacesi L, 314A, 340A
Massaquoi S, 328A
Massicotte P, 532A
Mastaglia FL, 957
Mathias CJ, 965
Matilla T, 68
Matsumoto J, 862
Matsumoto JY, 329A
Matsumura R, 292A
Matthews PM, 901
Matthews R, 502A
Mattson DH, 338A
Mattson RH, 295A
Mayer A, 330A
Mayer RF, 15
Mayer SA, 288A
Maytal J, 505A, 513A, 529A
Mazurek MF, 299A
Mazzocco MMM, 509A, 516A, 731
McArthur JC, 304A, 333A, 755
McCall A, 68
McCormick C, 342A
McCormick E, 550A
McCormick ME, 304A
McDonald II, 505A
McDonald J, 307A
McFarland HF, 137, 312A
McGuinness MC, 472
McGuire D, 336A
McIntosh GC, 331A
McKee A, 331A
McKee L, 511A, 540A
McKenna-Yasek D, 460
McKhann GM, 336A, 350A
McLean MJ, 21
McManus M, 519A
McNally E, 333A, 367
McNeil RS, 499A
Medina LS, 524A
Mehler MF, 309A, 310A
Meitner P, 341A
Melamed E, 317A, 328A, 330A
Melanson D, 951
Melhem E, 509A
Mellits ED, 317A
Melvin J, 541A
Mendell JR, 541A, 705
Menonna J, 341A
Ment LR, 502, 521A
Mentis MJ, 324A, 510A
Mercuri B, 284A
Metha S, 505A
Metz H, 300A
- Metz-Lutz M-N, 520A
Meyer B, 328A
Meyer JW, 509A
Meyer T, 328A
Mezaki T, 155
Michels M, 186
Michon AM, 549A, 550A
Mignot E, 317A
Mikati MA, 513A
Milazzo A, 312A
Miles DK, 524A, 531A, 540A, 541A
Miller B, 643
Miller CL, 525A
Miller DH, 294A
Miller DJ, 340A
Miller GM, 297A
Miller L, 321A
Miller M, 317A
Miller R, 336A
Miller RA, 331A
Miller RC, 921
Miller S, 328A
Miner L, 297A
Minoshima S, 291A
Mirra SS, 131
Miskovsky G, 321A
Mita S, 335A, 336A
Mitchell WG, 506A, 556A
Miura M, 649
Miyashita H, 350A
Mizuno Y, 335A
Moeckel R, 319A
Mokri B, 297A
Molenaar PC, 714
Mollee I, 674
Molloy PT, 517A, 530A
Montagna P, 21
Montera L, 352A
Montesanti R, 389
Moorjani BI, 512A
Morawetz R, 396
Moroney JT, 287A, 290A
Morris HH, 296A
Morrison W, 625
Morton DH, 539A
Moser AB, 472
Moser HW, 318A, 351A, 472, 547A
Moshe SL, 505A
Mott SH, 509A
Mottter R, 643
Moxley RT III, 273, 334A
Moyle M, 935
Mozell R, 92
Mui S, 460
Muizelaar P, 348A
Müller U, 300A, 797
Multiple Sclerosis Collaborative Research Group, 313A
Munell F, 554A
Munn R, 506A
Munroe B, 643
Munschauer F, 321A
Murahashi M, 304A
Muramatsu T, 649
- Muriello MA, 302A, 337A
Murnane A, 30
Murphy MF, 335A, 971A
Murro AM, 511A
Myers LW, 339A
Myles GL, 321A
- Nachamkin I, 350A
Nacmias B, 124, 323A
Nagashima K, 311A
Nagle JW, 267, 307A, 326A
Nagy TG, 817
Naidu S, 295A, 318A, 500A, 531A, 532A
Nakamura T, 335A
Nakamuro T, 15
Nakayama H, 45, 659
Nam M, 345A
Naraqi S, 916
Narayanan V, 520A, 545A
Nathan R, 556A
Natter H, 335A, 971A
Nauert GM, 379
Navia BA, 347A
Navratil M, 322A
Nee L, 972A
Needle MN, 517A
Neitzel H, 210
Nelson A, 515A
Nelson J, 297A
Nelson JA, 350A
Nelson KB, 504A
Nelson MD, 556A
Nelson PT, 972A
Neri G, 500A
Nernoff J, 507A
Neuwelt EA, 342A
Nevo Y, 514A
Newsom-Davis J, 111, 714
Newstein D, 505A
N'Guyen J-P, 580
Nicholson HS, 518A
Nichter C, 541A
Nicoletti G, 389
Niederman FG, 298A
Nigam M, 539A
Nigro MA, 304A, 543A, 549A, 550A
Nirenberg A, 553A
Nisen PD, 549A
Nishimura T, 334A
Nishino H, 343A
Nishino S, 317A
Nitschke M, 300A
Nizam MF, 535A
Noetzel MJ, 505A
Noll DC, 284A
Nordli DR, 523A
Norris JW, 319A
Norris L, 323A
North KN, 960
Northam RS, 532A
Northington FJ, 308A
Notarelli A, 292A, 325A
Novak G, 513A
Novotny EJ, 521A, 533A

- Nukuzuma S, 311A
Nwokolo NC, 916
Nylander KD, 517A
- Oaklander AL, 318A
O'Brien PC, 326A, 345A
O'Connell P, 85
O'Connor MJ, 618
Odaka A, 421
O'Dell C, 505A
O'Driscoll KR, 545A
Oexle K, 310A
O'Fallon A, 284A
Offen D, 328A
Ogata A, 311A
Ogunniyi AO, 463
Oh W, 521A
Oksaranta O, 465
Olanow CW, 379, 771
Olinsky S, 520A, 545A
Olsen TS, 45, 659
Olson D, 643
Oluwole SO, 463
O'Neill AM, 344A
O'Neill T, 283A, 667
Oniki H, 304A
Ono S, 326A
Oomes PG, 170, 832
Openshaw H, 342A
O'Reilly JP, 533A
O'Riordan J, 817
O'Riordan JL, 294A
Orrell RW, 38
Ortiz N, 218
Ortiz O, 516A
Osathanondh R, 92
Osborne D, 291A
Osborne S, 552A
Ossondo M, 454
Oster M, 286A
Ostrow P, 321A
O'Sullivan E, 38
Osuntokun BO, 463
Otero C, 302A
Otto V, 305A
Overstreet LS, 501A
Ozden S, 454
- Pachner AR, 283A, 667
Pacia S, 763
Packer R, 530A, 533A
Packer RJ, 343A, 505A, 518A
Pahwa R, 301A
Paik M, 290A
Paleologos N, 344A
Palmieri A, 389
Pan J, 396
Panasci D, 297A
Panelius M, 465
Panet H, 328A
Panitch HS, 339A
Papazian O, 687
Papero PH, 534A
Pappert EJ, 298A
Parano E, 524A
Parchi P, 21, 269
- Parfrey N, 817
Parisi JE, 297A, 346A, 697
Park YD, 511A
Parlato G, 389
Parrish JA, 326A
Parry D, 554A
Parry G, 336A
Parsa A, 331A
Partridge JC, 542A
Pascual-Leone A, 910
Pasha J, 293A
Paskavitz JF, 127
Pasternak JE, 501A
Pasupathy A, 512A
Patel A, 973A
Patel N, 527A
Patronas NJ, 328A
Patrosso MC, 231
Paty DW, 314A, 625
Pavakis S, 511A
Pearce R, 331A
Pearce WJ, 552A
Pedersen PM, 659
Pediatric Oncology Group, 527A, 546A
Pellock JM, 505A, 670
Penchaszadeh GK, 500A
Pendlebury WW, 291A
Peng S, 506A
Penney S, 518A
Pennington BF, 509A
Pepin MG, 960
Pepinsky RB, 313A
Pereira C, 749
Perfetti CA, 284A
Pericak-Vance MA, 319A, 537A
Peripheral Nerve Society, 478
Perkin R, 552A
Perlman JM, 548A, 549A
Peroutka S, 335A
Perrine K, 332A
Perry JR, 344A
Perry M, 119, 322A
Perry SW, 551A
Perryman J, 349A
Peschanski M, 580
Pestronk A, 505A, 514A
Petajan J, 336A
Peter JB, 315A
Petersen RB, 21
Petersen RC, 324A, 326A
Peterson K, 237, 344A
Petito CK, 698
Petroff OAC, 295A
Petrovich MS, 483
Pettigrew LC, 194
Petty B, 317A
Petty GW, 323A
Pfeiffer RF, 373
Pflughaupt KW, 186
Pham C, 540A
Phillips HS, 30
Phillips PC, 517A, 530A, 549A
Piacentini S, 124, 323A
- Piantadosi C, 500A
Piccini C, 292A, 325A
Piccininni M, 292A, 325A
Piccoli F, 327A
Picklo MJ, 310A
Piepgras DG, 297A
Pietrini P, 324A, 510A
Pilay N, 303A
Pinter JD, 524A
Pippenger CE, 543A, 544A
Plaetke R, 520A
Planas AM, 554A
Platonov F, 326A
Pleasure D, 507A
Plomp JJ, 714
Plyuscheva N, 283A
Pohost G, 396
Poikonen K, 465
Pollock S, 163
Pomeroy SL, 538A
Pons R, 545A
Popescu O, 321A
Popko B, 290A
Porada P, 788
Poser S, 788
Poskitt K, 544A
Posner JB, 102, 341A, 345A
Post RM, 284A
Poterucha JJ, 828
Potter NT, 528A
Powers WJ, 599
Pozzebon M, 633
Pranzatelli MR, 505A
Prasad AN, 534A
Preul M, 901
Price RW, 563
Price T, 289A
PSP Clinical Study Group, 299A
Pufky J, 290A
Pulicino P, 319A, 321A
Pulsifer MB, 514A
Pupi A, 292A
Puranam K, 525A
Purdy P, 58
- Qian W-H, 525A
Qiu H-L, 290A
Quan L, 536A
Quaskey SA, 317A
Quattrone A, 389
Quezado M, 307A
Quin E, 817
Quinlan D, 589
Quinn NP, 965
Quirós RE, 610
Quisling RG, 515A
Quisling RJ, 514A
- Raaschou HO, 45, 659
Rabinovich H, 540A
Radda GK, 681
Rader DJ, 287A
Rafal R, 264
Ragno M, 231
Raine CS, 312A
- Raja S, 296A
Rajput AH, 300A
Ramon G, 305A
Ramos LMP, 929
Ramsay RE, 670
Ramsby G, 512A
Randolph A, 342A
Rangaratnam S, 537A
Rapoport SI, 324A
Rarick T, 503A
Rask C, 317A, 335A
Rathbun J, 331A
Rauch RA, 520A
Rawlins P, 523A
Raymond GV, 472
Reader MJ, 516A
Rebeck GW, 254, 285A, 460
Reches A, 317A
Recht L, 341A
Reeder AT, 340A, 625
Rees JH, 809
Reichler B, 347A
Reichmann H, 332A
Reiman EM, 291A
Reiners K, 186
Reiss AL, 509A, 731
Relin M, 291A
Relkin NR, 698
Remillard GM, 951
Remsen L, 342A
Remtulla H, 307A
Remy P, 580, 954
Reunanen M, 465
Reuser AJJ, 450
Reutens DC, 951
Rey G, 301A
Reynolds L, 513A
Ricci E, 500A
Rice G, 973A
Rice J, 515A
Rice RR, 331A
Richert J, 313A
Richert JR, 312A, 313A
Richfield EK, 852
Rickert K, 293A
Ricolfi F, 580
Riddle M, 527A
Rieckmann P, 788
Riepe M, 310A
Rifai Z, 274, 302A, 334A
Rignani JE, 351A
Rinehart JE, 346A
Ringdahl DM, 515A
Rinkel GJE, 929
Rinne JO, 965
Ripepi B, 545A
Ris MD, 518A
Riviello JJ Jr, 519A
Rivkin MJ, 92
Rizzo M, 389
Ro T, 264
Roach ES, 528A
Robbins RS, 131
Roberts J, 289A
Roberts M, 111
Roberts T, 348A

- Robinson ED, 312A, 313A
 Rocca WA, 324A, 326A
 Rodriguez E, 544A
 Rodriguez M, 340A, 345A
 Rodriguez P, 555A
 Roessler B, 501A
 Rogaeva EA, 684
 Rogers SW, 283A
 Rohowsky-Kochan C, 339A
 Roig M, 554A
 Rojas ABN, 319A
 Roland EH, 544A
 Roldan EQ, 340A
 Rollins N, 58
 Rombolá G, 314A
 Ronen GM, 518A
 Ronthal M, 305A
 Roos RP, 245, 346A
 Ropper AH, 302A, 337A
 Rorke L, 518A
 Rorke LB, 518A, 530A, 549A
 Rosario J, 289A
 Rosebush PI, 299A
 Rosenbaum DM, 287A, 320A
 Rosenbaum PS, 320A
 Rosenberg GA, 291A, 322A
 Rosenberg PA, 502A
 Rosenblatt B, 512A
 Rosenblum MK, 344A, 563
 Rosenfeld J, 303A
 Rosenfeld MR, 345A
 Rosenfeld WE, 555A
 Rosenfield DB, 285A
 Rosenow F, 825
 Rosenthal H, 334A
 Roses AD, 6, 290A, 537A, 969
 Ross BM, 500A
 Ross JL, 731
 Ross ME, 286A
 Rossi G, 345A
 Rote WE, 935
 Rothman DL, 295A
 Rothner AD, 512A, 527A, 529A
 Rothrock T, 290A
 Rothstein JD, 73, 295A, 308A
 Rothwell JC, 155
 Rottach KG, 972A
 Roubin G, 283A
 Rouleau GA, 537A
 Rowland LP, 303A, 705, 834
 Rubin M, 509A
 Rudick RA, 313A, 349A
 Rudnicki S, 335A, 971A
 Rueben RN, 552A
 Rueger D, 507A
 Ruggieri PM, 527A, 529A
 Rugiero M, 333A
 Rusin J, 535A
 Russell JW, 306A
 Russman BS, 522A
 Rutchick J, 347A
 Rutkowski JL, 547A
 Ruttledge MH, 537A
 Ryan SG, 85
 Rybak S, 320A
 Ryder LP, 943
 Rye D, 298A
 Sabetta G, 544A
 Sabin TD, 349A
 Sacco RL, 320A, 322A
 Sacktor NC, 351A, 547A
 Sadato N, 910
 Sadun AA, 483
 Safar J, 245
 Sahota A, 463
 Sailer U, 210
 St. George-Hyslop P, 797, 972A
 St. Laurent RT, 176
 Saito Y, 349A
 Saitoh T, 653
 Sajanti J, 319A
 Sakoda S, 334A
 Sakurai M, 314A
 Salahuddin A, 293A
 Salazar A, 313A
 Salazar-Grueso EF, 307A
 Salganicoff L, 540A, 541A
 Saling MM, 633
 Salo D, 290A, 972A
 Salonen R, 465
 Salowich-Palm L, 119, 322A
 Saltzman WM, 294A
 Salvi F, 231
 Samaha FJ, 522A, 546A
 Samii A, 284A
 Samson D, 58
 Samson Y, 580, 954
 Samuel D, 296A
 Sanberg PR, 379
 Sandage BN, 287A
 Sander T, 210
 Sandson TA, 290A
 Sanes J, 329A
 Sanford R, 546A
 Sanghera DK, 282A
 Sanjak M, 294A
 San Martin RA, 245
 SanRoman R, 555A
 Saper CB, 339A, 972A
 Sapin J, 541A
 Sasaki H, 327A, 649
 Sato S, 534A
 Satoh J-i, 314A
 Saunders AM, 290A
 Sawaya KL, 119, 322A
 Sax DS, 332A
 Saya SH, 293A
 Scammell TE, 339A
 Schabitz WR, 287A
 Schachenmayr W, 332A
 Schaefer GB, 516A
 Schaid DJ, 324A
 Schapiro MB, 324A, 510A
 Scheffer IE, 633
 Scheithauer BW, 297A
 Schellenberg GD, 678
 Scheller J, 534A
 Schenk D, 643
 Scher MS, 537A
 Scherer SS, 429
 Schielke G, 295A
 Schiff D, 343A
 Schiff JM, 520A
 Schiffmann R, 547A
 Schipper HM, 323A, 327A
 Schmalzigaug K, 310A
 Schmechel D, 290A
 Schmelzer C, 30
 Schmitt FA, 194
 Schmitz B, 210
 Schneider JA, 131
 Schneider W, 284A
 Schofield IS, 916
 Schomer DL, 295A
 Schor NF, 516A, 517A
 Schuerholz LJ, 515A, 516A
 Schultz L, 322A, 323A
 Schumacher CP, 316A
 Schwartz A, 286A, 319A
 Schwartz ML, 521A, 533A
 Schwartz S, 317A
 Schweizer MP, 503A
 Schwid SR, 338A
 Sciacco M, 541A
 Sciabassi RJ, 537A
 Scott DE, 312A
 Seboun E, 319A
 Seeldrayers P, 186
 Seibel P, 332A
 Seibyl JP, 589
 Seiki H, 649
 Sekul EA, 302A
 Selcen D, 549A, 550A
 Sellebjerg F, 943
 Selnes OA, 317A
 Sena-Esteves M, 499A
 Sennlaub A, 311A
 Senut M-C, 289A
 Servidei S, 500A
 Seubert P, 643
 Seyal M, 264
 Sferra TJ, 546A
 Shah NS, 552A
 Shalev RS, 508A
 Shamoto H, 542A, 543A
 Shankroff J, 351A
 Shannon KM, 301A
 Shanske S, 468, 541A
 Shapiro RE, 318A
 Shapiro SM, 553A
 Sharbrough FW, 697
 Sharer L, 541A
 Sharma A, 499A
 Sharpe L, 297A
 Shaunak S, 38
 Shaw PJ, 691
 Shechter A, 529A
 Sheff K, 589
 Sheikh KA, 302A, 350A
 Sheinart KF, 289A
 Sheldon RA, 504A
 Sheller JR, 21
 Sheppard S, 298A
 Sheeth RD, 516A
 Shevell M, 528A
 Shi Y-j, 429
 Shiang R, 85
 Shibasaki H, 155, 837
 Shibuya S, 304A
 Shillito P, 714
 Shinkai Y, 421
 Shinnar S, 505A
 Shinohara Y, 331A
 Shinsky N, 30
 Shiojima T, 306A
 Shiojiri T, 327A
 Shirvan A, 328A
 Shodis KA, 294A
 Shoffner JM, 163, 797
 Shoubridge E, 274
 Shu S, 551A
 Shuaib A, 288A, 320A, 350A, 351A
 Shulman LM, 329A
 Shulman M, 548A
 Shy ME, 429
 Siddique T, 282A, 293A
 Siegall C, 342A
 Siegel K, 287A
 Siegel M, 30
 Siffert J, 553A, 554A
 Silber JH, 549A
 Siller KA, 292A, 297A
 Silverstein FS, 501A
 Simaan EM, 513A
 Simmons Z, 303A
 Simon J, 313A
 Simon JM, 509A
 Simon RP, 286A
 Simpson DM, 347A
 Singer C, 329A
 Singer HS, 509A, 515A, 527A
 Singleton JR, 342A
 Sirocchi G, 231
 Sirven JI, 618
 Sisk JM, 472
 Sivak M, 535A
 Sivakumar K, 267, 307A
 Skoff RP, 309A
 Sladsky JT, 538A, 539A
 Slasor P, 347A
 Slatkin NE, 342A
 Sloan MA, 289A
 Slogosky SL, 336A
 Slonim AE, 334A
 Small SL, 284A
 Smergel E, 524A
 Smietana S, 551A
 Smith CD, 194
 Smith DA, 379
 Smith E, 163
 Smith EO, 589
 Smith JR, 511A
 Smith KE, 525A
 Smith ME, 312A
 Smith TW, 338A
 Smith WS, 484

- Smitt PS, 102
 Smurawska LT, 319A
 Snodgrass SR, 555A
 Snow BJ, 379
 Soares MB, 500A
 Sobel EL, 525A
 Sodaar P, 674
 Solomon PR, 291A
 Sommer SS, 343A
 Sorbi S, 124, 323A
 Sosa MAG, 292A
 Sotgiu S, 723
 Sotrel A, 305A
 Sottini A, 340A
 Soueidan S, 302A
 Soule HR, 935
 Southwick P, 643
 Speer A, 328A
 Spencer DD, 763, 778
 Spencer SS, 763, 778
 Sperling RA, 290A
 Sposto R, 343A
 Sprinkle A, 288A
 Squires NK, 345A
 Stafstrom CE, 507A
 Stahl JS, 972A
 Stakkestad A, 528A
 Stanley C, 511A, 540A
 Stebbins GT, 298A, 301A, 331A
 Stefanatos G, 540A
 Stefanis L, 285A
 Stefansson K, 972A
 Steffler C, 315A
 Stein AS, 342A
 Stein D, 972A
 Stein DP, 302A
 Stein MC, 147
 Stein R, 328A
 Steinbach P, 305A
 Steinberger D, 300A
 Stemper B, 335A
 Steppe DA, 537A
 Sterio G, 332A
 Stern B, 289A
 Stern Y, 287A
 Steward O, 501A
 Stewart WB, 502, 521A
 St George-Hyslop PH, 684
 Stolp-Smith KA, 345A
 Stopa EG, 323A
 Storch G, 347A
 Strafella A, 330A
 Strauss S, 284A
 Streletz LJ, 540A
 Stuart RS, 317A
 Stugard C, 163
 Stumpf DA, 282A
 Subramony SH, 68
 Sufit R, 350A
 Sum JM, 526A
 Sun M, 202
 Surratt C, 297A
 Sutton LN, 530A
 Sutton ME, 548A
 Suzuki J, 347A
 Suzuki N, 421
 Svejgaard A, 943
 Swank PR, 525A
 Swann JW, 499A
 Swearer JM, 290A, 291A, 325A
 Sweeney D, 698
 Swift D, 528A
 Swink TD, 548A
 Swirduk M, 316A
 Syndulko K, 315A
 Szabó A, 529A
 Tabarias H, 957
 Taff IP, 352A
 Tagaya N, 306A
 Tagliati M, 347A
 Tahmoush AJ, 336A, 337A
 Taiuti R, 340A
 Takahashi T, 529A
 Takano K, 287A
 Takase S, 649
 Takayanagi T, 15
 Takeoka T, 331A
 Tamai S, 15
 Tamura R, 15
 Tangalos EG, 324A
 Tangy F, 454
 Tani M, 429
 Tanji K, 541A
 Taroni F, 544A
 Tarvonen S, 465
 Tashiro K, 311A
 Tatemichi TK, 285A, 287A, 290A
 Tatton W, 317A
 Tavaré CJ, 525A
 Taylor BV, 343A, 828
 Taylor DJ, 681
 Tchernakov CI, 512A
 Tedeschi G, 328A, 547A
 Tennekoon GI, 547A
 Terajima M, 649
 Teramoto H, 335A
 Thach WT, 881
 Thal L, 653
 Thangaraj V, 295A
 Thaut MH, 331A
 Theodore WH, 534A
 Theodore WT, 296A
 Thibodeau SN, 291A, 324A
 Thomas CE, 288A
 Thompson AJ, 294A
 Thompson LA, 532A
 Thorne GM, 519A
 Thornton CA, 273, 274, 302A, 303A, 334A
 Thyagarajan D, 468
 Tietjen GE, 323A
 Tilton AH, 556A
 Ting TY, 504A
 Tinkhtman AJ, 194
 Titanic MK, 543A
 Todd I, 274
 Tokunaga M, 336A
 Tomasi L, 552A
 Toms R, 547A
 Tonalì P, 500A
 Tone B, 552A
 Toro C, 862
 Torres O, 528A
 Tournay A, 506A
 Tournier-Lasserre E, 231, 817
 Tourtellotte WW, 315A
 Toyka KV, 186, 311A, 313A
 Trail PA, 342A
 Tran TA, 763
 Traystman RJ, 308A
 Trescher WH, 503A
 Trevett AJ, 916
 Trifiletti RR, 503A, 523A, 524A
 Trojaborg W, 303A, 334A
 Trojano L, 231
 Trojanowski JQ, 549A, 649
 Trommer BL, 501A
 Trucco GS, 537A
 Truemper EJ, 553A
 Truweit CL, 237
 Tsay CH, 542A
 Tuchman RF, 526A
 Tudor CA, 546A
 Tuhim S, 289A
 Tuite PJ, 684
 Tulyapronchote R, 320A
 Turkel S, 510A
 Turner R, 298A
 Tusa RJ, 351A, 515A
 Tuszyński MH, 289A
 Tyler KL, 127
 UBC MS/MRI Study Group, 314A
 Uchino M, 335A, 336A
 Ugokwe CC, 546A
 Uhl GR, 297A
 Ullman MD, 499A
 Ulug A, 318A
 Unverzagt FW, 463
 Unwin H, 58
 U.S. Phase III Copolymer I Study Group, 971A, 973A
 Usher D, 287A
 Uyama E, 336A
 Valentine C, 542A
 van Amstel HKP, 450
 van Bockxmeer FM, 957, 966
 van Broeckhoven C, 797
 Van den Berg LH, 674
 van den Berg RJ, 714
 Vandenbergh D, 297A
 van den Boogaard M-JH, 450
 VanderBrug MS, 349A
 van der Meché FGA, 170
 Vandervoort M, 303A
 Vandervoort P, 973A
 van Diggelen O, 450
 van Dijk JG, 714
 van Duijn CM, 225, 797
 van Duyn CM, 929
 Van Dyke C, 349A
 van Gijn J, 929
 van Gool WA, 225
 Van Heertum RL, 288A
 Van Kammen M, 73
 Van Kempen GThH, 714
 Van Ness PC, 296A
 Varlotta G, 297A
 Vasconcelos M, 505A
 Vasconcelos O, 267, 307A, 326A
 Vass A, 337A
 Vaughan T, 396
 Vaught JL, 315A, 317A
 Vazquez-Memije M, 468
 Venna N, 349A
 Ventimiglia J, 549A
 Vernant J-C, 454
 Verny M, 331A
 Verschuuren J, 341A, 345A
 Verson RD, 303A
 Vezina LG, 534A, 535A
 Vickers JA, 506A
 Vidailhet M, 954
 Vieregge P, 300A, 305A
 Vigo-Pelfrey C, 643
 Villa-Komaroff L, 92
 Vincent A, 111, 350A, 714
 Vingerhoets FJG, 379
 Vining EPG, 514A
 Visser LH, 832
 Viswanath NS, 285A
 Vitek JL, 283A, 296A, 298A
 Vladimirtsev V, 326A
 Vnencak-Jones CL, 21
 Voeller KKS, 508A
 Vogel T, 324A
 Vohr B, 521A
 Volicer L, 797
 Volpe JJ, 92, 502A
 Vonkeman HE, 852
 Vonsattel JPG, 254, 285A
 Voorn P, 852
 Vu TH, 541A
 Vuillemin M-O, 520A
 Vuk S, 556A
 Wade CK, 522A
 Wakayama Y, 304A
 Walker JR, 522A
 Walkup J, 527A
 Wallace DC, 163, 797
 Wallace S, 535A
 Wanders RJA, 544A
 Wang CH, 500A
 Wang HS, 293A
 Wang J-B, 297A, 316A
 Wang X, 327A
 Wang Y, 295A
 Wara W, 518A
 Warach S, 290A, 295A
 Waring SC, 324A, 326A
 Warrell DA, 916

- Warter J-M, 954
 Wasmuth JJ, 85
 Wassermann EM, 284A, 910
 Watkins PA, 472
 Wauschkuhn B, 300A
 Weber F, 723
 Weber J, 287A
 Webster HdeF, 348A
 Weilbach F, 311A
 Weinberg WA, 521A
 Weinberger J, 289A
 Weiner WJ, 301A, 329A
 Weinreb HJ, 292A, 340A
 Weinstein S, 505A, 534A, 535A
 Weinstock A, 529A
 Weisner RH, 828
 Weiss EH, 723
 Wekerle H, 723
 Wekstein DR, 194
 Wellington R, 284A
 Wells C, 288A
 Wells JM, 797
 Wells JT, 521A
 Welty D, 295A
 Weng W, 520A, 545A
 Wenger S, 520A
 Wenning G, 299A
 Wermeling DP, 194
 Werner S, 513A
 Wesley MH, 291A
 Wesselingh SL, 755
 Weuthen G, 825
 Whitaker JN, 625
 White M, 522A
 Whiteman DAH, 960
 Whyatt SA, 429
 Wical BS, 506A
 Wienker TF, 210
- Wijdicks EFM, 696, 697, 828
 Wijsman EM, 678
 Wildin SR, 525A
 Wiley CA, 559
 Wiley RG, 310A, 327A
 Wilhelmsen KC, 301A
 Wilkins AS, 508A
 Will R, 245
 Willcox T, 817
 Williams WA, 284A
 Williamson A, 778
 Willis JK, 515A, 556A
 Willison HJ, 111, 350A
 Willmore LJ, 670
 Wilson J, 681
 Wilson MA, 530A
 Wilson RS, 325A
 Wilson W, 300A
 Windebank AJ, 304A, 308A, 316A
 Winkfield DR, 535A
 Winslow JW, 30
 Wintzen AR, 714
 Wirrell EC, 536A
 Wishart T, 351A
 Wisniewski KE, 535A, 536A
 Wisniewski T, 324A
 Witte OW, 414
 Wittenberg N, 972A
 Wittrock DL, 304A
 Wityk R, 289A
 Wokke J, 450, 674
 Wolfert R, 643
 Wolgemuth B, 520A
 Wollmann R, 346A
 Wolpert C, 537A
 Wozniak M, 289A
 Wrenn CC, 310A, 327A
- Wszolek ZK, 301A, 373
 Wu K, 446
 Wüllner U, 329A
 Wyllie E, 520A, 529A
- Xia Q, 339A
 Xia Y, 653
 Xu J, 500A
 Xu P-T, 290A
 Xu S, 286A
 Xu YC, 324A
- Yabut M, 501A
 Yachnis AT, 515A, 549A
 Yadav SS, 283A
 Yager JY, 502A
 Yamamoto N, 347A
 Yamashita S, 85
 Yamashita T, 335A, 336A
 Yamashita Y, 349A
 Yamauchi M, 326A
 Yan Y, 520A
 Yanagihara T, 334A
 Yanagisawa K, 421
 Yang M, 463
 Yanovski JA, 547A
 Yao D-L, 348A
 Yarnell PR, 347A
 Yazaki K, 331A
 Ye FQ, 331A
 Yeakley J, 557A
 Yee A, 315A
 Yellin P, 504A
 Yeung M, 288A, 320A
 Yohai D, 535A
 Yokota T, 327A
 Yonezawa M, 502A
 Yoshii F, 331A
 Yoshikawa H, 334A
 Yoshimura M, 421
- Yoshino A, 327A
 Yoshioka A, 507A
 Youdim MBH, 316A, 317A
 Young M, 529A
 Young SD, 532A
 Youngman S, 330A
 Younkin DP, 507A
 Yu B-H, 347A
 Yu J, 499A
 Yuasa T, 327A
- Zachowski J, 532A
 Zaia B, 342A
 Zaninovic V, 454
 Zappata S, 500A
 Zappia M, 389
 Zea-Ponce Y, 589
 Zee P, 350A
 Zepp R, 527A
 Zettl U, 313A
 Zhai Q-h, 973A
 Zhang F, 286A
 Zhao GJ, 314A, 625
 Zhao H, 517A
 Zheng W, 714
 Zhong XH, 260
 Zhu S, 338A
 Zhu Y-Z, 85
 Zifko U, 307A, 337A
 Zilko PJ, 957
 Zimmer R, 797
 Zimmerman AW, 528A
 Zimmermann C, 297A
 Zimmermann E, 739
 Zipp F, 723
 Zito J, 352A
 Ziv I, 328A, 330A
 Zoghbi HY, 68
 Zoghbi S, 589
 Zurakowski D, 524A

Subject Index

Absence epilepsy; *see* Epilepsy, absence

Acetylcholine

D1 agonist stimulates acetylcholine release from dissociated adult rat striata (Login et al) 1995;38:300A

Acetylcysteine

reduction of excitotoxic injury in rat pups by glutathione and N-acetylcysteine (Trifiletti et al) 1995;38:503A

Acid maltase; *see* Glucan 1,4-alpha-glucosidase

Acoustic stimulation

regional cerebral glucose metabolism at rest and during audiovisual stimulation in young and older adult Down syndrome subjects (Pietrini et al) 1995;38:510A

rhythmic facilitation in gait training of Parkinson's disease (McIntosh et al) 1995;38:331A

Acquired immunodeficiency syndrome

brainstem syndrome associated with cytomegalovirus encephalitis in acquired immunodeficiency syndrome (Simpson et al) 1995;38:347A

double-blind, randomized, placebo-controlled trial of the calcium channel antagonist nimodipine for the neurological manifestations of acquired immunodeficiency syndrome, including dementia and painful neuropathy (Lipton et al) 1995;38:347A

inefficacy of interferon-alpha in acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy (Counihan et al) 1995;38:349A

Acyl coenzyme A

distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies (Watkins et al) 1995;38:472

Adenosine cyclic monophosphate

overexpression of fragile X gene (FMR-1) transcripts in neural cells results in increased levels of cyclic adenosine monophosphate production (Berry-Kravis and Ciurlionis) 1995;38:499A

Adenosine triphosphatase

novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis (Thyagarajan et al) 1995;38:468

Adenoviruses

adenoviral vector can transfer lacZ expression into Schwann cells in culture and in sciatic nerve (Shy et al) 1995;38:429

adenovirus-mediated overexpression of interleukin-1 receptor antagonist in perinatal rat brain decreases susceptibility to excitotoxic injury (Hagan et al) 1995;38:501A

recombinant adeno-associated virus-mediated gene transfer into the central nervous system (Lo et al) 1995;38:546A

Adhalin

adhalin gene mutations and autosomal recessive limb-girdle muscular dystrophy (Campbell) 1995;38:353 (Editorial)

autosomal-recessive childhood-onset muscular dystrophy associated with mutations of the 50-kDa dystrophin-associated glycoprotein adhalin (17q12-q21.33) (Boylan et al) 1995;38:333A

primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin (Ljunggren et al) 1995;38:367

ultrastructural localization of adhalin and its spacial relation to dystrophin in normal murine skeletal myofiber (Wakayama et al) 1995;38:304A

Adie's syndrome

comparison of colinergic supersensitivity of the iris sphincter in patients with third nerve palsies and Adie's pupils (Jacobson) 1995;38:318A

Adrenal cortex hormones

childhood idiopathic language deterioration: clinical characteristics, pathophysiological correlates, and response to treatment with corticosteroids (Stefanatos et al) 1995;38:540A

effect of corticosteroid pulses on bone density in multiple sclerosis (Schwid et al) 1995;38:338A

neuroendocrine effects of chronic stress: abnormal hormonal stress response in an infant rat model (Gilles et al) 1995;38:526A

Adrenocorticotrophic hormone

high-dose adrenocorticotrophic hormone or prednisone for infantile spasms? a prospective, randomized, blinded study (Baram et al) 1995;38:506A

Adrenoleukodystrophy

cognitive impairment in adrenomyeloneuropathy correlates with magnetic resonance imaging abnormalities (Sacktor et al) 1995;38:547A

cognitive impairment in an adult male form of adrenoleukodystrophy correlates with magnetic resonance imaging abnormalities (Sacktor et al) 1995;38:351A

proton magnetic resonance spectroscopy and imaging in adrenoleukodystrophy heterozygotes (Barker et al) 1995;38:318A

somatosensory-evoked potentials in adrenomyeloneuropathy patients on Lorenzo oil (Kaplan et al) 1995;38:351A

Adrenomyeloneuropathy; *see* Adrenoleukodystrophy

Afferent neurons; *see* Neurons, afferent

Age factors

aging, energy, and oxidative stress in neurodegenerative diseases (Beal) 1995;38:357 (Neurological progress)

aging and muscle mitochondrial abnormalities (Grau et al) (Letter); (Karpati and Shoubridge) (Reply); (Rifai and Thornton) (Reply) 1995;38:273

apolipoprotein E $\epsilon 4$ allele is not associated with earlier age at onset in amyotrophic lateral sclerosis (Mui et al) 1995;38:460

apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease (Levy-Lahad et al) 1995;38:678

behavioral slowing with age: boundary conditions of the generalized slowing model (Swearer and Kane) 1995;38:325A

effect of age, race, and gender on anti-oxidant defenses in healthy children (Glauser et al) 1995;38:543A

frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease (Smith et al) 1995;38:194

increasing striatal iron content associated with normal aging: a risk factor for free-radical-mediated neuronal damage (Martin et al) 1995;38:331A

striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? (Kish et al) 1995;38:260

Aged

lack of an association between apolipoprotein E $\epsilon 4$ and Alzheimer's disease in elderly Nigerians (Osuntokun et al) 1995;38:463

Aggression

longitudinal analysis of aggressive behavior in Alzheimer's disease (Gilley et al) 1995;38:325A

AIDS dementia complex

AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations (Brew et al) 1995;38:563

Alleles

apolipoprotein E $\epsilon 4$ allele is not associated with earlier age at onset in amyotrophic lateral sclerosis (Mui et al) 1995;38:460

CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease (Chen et al) 1995;38:653

DRB1 alleles share a specific common sequence associated with multiple sclerosis (Ballerini et al) 1995;38:314A

interrupted repeat configuration in expanded alleles from Machado-Joseph disease patients (Matsumura) 1995;38:292A

Allodynia; see Pain

Alpha-1 antichymotrypsin

alpha-1 antichymotrypsin genetic polymorphism modifies the risk of Alzheimer's disease conferred by the apolipoprotein E type 4 allele (DeKosky et al) 1995;38:282A

Alpha coma; see Coma

Alpha-tocopherol transfer protein

isolation and chromosome localization of the gene for human [alpha]-tocopherol transfer protein and identification of mutations in patients with familial vitamin E deficiency (Hentati et al) 1995;38:282A

Alternating hemiplegia of childhood; see Hemiplegia

Alzheimer's disease, diagnosis

apolipoprotein E genotyping in the diagnosis of Alzheimer's disease (Kamboh and DeKosky) (Letter); (Roses) (Reply); (Bird) (Reply) 1995;38:967

apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view (Kakulas and van Bockxmeer) (Letter); (Bird) (Reply) 1995;38:966

perfusion magnetic resonance imaging with echo planar imaging and signal targeting with alternating radiofrequency in Alzheimer's disease (Sandson et al) 1995;38:290A

proton magnetic resonance spectroscopy separates Alzheimer's disease and vascular dementia (Kattapong et al) 1995;38:291A

tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease (Arai et al) 1995;38:649

Alzheimer's disease, drug therapy

long-term treatment effects of tacrine in Alzheimer's disease patients (Pendlebury et al) 1995;38:291A

Alzheimer's disease, etiology

smoking and Alzheimer's disease: a case-control study (Rocca et al) 1995;38:326A

Alzheimer's disease, genetics

alpha-1 antichymotrypsin genetic polymorphism modifies the risk of Alzheimer's disease conferred by the apolipoprotein E type 4 allele (DeKosky et al) 1995;38:282A

apolipoprotein E in Alzheimer's disease (Wisniewski et al) 1995;38:324A

apolipoprotein E and Alzheimer's disease: trends in risk by age at onset (Waring et al) 1995;38:324A

apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives (Farrer et al) 1995;38:797

apolipoprotein E genotypes and age of onset in early-onset

familial Alzheimer's disease (Levy-Lahad et al) 1995;38:678

apolipoprotein E genotyping in the diagnosis of Alzheimer's disease (Kamboh and DeKosky) (Letter); (Roses) (Reply); (Bird) (Reply) 1995;38:967

apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view (Bird) 1995;38:2 (Editorial)

apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view (Kakulas and van Bockxmeer) (Letter); (Bird) (Reply) 1995;38:966

apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease (Roses) 1995;38:6 (Point of view)

case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome (van Gool et al) 1995;38:225

epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease (Sorbi et al) 1995;38:124

identification of a new Italian Alzheimer's disease family with APP717 mutation in which Apo E genotype correlates with age of onset (Sorbi et al) 1995;38:323A

immunoexpression of a polyclonal antibody directed against the S182 and E5-1 proteins (Lippa et al) 1995;38:972A

lack of an association between apolipoprotein E $\epsilon 4$ and Alzheimer's disease in elderly Nigerians (Osuntokun et al) 1995;38:463

molecular mimicry between cellular phenotypes of sporadic inclusion-body myositis, hereditary inclusion-body myopathy, Alzheimer's disease, and prion diseases (Askanas and Engel) 1995;38:282A

preclinical evaluation of a genetic risk factor for Alzheimer's disease II: neuropsychological studies (Caselli et al) 1995;38:291A

Alzheimer's disease, pathology

Alzheimer's disease: role of magnetic resonance imaging in the early diagnosis and modeling of disease progression (Manfredi et al) 1995;38:325A

Alzheimer's disease with and without Lewy bodies: can they be distinguished at initial presentation? (Lippa et al) 1995;38:290A

CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease (Chen et al) 1995;38:653

evolutionary analysis of tau-encoding transcripts: implications for Alzheimer's disease (Nelson et al) 1995;38:972A

frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease (Smith et al) 1995;38:194

overexpression of heme oxygenase-1 in Alzheimer's disease (Schipper et al) 1995;38:323A

reduction of β -amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease (Mottet et al) 1995;38:643

regional cerebral glucose metabolism at rest and during sensory stimulation in patients with Alzheimer's disease (Pietrini et al) 1995;38:324A

Alzheimer's disease, physiopathology

absolute versus semiquantitative technetium 99m hexamethylpropyleneamine oxime evaluation of regional cerebral blood flow pattern in Alzheimer's disease (Falcini et al) 1995;38:292A

brief neuropsychological instrument for the assessment of severely impaired Alzheimer's patients (Harrell et al) 1995;38:326A

Alzheimer's disease (continued)

- longitudinal analysis of aggressive behavior in Alzheimer's disease (Gilley et al) 1995;38:325A
- longitudinal changes in behavior in Alzheimer's disease (Swearer et al) 1995;38:291A
- variability in Mini-Mental State Examination scores at one-month retest: a consortium to establish a registry for Alzheimer's disease finding (Edland and Beekly) 1995;38:325A

Alzheimer's disease, psychology

- frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease (Smith et al) 1995;38:194

Alzheimer's disease, therapy

- gene therapy in primate correlative models of Alzheimer's disease: intraparenchymal nerve growth factor gene transfer prevents cholinergic degeneration (Tuszynski et al) 1995;38:289A

Amino acids

- cerebrospinal fluid excitatory amino acid levels in neurologically normal neonates (Nigam et al) 1995;38:539A

Amish

- Amish "children breast disease" with unusual nemaline rod myopathy (Crawford et al) 1995;38:539A

Amobarbital

- amytal test in pediatric neurology (Khan et al) 1995;38:552A

Amyloid beta-protein

- amyloid β -proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels (Shinkai et al) 1995;38:421
- intracerebral distribution of infectious amyloid protein in spongiform encephalopathy (Brown et al) 1995;38:245
- reduction of β -amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease (Mottet et al) 1995;38:643

Amyloid beta-protein precursor

- epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease (Sorbi et al) 1995;38:124
- exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy (Sivakumar et al) 1995;38:267

Amyotrophic lateral sclerosis

- apolipoprotein E ϵ 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis (Mui et al) 1995;38:460
- BDNF trial in ALS (Bradley) 1995;38:971A
- double-blind, placebo-controlled study of myotrophin (CEP-151) in the treatment of amyotrophic lateral sclerosis (Murphy et al) 1995;38:335A
- double-blind, placebo-controlled study of recombinant human insulin-like growth factor I in the treatment of amyotrophic lateral sclerosis (Lai et al) 1995;38:971A
- expression of unique genes in subtracted amyotrophic lateral sclerosis libraries (Rickert et al) 1995;38:293A
- hyaluronic acid is increased in the skin and urine in patients with amyotrophic lateral sclerosis (Ono and Yamauchi) 1995;38:326A
- immunoreactivities of nitric oxide synthase and nitrotyrosine in neurofilamentous spheroids and conglomerates of amyotrophic lateral sclerosis (Chou et al) 1995;38:293A
- oculomotor function in amyotrophic lateral sclerosis: evidence for frontal impairment (Shaunak et al) 1995;38:38
- selective loss of glial glutamate transporter GLT-1 in

amyotrophic lateral sclerosis (Rothstein et al) 1995;38:73

- studies of the high-affinity glutamate transporter cDNAs in amyotrophic lateral sclerosis (Meyer et al) 1995;38:328A

temporal distinction of spinal and bulbar stages of amyotrophic lateral sclerosis (ALS): validation with time-to-failure analysis employing ALS functional rating scale (Brooks et al) 1995;38:294A

Tuft's quantitative neuromuscular examination: high correlation with the sickness impact profile in measuring progression of amyotrophic lateral sclerosis (McGuire et al) 1995;38:336A

Amytal; see Amobarbital

Analgesia, patient-controlled

- neurological complications of patient-controlled analgesia (Lederman) 1995;38:298A

Anastomosis, surgical

- central motor reorganization after anastomosis of the musculocutaneous and intercostal nerves following cervical root avulsion (Mano et al) 1995;38:15

Aneurysm

- cerebrovascular complications in Ehlers-Danlos syndrome type IV (North et al) 1995;38:960

Angiography

- comparison of magnetic resonance angiography and magnetic resonance imaging in the evaluation of children with neurological conditions (Husain et al) 1995;38:524A

Angioplasty, transluminal

- carotid and vertebral artery angioplasty and stenting (Yadav et al) 1995;38:283A

Animal disease models; see Disease models, animal

Anosognosia

- hemichorea-athetosis, anosognosia, and hypomania: a unique triad resulting from left thalamic infarction (Gottfried and Balish) 1995;38:285A

Anoxia

- acute hypoxic-ischemic basal ganglia/thalamic injury in the term newborn: computed tomography and clinical syndrome (Rodriguez et al) 1995;38:544A
- adaptive mechanisms in developing brain: I. neuropathology (Ment et al) 1995;38:521A
- adaptive mechanisms in developing brain: II. effect of chronic hypoxia on neuronal excitability (O'Reilly et al) 1995;38:533A
- effect of pre-hypoxic-ischemic hypothermia and hyperthermia on brain damage in the immature rat (Yager and Asselin) 1995;38:502A
- effect of temperature on graded cerebral hypoxic-ischemic injury in immature rats (Trescher et al) 1995;38:503A
- global hypoxic-ischemic events increase the risk of dementia after stroke (Moroney et al) 1995;38:290A
- hypoxic-ischemic injury in the neonatal rat evaluated with magnetic resonance imaging (Filloux et al) 1995;38:503A
- mice without neuronal nitric oxide synthase have less injury after perinatal hypoxia-ischemia (Ferriero et al) 1995;38:504A
- postanoxic coma: good recovery despite myoclonus status (Arnoldus and Lammers) (Letter); (Wijdsicks et al) (Reply) 1995;38:697
- rolandic cerebral palsy as a pattern of hypoxic-ischemic injury in full-term neonates (Maller et al) 1995;38:557A

Anti-D β H-saporin; see Immunotoxins

Anti-Yo; see Antibodies

Antibodies

- acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides (Illa et al) 1995;38:218
 - acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system (Sel-lebjerg et al) 1995;38:943
 - anti-ganglioside GM₁ antibodies in Guillain-Barré syndrome and their relationship to *Campylobacter jejuni* infection (Rees et al) 1995;38:809
 - anti-GM₁ IgG antibodies and *Campylobacter* bacteria in Guillain-Barré syndrome: evidence of molecular mimicry (Oomes et al) 1995;38:170
 - anti-Hu antibodies in patients with small-cell lung cancer but no paraneoplastic disorder (Mason et al) 1995;38:341A
 - antibodies to copolymer 1 do not interfere with its clinical effect (Johnson et al) 1995;38:971A
 - antibodies to glutamate receptor subunit proteins in sera from patients with paraneoplastic cerebellar degeneration and type I ("anti-Yo") antibody response (Greenlee et al) 1995;38:283A
 - antibodies to two postsynaptic membrane cytoskeletal proteins in procainamide-induced myopathy (Agius et al) 1995;38:338A
 - antibody responses and central nervous system involvement in the hemolytic-uremic syndrome (Gleeson et al) 1995;38:519A
 - canine distemper virus-specific antibodies in multiple sclerosis (Rohowsky-Kochan et al) 1995;38:339A
 - chronic inflammatory demyelinating polyneuropathy associated with small-cell lung cancer and Hu antibodies (Einberg et al) 1995;38:306A
 - GM1b is a new member of antigen specifically recognized by serum antibody in Guillain-Barré syndrome (Kusunoki et al) 1995;38:338A
 - Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites (Manley et al) 1995;38:102
 - identification of the Huntington's disease protein in rat, monkey, and human using antifusion protein antibodies (Hersch et al) 1995;38:298A
 - immunoexpression of a polyclonal antibody directed against the S182 and E5-1 proteins (Lippa et al) 1995;38:972A
 - model to predict anticardiolipin antibody positivity in adults under age 60 with transient focal neurological events (Tietjen et al) 1995;38:323A
 - specificity and titer distribution of anticardiolipin antibodies in brain disease (Levine et al) 1995;38:322A
 - spectrum of motor system disorders associated with anti-ganglioside antibodies (Bernath and Salazar-Grueso) 1995;38:307A
- ## Anticonvulsants
- barbiturate anticonvulsants: a psychometric and quantitative electroencephalographic study (Willis et al) 1995;38:515A
 - identifying children at high risk for idiosyncratic anticonvulsant drug reactions: the calculated oxidative protection ratios (Glauser et al) 1995;38:543A
 - status epilepticus and anti-epileptic medication levels in children (Maytal et al) 1995;38:513A
 - topiramate: a new anti-epileptic drug with success in children (Rosenfeld) 1995;38:555A
- ## Antiepileptics; see Anticonvulsants

Antifusion protein antibodies; see Antibodies

Antigens

- GM1b is a new member of antigen specifically recognized by serum antibody in Guillain-Barré syndrome (Kusunoki et al) 1995;38:338A
 - Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites (Manley et al) 1995;38:102
- ## Antioxidants
- cellular protective effect of bcl-2 against dopamine-induced apoptosis: an association with anti-oxidant pathways (Offen et al) 1995;38:328A
 - effect of age, race, and gender on anti-oxidant defenses in healthy children (Glauser et al) 1995;38:543A
- ## Antiphospholipid syndrome
- recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome (Levine et al) 1995;38:119
- ## Antiretroviral agents
- effect of antiretroviral therapy on neurodevelopment in human immunodeficiency virus-infected children (Legido et al) 1995;38:531A
- ## Antisense oligonucleotides; see Oligonucleotides, antisense
- ## Antisulfatide IgG; see IgG
- ## Aphasia
- aphasia in acute stroke: incidence, determinants, and recovery (Pedersen et al) 1995;38:659
 - crossed-conduction aphasia with impairment of visuospatial memory: a case report (Stefanis et al) 1995;38:285A
- ## Aphasia, acquired
- Landau-Kleffner syndrome: glucose metabolism patterns in 17 children (da Silva and Chugani) 1995;38:510A
 - regression in pervasive developmental disorders: is there a relationship with Landau-Kleffner syndrome? (Tuchman) 1995;38:526A
 - superoxide dismutase over activity, excessive selenium, and low copper in acquired epileptic aphasia (the Landau-Kleffner syndrome) (Chez et al) 1995;38:544A
- ## Apolipoprotein E
- alpha-1 antichymotrypsin genetic polymorphism modifies the risk of Alzheimer's disease conferred by the apolipoprotein E type 4 allele (DeKosky et al) 1995;38:282A
 - apolipoprotein E in Alzheimer's disease (Wisniewski et al) 1995;38:324A
 - apolipoprotein E and Alzheimer's disease: trends in risk by age at onset (Waring et al) 1995;38:324A
 - apolipoprotein E ϵ 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis (Mui et al) 1995;38:460
 - apolipoprotein E ϵ 4 and cerebral hemorrhage associated with amyloid angiopathy (Greenberg et al) 1995;38:254 (Expedited publication)
 - apolipoprotein E ϵ 4 and fatal cerebral amyloid angiopathy associated with dementia pugilistica (Jordan et al) 1995;38:698 (Letter)
 - apolipoprotein E ϵ 4 in inclusion body myositis (Garlepp et al) 1995;38:957
 - apolipoprotein E genotype in diverse neurodegenerative disorders (Schneider et al) 1995;38:131
 - apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives (Farrer et al) 1995;38:797
 - apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease (Levy-Lahad et al) 1995;38:678
 - apolipoprotein E genotyping in the diagnosis of Alzheimer's

Apolipoprotein E (*continued*)

- mer's disease (Kamboh and DeKosky) (Letter); (Roses) (Reply); (Bird) (Reply) 1995;38:967
- apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view (Bird) 1995;38:2 (Editorial)
- apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view (Kakulas and van Bockxmeer) (Letter); (Bird) (Reply) 1995;38:966
- apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease (Roses) 1995;38:6 (Point of view)
- apolipoprotein E type 4 allele and risk of intracerebral hemorrhage associated with cerebral amyloid angiopathy (Greenberg et al) 1995;38:285A
- case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome (van Gool et al) 1995;38:225
- epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease (Sorbi et al) 1995;38:124
- generation of human apolipoprotein E isoform-specific transgenic mice (Xu et al) 1995;38:290A
- identification of a new Italian Alzheimer's disease family with APP717 mutation in which Apo E genotype correlates with age of onset (Sorbi et al) 1995;38:323A
- lack of an association between apolipoprotein E ϵ 4 and Alzheimer's disease in elderly Nigerians (Osuntokun et al) 1995;38:463
- preclinical evaluation of a genetic risk factor for Alzheimer's disease II: neuropsychological studies (Caselli et al) 1995;38:291A

Apolipoprotein(a)

- apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels (Jamieson et al) 1995;38:287A

Apomorphine

- controlled clinical trial of intranasal apomorphine as rescue therapy for "off" periods in fluctuating Parkinson's disease (Dewey et al) 1995;38:329A

Apoptosis; see Cell death

Apraxia

- axial and limb apraxia in progressive supranuclear palsy (Lindholm et al) 1995;38:301A

Ara-C; see Cytarabine

Arrhythmia, sinus

- respiratory sinus arrhythmia in children with severe cyanotic and pallid breath-holding spells (DiMario et al) 1995;38:512A

Astrocytes

- abnormal neuronal activity can alter astrocytic gene expression: spreading depression upregulates mRNA for glial fibrillary acidic protein (Bonthius et al) 1995;38:501A
- astrocyte factors regulate substance P in sensory neurons (Adler and Skoff) 1995;38:309A
- genetically transformed astrocytes from adult and aged animals as donors for cell replacement therapy (Azizi) 1995;38:311A
- lymphocyte costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture (Satoh et al) 1995;38:314A
- parkinsonism associated with neurofibrillary tangles and tufted astrocytes (Handler et al) 1995;38:301A

Astrocytoma

- early diagnosis of giant-cell astrocytoma in patients with tuberous sclerosis complex (Torres et al) 1995;38:528A

Ataxia

- celiac disease presenting as gait disturbance and ataxia in infancy (Sum et al) 1995;38:526A

- familial paroxysmal ataxia (Lewis et al) 1995;38:532A
- periodic ataxia with myokymia syndrome (Comu et al) 1995;38:545A

- sensory ataxic neuropathy as the predominant manifestation of multiple mitochondrial DNA deletions (Johns et al) 1995;38:282A

Atherosclerosis

- apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels (Jamieson et al) 1995;38:287A

Athetosis

- hemichorea/athetosis, anosognosia, and hypomania: a unique triad resulting from left thalamic infarction (Gottfried and Balish) 1995;38:285A

ATPase; see Adenosine triphosphatase

Atrophy

- olivopontocerebellar atrophy (Coplin and Bird) (Letter); (Rinne et al) (Reply) 1995;38:965
- reversible dementia and apparent brain atrophy during valproate therapy (Papazian et al) 1995;38:687

Attention

- interactions of attention and cognitive ability with school performance: a twin study (Klein et al) 1995;38:532A

Attention deficit disorder with hyperactivity

- attention-deficit hyperactivity disorder in epileptic children: a new indication for methylphenidate? (Finck et al) 1995;38:520A
- evidence against a deficit in sustaining attention in children with attention-deficit hyperactivity disorder (Denckla et al) 1995;38:516A
- morphology of the corpus callosum in children with Tourette's syndrome and attention-deficit hyperactivity disorder (Singer et al) 1995;38:509A
- neuropsychological performance of children with attention-deficit hyperactivity disorder with and without reading disability (Reader et al) 1995;38:516A
- neuropsychological status of children with Tourette's syndrome with and without attention-deficit hyperactivity disorder (Schuerholz et al) 1995;38:515A
- parcellating prefrontal functions: comparison of diagnostic efficiency of prefrontal tasks in attention-deficit hyperactivity disorder (Voeller and Edge) 1995;38:508A
- speed of coordination in children with Tourette's syndrome (TS), attention-deficit hyperactivity disorder (ADHD), and TS plus ADHD (Denckla et al) 1995;38:515A

Atypical teratoid tumor; see Teratoma

Audiovisual stimulation; see Acoustic stimulation; Photic stimulation

Auditory evoked potentials; see Evoked potentials, auditory

Aurintricarboxylic acid

- endonuclease inhibitor aurintricarboxylic acid protects from transient neuronal ischemia (Rosenbaum et al) 1995;38:320A

Autism

- serum immunoglobulins and autoimmune profiles in children with autism (Zimmerman et al) 1995;38:528A

Autoantibodies

- acquired neuromyotonia: evidence for autoantibodies directed against K⁺ channels of peripheral nerves (Shillito et al) 1995;38:714
- association of inclusion body myositis with autoimmune diseases and autoantibodies (Rugiero et al) 1995;38:333A
- autoantibodies in childhood opsoclonus-myoclonus syndrome (Connolly et al) 1995;38:505A

Autoimmune diseases

- association of inclusion body myositis with autoimmune

- diseases and autoantibodies (Rugiero et al) 1995; 38:333A
- neuromyotonia: a new autoimmune disease (Layzer) 1995; 38:701 (Editorial)
- serum immunoglobulins and autoimmune profiles in children with autism (Zimmerman et al) 1995;38:528A
- Autoimmune T-cells; see T-lymphocytes**
- Autoimmunity**
- absence of glutamic acid decarboxylase autoimmunity in symptomatic palatal tremor (Davenport et al) 1995;38:274 (Letter)
- Autonomic neuropathies; see Neuropathies, autonomic**
- Autosomal recessive limb-girdle muscular dystrophy; see Muscular dystrophy**
- Axons**
- acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides (Illa et al) 1995;38:218
- developmental expression of guidance molecules direct axon growth in the cerebellum (Bicknese et al) 1995; 38:499A
- idiopathic axonal neuropathy responsive to immunosuppression (Slogosky et al) 1995;38:336A
- mechanism of paralysis and recovery in post-*Campylobacter* acute motor axonal neuropathy (Ho et al) 1995; 38:350A
- multifocal noninflammatory progressive axonal neuropathy without conduction block (Zifko et al) 1995;38:337A
- Penner's serotype 19 *Campylobacter jejuni* lipopolysaccharide isolated from a patient with acute motor axonal neuropathy bears L2/HNK1 and GM1 epitopes (Sheikh et al) 1995;38:350A
- plastic brain (Hallett) 1995;38:4 (Editorial)
- Baclofen**
- alternating hemiplegia of childhood and beneficial effects of baclofen (Awaad et al) 1995;38:550A
- Barbiturates**
- barbiturate anticonvulsants: a psychometric and quantitative electroencephalographic study (Willis et al) 1995; 38:515A
- Basal forebrain; see Prosencephalon**
- Basal ganglia**
- acute hypoxic-ischemic basal ganglia/thalamic injury in the term newborn: computed tomography and clinical syndrome (Rodriguez et al) 1995;38:544A
- decreased glutamate receptor density in the basal ganglia in Rett syndrome (Blue et al) 1995;38:531A
- Bcl-2; see Oncogene products**
- BDNF**
- BDNF trial in ALS (Bradley) 1995;38:971A
- Behavior disorders; see Mental disorders**
- Behavioral slowing**
- behavioral slowing with age: boundary conditions of the generalized slowing model (Swearer and Kane) 1995; 38:325A
- Benzodiazepine receptors; see Receptors, GABA-benzodiazepine**
- Beta-N-oxalylamino-L-alanine**
- beta-N-oxalylamino-L-alanine toxicity on motoneuron-hybrid cells (La Bella et al) 1995;38:327A
- Biceps brachii muscle**
- central motor reorganization after anastomosis of the musculocutaneous and intercostal nerves following cervical root avulsion (Mano et al) 1995;38:15
- Bilirubin**
- somatosensory and brainstem auditory-evoked potentials in an experimental model of acute bilirubin neurotoxicity (Shapiro) 1995;38:553A
- Biopsy**
- reducing laboratory costs in the workup of neurometabolic diseases: role for skin biopsy as a rapid diagnostic tool in lysosomal storage disorders (Prasad et al) 1995; 38:534A
- Blindness**
- role of reading activity on the modulation of motor cortical outputs to the reading hand in Braille readers (Pascual-Leone et al) 1995;38:910
- Blood-brain barrier**
- food dyes do not cross the blood-brain barrier: a pediatric myth contested (Makary et al) 1995;38:538A
- neurotoxicity of chemotherapeutic agents and immunconjugates delivered after blood-brain barrier modification: neuropathological studies (Mass et al) 1995; 38:342A
- Blood flow velocity**
- detection of flow velocity and flow direction in the posterior communicating artery by transcranial color-coded duplex sonography (Popescu et al) 1995;38:321A
- prognostic significance of middle cerebral artery blood flow velocity patterns in pediatric brain injury (Truemper and Fischer) 1995;38:553A
- Blood vessels**
- amyloid β -proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels (Shinkai et al) 1995;38:421
- Body temperature**
- clinical and immunological effects of cooling in multiple sclerosis (Coyle et al) 1995;38:312A
- cooling and multiple sclerosis: an auditory-evoked potential and neuropsychological analysis (Geisler et al) 1995; 38:345A
- effects of body temperature on myoclonus in a rat pup model (Trifiletti and Bolan) 1995;38:524A
- Bone density**
- effect of corticosteroid pulses on bone density in multiple sclerosis (Schwid et al) 1995;38:338A
- Bone marrow transplantation**
- acute neurological dysfunction in children with brain tumors treated with high-dose chemotherapy with autologous bone marrow rescue: incidence, etiology, and outcome (Kramer et al) 1995;38:533A
- Bone morphogenetic protein**
- bone morphogenetic protein regulation of neural development (Mabie et al) 1995;38:310A
- Book reviews**
- Companion to Clinical Neurology*, by Pryse-Phillips (Fishman) 1995;38:484
- Disorders of Voluntary Muscle*, ed 6, edited by Walton et al (Layzer) 1995;38:136
- Ethical Issues in Neurology*, by Bernat (Smith) 1995;38:484
- Evaluation and Treatment of Myopathies*, by Griggs et al (Engel) 1995;38:484
- Handbook of Dystonia. Neurological Disease and Therapy Series, No 39*, edited by Tsui and Calne (Aminoff) 1995; 38:484
- Pediatric Neuropathology* edited by Duckett (Ferriero) 1995;38:136
- Books received**
- books received 1995;38:136, 485
- Borrelia burgdorferi***
- neuroborreliosis in the nonhuman primate: *Borrelia burgdorferi* persists in the central nervous system (Pachner et al) 1995;38:667

Botulinum toxins

- botulinum toxin injection for tongue protrusion (Charles et al) 1995;38:299A
- change in quality of life in cerebral palsy children after botulinum toxin type A injection (Awaad et al) 1995;38:550A
- open-label use of botulinum A in the management of children with spastic hemiplegia or diplegia (Russman et al) 1995;38:522A

Braille reading; see Blindness

Brain, blood supply

- absolute versus semiquantitative technetium 99m hexamethylpropyleneamine oxime evaluation of regional cerebral blood flow pattern in Alzheimer's disease (Falcini et al) 1995;38:292A

Brain, drug effects

- reversible dementia and apparent brain atrophy during valproate therapy (Papazian et al) 1995;38:687

Brain, growth and development

- adaptive mechanisms in developing brain: I. neuropathology (Ment et al) 1995;38:521A
- adaptive mechanisms in developing brain: II. effect of chronic hypoxia on neuronal excitability (O'Reilly et al) 1995;38:533A
- adaptive mechanisms in developing brain: III. metabolism (Novotny et al) 1995;38:533A
- prenatal and early postnatal abnormalities of Down syndrome brain development and maturation (Wisniewski and Kida) 1995;38:536A

Brain, metabolism

- adaptive mechanisms in developing brain: III. metabolism (Novotny et al) 1995;38:533A
- cellular activity underlying altered brain metabolism during focal epileptic activity (Bruehl and Witte) 1995;38:414
- cerebral transport and metabolism of $1\text{-}^{11}\text{C}$ -D-glucose during stepped hypoglycemia (Powers et al) 1995;38:599

Brain, physiology

- plastic brain (Hallett) 1995;38:4 (Editorial)

Brain injuries

- positron emission tomography hypermetabolism in radiotherapy-induced brain injury (O'Neill et al) 1995;38:344A
- prognostic significance of middle cerebral artery blood flow velocity patterns in pediatric brain injury (Truemper and Fischer) 1995;38:533A

Brain neoplasms

- acute neurological dysfunction in children with brain tumors treated with high-dose chemotherapy with autologous bone marrow rescue: incidence, etiology, and outcome (Kramer et al) 1995;38:533A
- childhood atypical teratoid tumors: an expanding clinical spectrum in older children (Packer and Rorke) 1995;38:518A
- measuring quality of life in brain tumor patients: methodological issues and priorities for research (Perry) 1995;38:344A
- Pneumocystis carinii* pneumonia is associated with lymphopenia in brain tumor patients (Schiff) 1995;38:343A
- positron emission tomographic evaluation of glucose metabolism in childhood brain tumors (Smietana et al) 1995;38:551A
- presentation and initial neuroradiological findings in 38 infants with intracranial ependymomas (Comi et al) 1995;38:527A
- prognostic factors in infants with ependymomas (Duffner et al) 1995;38:546A
- relapse of primary brain tumors in infants following postoperative chemotherapy: magnetic resonance imaging

surveillance and salvage therapy (Fisher et al) 1995;38:517A

Brain stem

- brainstem lesions in children with neurofibromatosis type 1 (Weinstock et al) 1995;38:529A
- brainstem syndrome associated with cytomegalovirus encephalitis in acquired immunodeficiency syndrome (Simpson et al) 1995;38:347A
- carboplatin as a radiopotentiating agent for newly diagnosed children with brainstem gliomas (Allen et al) 1995;38:553A
- significance of gadolinium-pentetic acid contrast enhancement and thallium-201 chloride uptake in pediatric brainstem gliomas (Maria et al) 1995;38:514A

Brainstem auditory evoked potentials; see Evoked potentials, auditory, brainstem

Breath-holding spells

- breath-holding spells and prolonged seizures (Moorjani et al) 1995;38:512A
- respiratory sinus arrhythmia in children with severe cyanotic and pallid breath-holding spells (DiMario et al) 1995;38:512A

CADASIL; see Cerebral artery diseases

Campylobacter

- anti-GM₁ IgG antibodies and *Campylobacter* bacteria in Guillain-Barré syndrome: evidence of molecular mimicry (Oomes et al) 1995;38:170

Campylobacter jejuni

- anti-ganglioside GM₁ antibodies in Guillain-Barré syndrome and their relationship to *Campylobacter jejuni* infection (Rees et al) 1995;38:809
- mechanism of paralysis and recovery in post-*Campylobacter* acute motor axonal neuropathy (Ho et al) 1995;38:350A
- patterns of recovery in different forms of the Guillain-Barré syndrome associated with *Campylobacter jejuni* (Ho et al) 1995;38:336A
- Penner's serotype 19 *Campylobacter jejuni* lipopolysaccharide isolated from a patient with acute motor axonal neuropathy bears L2/HNK1 and GM1 epitopes (Sheikh et al) 1995;38:350A

Cancer; see Neoplasms

Canine distemper virus; see Distemper virus, canine

Carbamazepine

- carbamazepine rectal administration: safety and effectiveness in induction and maintenance (Selcen et al) 1995;38:550A

Carbidopa

- liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation (Pappert et al) 1995;38:298A

Carboplatin

- carboplatin as a radiopotentiating agent for newly diagnosed children with brainstem gliomas (Allen et al) 1995;38:553A

Carcinogenesis; see Neoplasms

Carcinoma, oat cell

- anti-Hu antibodies in patients with small-cell lung cancer but no paraneoplastic disorder (Mason et al) 1995;38:341A
- chronic inflammatory demyelinating polyneuropathy associated with small-cell lung cancer and Hu antibodies (Einberg et al) 1995;38:306A

Carotid artery

- carotid and vertebral artery angioplasty and stenting (Yadav et al) 1995;38:283A

Catheterization

treatment of dural sinus thrombosis using selective catheterization and urokinase (Horowitz et al) 1995;38:58

Celiac disease

celiac disease presenting as gait disturbance and ataxia in infancy (Sum et al) 1995;38:526A

Cell adhesion

enhanced endothelial cell adhesion of human cerebrospinal fluid lymphocytes (Elfont et al) 1995;38:405

Cell adhesion molecules

circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging (Harrung et al) 1995;38:186

developmental expression of guidance molecules direct axon growth in the cerebellum (Bicknese et al) 1995;38:499A

Cell death

apoptosis in inherited neurodegenerative diseases (Boustany et al) 1995;38:525A

cellular protective effect of bcl-2 against dopamine-induced apoptosis: an association with anti-oxidant pathways (Offen et al) 1995;38:328A

cyclosporin-A induces apoptosis in culture cortical neurons (McDonald et al) 1995;38:307A

effects of tumor necrosis factor- α and platelet-activating factor, human immunodeficiency virus-type 1-induced neurotoxins, on pro-apoptosis gene products in primary human neuronal cultures (Perry et al) 1995;38:551A

evidence of DNA fragmentation and immediate early gene induction in naturally occurring, ischemic, and x-ray-induced cell death in the developing brain (Macaya et al) 1995;38:554A

immediate early gene induction by programmed cell death in skeletal muscle (Abu-Shakra et al) 1995;38:307A

insulin-like growth factor-II prevents *cis*-platinum and etoposide-induced apoptosis in human neuroblastoma cells (Singleton et al) 1995;38:342A

intracellular and extracellular oxidant injury lead to cell death by different mechanisms (Rosenbaum et al) 1995;38:287A

nerve growth factor-mediated resistance of neuroblastoma to chemotherapeutic-induced apoptosis: the role of the low-affinity receptor (Cortazzo et al) 1995;38:517A

neural apoptosis (Bredesen) 1995;38:839 (Neurological progress)

neurotrophins brain-derived neurotrophic factors, NT-4/5, and NT-3 protect injured skeletal muscle from cell death (Alhalabi and Abu-Shakra) 1995;38:332A

oligodendrocyte death induced by cystine deprivation occurs via apoptosis (Back et al) 1995;38:502A

programmed cell death in multiple sclerosis patients (Dowling et al) 1995;38:341A

Cell replacement therapy

genetically transformed astrocytes from adult and aged animals as donors for cell replacement therapy (Azizi) 1995;38:311A

Cellular inclusions

apolipoprotein E $\epsilon 4$ in inclusion body myositis (Garlepp et al) 1995;38:957

association of inclusion body myositis with autoimmune diseases and autoantibodies (Rugiero et al) 1995;38:333A

exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy (Sivakumar et al) 1995;38:267

inclusion body myositis and myopathies (Griggs et al) 1995;38:705 (Neurological progress)

role of quantitative electromyography in inclusion body myositis (Brannagan et al) 1995;38:334A

Central alveolar hypoventilation syndrome; see Sleep apnea syndromes

Central nervous system, physiopathology

catastrophic central nervous system dysfunction during methylprednisolone injection for refractory pain syndromes: report of 2 cases (Siller et al) 1995;38:297A

Central nervous system neoplasms

leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications (Balmaceda et al) 1995;38:202

Cerebellar ataxia

autosomal-dominant cerebellar ataxia linked to SCA3 in German families (Klockgether et al) 1995;38:299A

Cerebellar diseases

benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography (Gilman et al) 1995;38:176

cerebellar mutism in children: report of seven cases and potential mechanisms (Koh et al) 1995;38:510A

cerebellar outflow lesions: a comparison of movement deficits resulting from lesions at the levels of the cerebellum and thalamus (Bastian and Thach) 1995;38:881

clinical features of developmental disability associated with cerebellar hypoplasia (Shevell and Majnemer) 1995;38:528A

multislice proton magnetic resonance spectroscopic imaging in cerebellar degeneration (Tedeschi et al) 1995;38:328A

ondansetron for disabling cerebellar tremor (Rice et al) 1995;38:973A

Cerebellar nuclei

depth electrode studies and intracellular dentate granule cell recordings in temporal lobe epilepsy (Williamson et al) 1995;38:778

motor effects of stimulating deep brain nuclei in awake cooperating human subjects (Ashby et al) 1995;38:330A

Cerebellum, growth and development

gene expression within the developing rat cerebellum (Narayanan et al) 1995;38:545A

Cerebellum, injuries

recovery of hypermetria after a cerebellar stroke occurs as a multistage process (Manto et al) 1995;38:437

Cerebellum, metabolism

ontogeny of glucose metabolism in the human cerebellum (Shamoto et al) 1995;38:543A

Cerebral amyloid angiopathy

amyloid β -proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels (Shinkai et al) 1995;38:421

apolipoprotein E $\epsilon 4$ and cerebral hemorrhage associated with amyloid angiopathy (Greenberg et al) 1995;38:254 (Expedited publication)

apolipoprotein E $\epsilon 4$ and fatal cerebral amyloid angiopathy associated with dementia pugilistica (Jordan et al) 1995;38:698 (Letter)

apolipoprotein E type 4 allele and risk of intracerebral hemorrhage associated with cerebral amyloid angiopathy (Greenberg et al) 1995;38:285A

Cerebral angiography

source of transcranial Doppler signals during cerebral and coronary angiography and its significance (Khan et al) 1995;38:288A

Cerebral arteries

prognostic significance of middle cerebral artery blood flow velocity patterns in pediatric brain injury (Truemper and Fischer) 1995;38:553A

Cerebral artery diseases

familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL) (Hutchinson et al) 1995;38:817

Italian kindred with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (Ragno et al) 1995;38:231

Cerebral blood flow; see Brain, blood supply

Cerebral cortex

cortical control of double-step saccades: implications for spatial orientation (Heide et al) 1995;38:739

mathematical model of neocortical neuronogenesis (Takahashi and Caviness) 1995;38:529A

Cerebral decortication

fibronectin expression measured by Western blot following unilateral hemidecortication and frontal decortication in developing rat brain (Shamoto et al) 1995;38:542A

Cerebral hemorrhage

apolipoprotein E $\epsilon 4$ and cerebral hemorrhage associated with amyloid angiopathy (Greenberg et al) 1995;38:254 (Expedited publication)

apolipoprotein E type 4 allele and risk of intracerebral hemorrhage associated with cerebral amyloid angiopathy (Greenberg et al) 1995;38:285A

effect of intraventricular blood on global cortical perfusion in acute intracerebral hemorrhage: a single-photon emission computed tomographic study (Mayer et al) 1995;38:288A

intracerebral hemorrhage versus infarction: stroke severity, risk factors, and prognosis (Jørgensen et al) 1995;38:45

localization and etiology of intracerebral hemorrhage in young adults: the Baltimore Washington Cooperative Young Stroke Study (Sloan et al) 1995;38:289A

neurodevelopmental outcome of infants with bilateral cystic periventricular leukomalacia is worse than outcome of infants with intraventricular hemorrhage and intraparenchymal echodensity (Perlman et al) 1995;38:548A

Cerebral infarction

effects of Citicholine on infarct volume, mortality, and behavioral outcome after temporary focal ischemia (Fisher et al) 1995;38:287A

intracerebral hemorrhage versus infarction: stroke severity, risk factors, and prognosis (Jørgensen et al) 1995;38:45

intracranial vasculopathy and cerebral infarction in a patient with hepatitis C virus and mixed cryoglobulinemia (Petty and Duffy) 1995;38:323A

Italian kindred with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (Ragno et al) 1995;38:231

stroke mechanisms in large subcortical infarctions (Horowitz and Tuhim) 1995;38:289A

suppression of TNF- α by antisense oligodeoxynucleotide enhanced TGF- β_1 mRNA expression, correlating with enlarged infarct volume following cerebral ischemia in the rat (Zhai et al) 1995;38:973A

varicella with delayed cerebral infarction: a series of six cases (Sutton et al) 1995;38:548A

Cerebral ischemia, drug therapy

effect of magnesium on ischemic brain lesions in the preterm infant (FineSmith et al) 1995;38:504A

effects of Citicholine on infarct volume, mortality, and behavioral outcome after temporary focal ischemia (Fisher et al) 1995;38:287A

neuroprotective effects of lamotrigine in global ischemia in gerbils: a histological, behavioral, and microdialysis study (Shuaib et al) 1995;38:351A

Cerebral ischemia, pathology

acute hypoxic-ischemic basal ganglia/thalamic injury in the term newborn: computed tomography and clinical syndrome (Rodriguez et al) 1995;38:544A

heat shock protein expression does not alone explain the induction of ischemic tolerance in rat brain (Simon et al) 1995;38:286A

hypoxic-ischemic injury in the neonatal rat evaluated with magnetic resonance imaging (Filloux et al) 1995;38:503A

inducible nitric oxide synthase (iNOS) gene expression contributes to cerebral ischemic damage: a novel approach to stroke treatment using an iNOS inhibitor (Iadecola et al) 1995;38:286A

mice without neuronal nitric oxide synthase have less injury after perinatal hypoxia-ischemia (Ferriero et al) 1995;38:504A

protein S and protein C deficiency in children with ischemic cerebral vascular accident (Koh et al) 1995;38:556A

rolandic cerebral palsy as a pattern of hypoxic-ischemic injury in full-term neonates (Maller et al) 1995;38:557A

suppression of TNF- α by antisense oligodeoxynucleotide enhanced TGF- β_1 mRNA expression, correlating with enlarged infarct volume following cerebral ischemia in the rat (Zhai et al) 1995;38:973A

Cerebral ischemia, physiopathology

global hypoxic-ischemic events increase the risk of dementia after stroke (Moroney et al) 1995;38:290A

Cerebral ischemia, prevention and control

effect of pre-hypoxic-ischemic hypothermia and hyperthermia on brain damage in the immature rat (Yager and Asselin) 1995;38:502A

effect of temperature on graded cerebral hypoxic-ischemic injury in immature rats (Trescher et al) 1995;38:503A

neutrophil inhibitory factor is neuroprotective after focal ischemia in rats (Jiang et al) 1995;38:935

Cerebral ischemia, transient

endonuclease inhibitor aurintricarboxylic acid protects from transient neuronal ischemia (Rosenbaum et al) 1995;38:320A

model to predict anticardiolipin antibody positivity in adults under age 60 with transient focal neurological events (Tietjen et al) 1995;38:323A

occurrence of patent foramen ovale in acute stroke and transient ischemic attacks using transcranial Doppler ultrasonography (Yeung et al) 1995;38:320A

role of nitric oxide during reperfusion injury in a model of transient focal cerebral ischemia in the rat pup (Ashwal et al) 1995;38:552A

Cerebral palsy

change in quality of life in cerebral palsy children after botulinum toxin type A injection (Awaad et al) 1995;38:550A

clinical antecedents of cerebral palsy, mental retardation, and hearing loss in survivors of severe, progressive respiratory failure treated with extracorporeal membrane oxygenation (Graziani et al) 1995;38:540A

hypoplasia of the corpus callosum and cerebral palsy (Sheth et al) 1995;38:516A

intrapartum electronic fetal monitoring and cerebral palsy in a population-based study (Ting et al) 1995;38:504A

- rolandic cerebral palsy as a pattern of hypoxic-ischemic injury in full-term neonates (Maller et al) 1995;38:557A
- Cerebral sclerosis, diffuse**
 overexpression of DM20 messenger RNA in two brothers with Pelizaeus-Merzbacher disease (Carango et al) 1995;38:610
 overexpression of DM20 mRNA in two brothers with Pelizaeus-Merzbacher disease (Marks et al) 1995;38:514A
 X-linked spastic paraparesis secondary to Pelizaeus-Merzbacher disease and coincidental lysinuria (Naidu and Hodes) 1995;38:295A
- Cerebrospinal fluid**
 enhanced endothelial cell adhesion of human cerebrospinal fluid lymphocytes (Elfont et al) 1995;38:405
 influx of nonactivated T lymphocytes into the cerebrospinal fluid during relapse of multiple sclerosis (Oksaranta et al) 1995;38:465
 neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis (Freilich et al) 1995;38:51
 reduction of β -amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease (Mottet et al) 1995;38:643
 tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease (Arai et al) 1995;38:649
- Cerebrospinal fluid pressure**
 syndrome of low cerebrospinal fluid pressure headaches and pachymeningeal gadolinium enhancement on magnetic resonance imaging (Mokri et al) 1995;38:297A
- Cerebrotendinous xanthomatosis; see Xanthomatosis**
- Cerebrovascular disorders, complications**
 impact of dehydration on outcome of acute ischemic stroke (Chang et al) 1995;38:321A
- Cerebrovascular disorders, ethnicity**
 stroke recurrence is more frequent in Blacks and Hispanics (Sheinart et al) 1995;38:289A
- Cerebrovascular disorders, etiology**
 cerebrovascular complications in Ehlers-Danlos syndrome type IV (North et al) 1995;38:960
 impact of the extent of evaluation on stroke management (Burch et al) 1995;38:321A
 localization and etiology of intracerebral hemorrhage in young adults: the Baltimore Washington Cooperative Young Stroke Study (Sloan et al) 1995;38:289A
 occurrence of patent foramen ovale in acute stroke and transient ischemic attacks using transcranial Doppler ultrasonography (Yeung et al) 1995;38:320A
 paradoxical embolism is the most frequent cause of juvenile stroke (Klötzsch et al) 1995;38:288A
 recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome (Levine et al) 1995;38:119
 stroke mechanisms in large subcortical infarctions (Horowitz and Tuhim) 1995;38:289A
- Cerebrovascular disorders, immunology**
 specificity and titer distribution of anticardiolipin antibodies in brain disease (Levine et al) 1995;38:322A
- Cerebrovascular disorders, mortality**
 computed tomographic criteria for early fatal outcome in acute stroke (Pulicino et al) 1995;38:319A
- Cerebrovascular disorders, pathology**
 matrix metalloproteinases and urokinase increase in stroke in rat (Rosenberg et al) 1995;38:322A
- Cerebrovascular disorders, physiopathology**
 aphasia in acute stroke: incidence, determinants, and recovery (Pedersen et al) 1995;38:659
 global hypoxic-ischemic events increase the risk of dementia after stroke (Moroney et al) 1995;38:290A
- intracerebral hemorrhage versus infarction: stroke severity, risk factors, and prognosis (Jørgensen et al) 1995;38:45
 quality of life after ischemic stroke: the Northern Manhattan Stroke Study (Sacco et al) 1995;38:322A
- Cerebrovascular disorders, prevention and control**
 prothrombin fragment 1+2: a risk factor for ischemic stroke (Kargman et al) 1995;38:320A
- Cerebrovascular disorders, rehabilitation**
 recovery of cognitive function after stroke (Desmond et al) 1995;38:287A
 recovery of hypermetria after a cerebellar stroke occurs as a multistage process (Manto et al) 1995;38:437
- Cerebrovascular disorders, therapy**
 impact of consulting with stroke specialists in ambulatory clinical practice (Gomez et al) 1995;38:320A
 impact of the extent of evaluation on stroke management (Burch et al) 1995;38:321A
 inducible nitric oxide synthase (iNOS) gene expression contributes to cerebral ischemic damage: a novel approach to stroke treatment using an iNOS inhibitor (Iadecola et al) 1995;38:286A
- Cerebrum, growth and development**
 oligodendroglial development in human fetal cerebrum (Rivkin et al) 1995;38:92
- Cervical dystonia; see Dystonia**
- Charcot-Marie disease**
 immunohistochemical study of peripheral myelin protein 22 on biopsied nerves of patients with Charcot-Marie-Tooth disease type 1A (Nishimura et al) 1995;38:334A
- Child development disorders, pervasive**
 regression in pervasive developmental disorders: is there a relationship with Landau-Kleffner syndrome? (Tuchman) 1995;38:526A
- Children breast disease; see Funnel chest**
- Cholinergic fibers**
 destruction of the cholinergic basal forebrain in rats using immunotoxin (Wiley et al) 1995;38:327A
- Chorea**
 hemichorea/athetosis, anosognosia, and hypomania: a unique triad resulting from left thalamic infarction (Gottfried and Balish) 1995;38:285A
- Chromosome deletion**
 deletion analysis of the survival motor neuron gene: confirmation of a powerful diagnostic tool in childhood proximal spinal muscular atrophy (Bertini et al) 1995;38:500A
- Chromosome mapping**
 mapping the human and murine M6 genes within the genome (Narayanan et al) 1995;38:520A
- Chromosomes, human, pair 14**
 new family with dopa-responsive dystonia and linkage mapping to chromosome 14q: dopa-responsive neuropsychology (Heberlein et al) 1995;38:300A
- Chromosomes, human, pair 17**
 two large parkinsonian kindreds linked to *wld* locus on chromosome 17q 21-22 (Wilhelmsen et al) 1995;38:301A
- Chronic fatigue syndrome; see Fatigue syndrome, chronic**
- Chronic inflammatory demyelinating polyneuropathy; see Demyelinating diseases**
- Chronic lymphocytic leukemia; see Leukemia, lymphocytic, chronic**
- Cilia**
 congenital central alveolar hypoventilation syndrome, Hirschsprung's disease, and ciliary ganglia dysfunction with *RET* mutation (Leber et al) 1995;38:538A

Ciliary neurotrophic factor

phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy (Franz et al) 1995; 38:546A

Circulating adhesion molecules; see Cell adhesion molecules

Cisplatin

insulin-like growth factor-I prevents the peripheral neuropathy induced by paclitaxel, cisplatin, and vincristine (Contreras et al) 1995;38:315A
neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy (Gao et al) 1995;38:30

Citicholine

effects of Citicholine on infarct volume, mortality, and behavioral outcome after temporary focal ischemia (Fisher et al) 1995;38:287A

Clinical trials

diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society (Peripheral Nerve Society) 1995;38:478 (Special report)
useful entry criterion for multiple sclerosis clinical trials to prevent progression (Myers et al) 1995;38:339A

Clozapine

clozapine and tardive dyskinesia: analysis of clinical trials (Barak et al) 1995;38:972A

Cocaine

neonatal cocaine intoxication, withdrawal, and fetopathic effects (Dempsey et al) 1995;38:502A
neurological and ophthalmological findings in asymptomatic infants with prenatal cocaine exposure (Hajnal et al) 1995;38:542A

Cognition

interactions of attention and cognitive ability with school performance: a twin study (Klein et al) 1995;38:532A
long-term cognitive effects of early low-dose indomethacin in very preterm neonates (Ment et al) 1995;38:521A
longitudinal stability in asymmetry of motor symptom onset and its influence on cognition in Parkinson's disease (Levin et al) 1995;38:301A
recovery of cognitive function after stroke (Desmond et al) 1995;38:287A

Cognition disorders

autosomal dominant rolandic epilepsy and speech dyspraxia: a new syndrome with anticipation (Scheffer et al) 1995;38:633
brief neuropsychological instrument for the assessment of severely impaired Alzheimer's patients (Harrell et al) 1995;38:326A
cognitive impairment in adrenomyeloneuropathy correlates with magnetic resonance imaging abnormalities (Sacktor et al) 1995;38:547A
cognitive impairment in an adult male form of adrenoleukodystrophy correlates with magnetic resonance imaging abnormalities (Sacktor et al) 1995;38:351A

Coma

outcome comparison between spindle coma and alpha coma, and the relationship to theoretical pathophysiological mechanisms (Ho and Kaplan) 1995;38:346A
postanoxic coma: good recovery despite myoclonus status (Arnoldus and Lammers) (Letter); (Wijdicks et al) (Reply) 1995;38:697

Complement

role of complement in acute inflammatory demyelinating polyneuropathy (Macko et al) 1995;38:302A

Complex partial epilepsy; see Epilepsy, complex partial

Conduction; see Neural conduction

Cooling; see Body temperature

Copolymer 1

antibodies to copolymer 1 do not interfere with its clinical effect (Johnson et al) 1995;38:971A
copolymer 1: multi-center multiple sclerosis (MS) trial extension shows improved effects on relapse rate and disability (Johnson and U.S. Phase III Copolymer 1 Study Group) 1995;38:973A

Copper

early copper therapy in classical Menkes' disease patients with a novel splicing mutation (Kaler et al) 1995;38:921
superoxide dismutase over activity, excessive selenium, and low copper in acquired epileptic aphasia (the Landau-Kleffner syndrome) (Chez et al) 1995;38:544A

Coronary angiography

source of transcranial Doppler signals during cerebral and coronary angiography and its significance (Khan et al) 1995;38:288A

Coronary artery bypass

prospective study of neurological sequelae following coronary artery bypass grafting (KcKhann et al) 1995; 38:317A

Corpus callosum

hypoplasia of the corpus callosum and cerebral palsy (Sheth et al) 1995;38:516A
morphology of the corpus callosum in children with Tourette's syndrome and attention-deficit hyperactivity disorder (Singer et al) 1995;38:509A

Corpus striatum

D1 agonist stimulates acetylcholine release from dissociated adult rat striata (Login et al) 1995;38:300A
decreased single-photon emission computed tomographic [123 I] β -CIT striatal uptake correlates with symptom severity in Parkinson's disease (Seibyl et al) 1995;38:589
increasing striatal iron content associated with normal aging: a risk factor for free-radical-mediated neuronal damage (Martin et al) 1995;38:331A
novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis (Thyagarajan et al) 1995;38:468
preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients (Richfield et al) 1995;38:852
striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? (Kish et al) 1995;38:260
striatal dopaminergic denervation in pallidopyramidal disease demonstrated by positron emission tomography (Remy et al) 1995;38:954

Correction

apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels (Jamieson et al) (1995;38:287A) 1995; 38:486

Corticosteroids; see Adrenal cortex hormones

Cost analysis

annual costs of Guillain-Barré syndrome in the United States (Buzby et al) 1995;38:348A
reducing laboratory costs in the workup of neurometabolic diseases: role for skin biopsy as a rapid diagnostic tool in lysosomal storage disorders (Prasad et al) 1995;38:534A

Cranial fossa, posterior

posterior fossa syndrome following tumor resection: incidence, clinical features, and long-term outcome (Siffert et al) 1995;38:553A

Cranium; see Skull

Creutzfeldt-Jakob disease

Creutzfeldt-Jakob disease after liver transplantation (Créange et al) 1995;38:269

Crossed-conduction aphasia; see Aphasia

Cryoglobulinemia

intracranial vasculopathy and cerebral infarction in a patient with hepatitis C virus and mixed cryoglobulinemia (Petty and Duffy) 1995;38:323A

CTG repeats; see Trinucleotide repeats

Cushing's syndrome

reversible proximal myopathy in epilepsy-related Cushing's syndrome (Herzog et al) 1995;38:305A

Cyanides

neurological sequelae of cyanide intoxication—the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings (Rosenow et al) 1995;38:825

Cyanosis

respiratory sinus arrhythmia in children with severe cyanotic and pallid breath-holding spells (DiMario et al) 1995;38:512A

Cyclic adenosine monophosphate; see Adenosine cyclic monophosphate

Cyclophosphamide

unexpected in vitro chemosensitivity of malignant gliomas to activated analogue of cyclophosphamide (Recht et al) 1995;38:341A

Cyclosporine

cyclosporin-A induces apoptosis in culture cortical neurons (McDonald et al) 1995;38:307A

cyclosporin A-induced seizures: clinical, electroencephalographic, and neuroimaging findings with emphasis on seizure recurrence (Gleeson et al) 1995;38:519A

myopathy with myotonia in patients taking cyclosporine (Verson et al) 1995;38:303A

CYP2D6B; see Cytochrome P450

Cystine

oligodendrocyte death induced by cystine deprivation occurs via apoptosis (Back et al) 1995;38:502A

Cysts

nonneoplastic pineal cysts in children (Ugokwe et al) 1995;38:546A

Cytarabine

association of high-dose ara-C and demyelinating polyneuropathy (Openshaw et al) 1995;38:342A

Cytochrome P450

CYP 2D6 mutant alleles and sporadic Parkinson's disease in a carefully defined population (Diederich et al) 1995;38:300A

CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease (Chen et al) 1995;38:653

Cytokines

cytokine-activated transcription proteins in muscle: implications in inflammatory myopathies (Isabel et al) 1995;38:305A

interferon- β_{1b} effects on cytokine mRNA in multiple sclerosis (Bysskosh and Reder) 1995;38:340A

resistance to clinical experimental allergic encephalomyelitis during development correlates with TH2 cytokine gene expression (Smith et al) 1995;38:312A

tumor necrosis factor: immunogenetics and disease (Hauser) 1995;38:702 (Editorial)

Cytomegaloviruses

brainstem syndrome associated with cytomegalovirus encephalitis in acquired immunodeficiency syndrome (Simpson et al) 1995;38:347A

Cytoskeletal proteins

antibodies to two postsynaptic membrane cytoskeletal proteins in procainamide-induced myopathy (Agius et al) 1995;38:338A

Dehydration

impact of dehydration on outcome of acute ischemic stroke (Chang et al) 1995;38:321A

Dementia

apolipoprotein E $\epsilon 4$ and fatal cerebral amyloid angiopathy associated with dementia pugilistica (Jordan et al) 1995;38:698 (Letter)

apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives (Farrer et al) 1995;38:797

double-blind, randomized, placebo-controlled trial of the calcium channel antagonist nimodipine for the neurological manifestations of acquired immunodeficiency syndrome, including dementia and painful neuropathy (Lipton et al) 1995;38:347A

global hypoxic-ischemic events increase the risk of dementia after stroke (Moroney et al) 1995;38:290A

human immunodeficiency virus encephalitis and dementia (Wiley and Achim) 1995;38:559 (Editorial)

immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia (Glass et al) 1995;38:755

magnetic resonance volumetric measurements of the hippocampus in the parkinsonism-dementia complex of Guam (Petersen et al) 1995;38:324A

reversible dementia and apparent brain atrophy during valproate therapy (Papazian et al) 1995;38:687

treatable dementia of concurrent Klinefelter's and primary Sjögren's syndromes (Siller et al) 1995;38:292A

Dementia, vascular

evidence for a sequential involvement of subcortical frontal white matter lesions in progressive vascular encephalopathy (Hennerici et al) 1995;38:286A

proton magnetic resonance spectroscopy separates Alzheimer's disease and vascular dementia (Kattapong et al) 1995;38:291A

Demyelinating diseases

acute arcuate fiber demyelinating encephalopathy following Epstein-Barr virus infection (Paskavitz et al) 1995;38:127

acute Guillain-Barré syndrome as the initial presentation of relapsing chronic inflammatory demyelinating polyneuropathy (Muriello et al) 1995;38:302A

association of high-dose ara-C and demyelinating polyneuropathy (Openshaw et al) 1995;38:342A

chemical pathology of acute demyelinating lesions and its correlation with disability (De Stefano et al) 1995;38:901

childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up (Nevo et al) 1995;38:514A

chronic inflammatory demyelinating polyneuropathy associated with small-cell lung cancer and Hu antibodies (Einberg et al) 1995;38:306A

chronic inflammatory demyelinating polyneuropathy complicating liver transplantation (Taylor et al) 1995;38:828

electrophysiological studies of the diaphragm in acute inflammatory demyelinating polyneuropathy (Zifko et al) 1995;38:307A

high-dose intravenous immunoglobulin in patients with IgM monoclonal gammopathy and demyelinating polyneuropathy: a double-blind placebo-controlled study (Dalakas et al) 1995;38:302A

plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled crossover study (Hahn et al) 1995;38:303A

role of complement in acute inflammatory demyelinating polyneuropathy (Macko et al) 1995;38:302A

Dendrites

phenobarbital inhibits dendritic development induced by osteogenic protein-1 in cultures of sympathetic neurons (Loefering et al) 1995;38:507A

Denervation

effects of skin denervation on keratinocytes and epidermal Langerhans cells (Hsieh et al) 1995;38:333A

Dentate nucleus; see Cerebellar nuclei

Deprenyl; see Selegiline

Depression

chronic daily left prefrontal repetitive transcranial magnetic stimulation improves mood in depression (George et al) 1995;38:284A

decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome and depression (Samii et al) 1995;38:284A

homosynaptic long-term depression in developing hippocampal dentate gyrus (Trommer et al) 1995;38:501A

Depression, neural; see Neural transmission

Depth electrode studies; see Electrodes

Desmin

desmin, vimentin, tenascin, and N-CAM expression in developmental myopathies (Roig and Gratacòs) 1995;38:554A

Developmental dyslexia; see Dyslexia

Developmental genes; see Genes, structural

Devic's neuromyelitis optica; see Neuromyelitis optica

Dexamethasone

glial fibrillary acidic protein mRNA gene expression in human astroglial cells is modulated by dexamethasone (Perlman and Nisen) 1995;38:549A

Diabetes

effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial (Diabetes Control and Complications Trial Research Group) 1995;38:869

Diabetic neuropathies

diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society (Peripheral Nerve Society) 1995;38:478 (Special report)

Diaphragm

electrophysiological studies of the diaphragm in acute inflammatory demyelinating polyneuropathy (Zifko et al) 1995;38:307A

Dideoxycytidine

electrophysiological and pathological changes in 2',3'-dideoxycytidine-induced neuropathy in an animal model (Russell et al) 1995;38:306A

Diet

food dyes do not cross the blood-brain barrier: a pediatric myth contested (Makary et al) 1995;38:538A

Diet therapy

efficacy and toxicity of the ketogenic diet in children with intractable epilepsy (Vasconcelos et al) 1995;38:505A

pancreatitis, epilepsy, mitochondrial myopathy, and neuropathy: a new diet-responsive mitochondrial syndrome? (Foley et al) 1995;38:540A

seizure frequency, behavioral, and performance effects of the ketogenic diet (Nigro et al) 1995;38:549A

successful treatment of infants with the ketogenic diet (Nordli et al) 1995;38:523A

Diffuse Lewy body disease; see Parkinson's disease entries

Dihydroxyphenylalanine decarboxylase; see Dopa decarboxylase

Diplegia

open-label use of botulinum A in the management of chil-

dren with spastic hemiplegia or diplegia (Russman et al) 1995;38:522A

Disease models, animal

effects of body temperature on myoclonus in a rat pup model (Trifiletti and Bolan) 1995;38:524A

electrophysiological and pathological changes in 2',3'-dideoxycytidine-induced neuropathy in an animal model (Russell et al) 1995;38:306A

gene therapy in primate correlative models of Alzheimer's disease: intraparenchymal nerve growth factor gene transfer prevents cholinergic degeneration (Tuszynski et al) 1995;38:289A

microtubule-associated protein 2 is abnormally expressed in the neocortex of Rett syndrome subjects and in a related animal model (Kaufmann et al) 1995;38:500A

neuroendocrine effects of chronic stress: abnormal hormonal stress response in an infant rat model (Gilles et al) 1995;38:526A

neurological Lyme disease: is there a true animal model? (Coyle) 1995;38:560 (Editorial)

role of nitric oxide during reperfusion injury in a model of transient focal cerebral ischemia in the rat pup (Ashwal et al) 1995;38:552A

somatosensory and brainstem auditory-evoked potentials in an experimental model of acute bilirubin neurotoxicity (Shapiro) 1995;38:553A

transplacental cocaine exposure: a mouse model demonstrating growth, behavioral, and signal transduction abnormalities (Kosofsky et al) 1995;38:508A

vaccination is effective in protecting against Lyme neuroborreliosis in the nonhuman primate model (Pachner et al) 1995;38:283A

Distemper virus, canine

canine distemper virus-specific antibodies in multiple sclerosis (Rohowsky-Kochan et al) 1995;38:339A

Dizocilpine maleate

MK801 exacerbates kainic acid-induced seizures in neonatal rats (Staflstrom et al) 1995;38:507A

neuroprotective agent MK-801 increases expression of the N-methyl-D-aspartate receptor subunits NR2A and NR2B in neonatal rats (Kinsman et al) 1995;38:530A

DM20 messenger RNA; see RNA, messenger

DNA

CTG repeat expansion in leukocyte but not in muscle DNA correlates with muscle weakness in myotonic dystrophy (Thornton et al) 1995;38:334A

DNA sequences of simian virus 40 large T antigen are present in the D283 medulloblastoma cell line (Pomeroi) 1995;38:538A

evidence of DNA fragmentation and immediate early gene induction in naturally occurring, ischemic, and x-ray-induced cell death in the developing brain (Macaya et al) 1995;38:554A

expression of unique genes in subtracted amyotrophic lateral sclerosis libraries (Rickert et al) 1995;38:293A

kindreds of dominantly inherited Parkinson's disease: keys to the riddle (Duvoisin and Golbe) 1995;38:355 (Editorial)

sequence heterogeneity of human T-lymphotropic virus type I (HTLV-I) proviral DNA in the central nervous system of patients with HTLV-I-associated myelopathy and the possible expression of the mutant pX gene products in vivo (Kira et al) 1995;38:347A

studies of the high-affinity glutamate transporter cDNAs in amyotrophic lateral sclerosis (Meyer et al) 1995;38:328A

DNA, mitochondrial

- Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation (Shoffner et al) 1995;38:163
- mitochondrial DNA depletion and clinical manifestations (Vu et al) 1995;38:541A
- sensory ataxic neuropathy as the predominant manifestation of multiple mitochondrial DNA deletions (Johns et al) 1995;38:282A
- single-strand conformational polymorphism analysis of mtDNA in Rett syndrome (Lewis et al) 1995;38:532A

DNA mutational analysis

- mutational analysis of familial and sporadic hyperekplexia (Shiang et al) 1995;38:85
- why do DNA testing? practical and ethical implications of new neurogenetic tests (Bird and Bennett) 1995;38:141 (Point of view)

Dolastatin

- potential neurotoxicity of dolastatin 10: a new chemotherapeutic agent (Schumacher and Windebank) 1995;38:316A

Dopa decarboxylase

- striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? (Kish et al) 1995;38:260

Dopamine

- antiparkinsonian action of glutamate antagonists: interaction with dopamine D1 and D2 agonists (Klockgether et al) 1995;38:329A
- cellular protective effect of bcl-2 against dopamine-induced apoptosis: an association with anti-oxidant pathways (Offen et al) 1995;38:328A
- cytotoxic dopamine mimics as targeted therapy for neuroblastoma (Schor) 1995;38:516A
- striatal dopamine release following acute or chronic selective inhibition of monoamine oxidase-B TYP-1012 and deprenyl (Finberg et al) 1995;38:316A
- striatal dopaminergic denervation in pallidopyramidal disease demonstrated by positron emission tomography (Remy et al) 1995;38:954
- use of the opiate antagonist naltrexone in the treatment of dopa-induced dystonia in patients with Parkinson's disease (Sax and Kornetsky) 1995;38:332A

Down's syndrome

- case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome (van Gool et al) 1995;38:225
- prenatal and early postnatal abnormalities of Down syndrome brain development and maturation (Wisniewski and Kida) 1995;38:536A
- regional cerebral glucose metabolism at rest and during audiovisual stimulation in young and older adult Down syndrome subjects (Pietrini et al) 1995;38:510A

DRB1 alleles; see Alleles

Drowning

- prediction of neurological outcome after submersion injury (Graf et al) 1995;38:536A

Drug implants

- nigral implantation differentially affects initial and long-term drug response in rodents with hemiparkinsonism (Ganchar et al) 1995;38:330A

Duchenne muscular dystrophy; see Muscular dystrophy

Dura mater

- treatment of dural sinus thrombosis using selective catheterization and urokinase (Horowitz et al) 1995;38:58

Dyes

- food dyes do not cross the blood-brain barrier: a pediatric myth contested (Makary et al) 1995;38:538A

Dyscalculia; see Mathematics

Dyskinesia

- liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation (Pappert et al) 1995;38:298A
- paroxysmal dyskinesias: clinical features and classification (Demirkiran and Jankovic) 1995;38:571

Dyskinesia, drug-induced

- clozapine and tardive dyskinesia: analysis of clinical trials (Barak et al) 1995;38:972A

Dyslexia

- developmental dyslexia: cortical and subcortical anomalies by magnetic resonance imaging-based morphometry (Filipek et al) 1995;38:509A

Dystonia

- diurnal variation in acute neuroleptic-induced dystonia (Mazurek and Rosebush) 1995;38:299A
- geste antagonist in cervical dystonia: frequency and associated factors (Comella et al) 1995;38:328A
- is dystonia a sensory disorder? (Hallett) 1995;38:139 (Editorial)
- Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation (Shoffner et al) 1995;38:163
- movement-related cortical potentials in writer's cramp (Deuschl et al) 1995;38:862
- new family with dopa-responsive dystonia and linkage mapping to chromosome 14q: dopa-responsive neuropsychology (Heberlein et al) 1995;38:300A
- tonic vibration reflex and muscle afferent block in writer's cramp (Kaji et al) 1995;38:155
- use of the opiate antagonist naltrexone in the treatment of dopa-induced dystonia in patients with Parkinson's disease (Sax and Kornetsky) 1995;38:332A
- writer's cramp: a disorder of motor subroutine? (Kaji et al) 1995;38:837 (Editorial)

Dystroglycan

- distribution of dystrophin and β -dystroglycan in the brains of normal controls and of patients with Duchenne muscular dystrophy (Uchino et al) 1995;38:335A

Dystrophin

- deficiency of brain synaptic dystrophin in human Duchenne muscular dystrophy (Kim et al) 1995;38:446 (Expedited publication)
- distribution of dystrophin and β -dystroglycan in the brains of normal controls and of patients with Duchenne muscular dystrophy (Uchino et al) 1995;38:335A
- pharmacological intervention to mitigate dystrophin deficiencies (Wade et al) 1995;38:522A
- primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin (Ljunggren et al) 1995;38:367
- quantitative Southern blot analysis in the dystrophin gene of polymerase chain reaction-negative patients with Duchenne muscular dystrophy (Kawamura et al) 1995;38:305A
- ultrastructural localization of adhalin and its spacial relation to dystrophin in normal murine skeletal myofiber (Wakayama et al) 1995;38:304A

Editorials

- adhalin gene mutations and autosomal recessive limb-girdle muscular dystrophy (Campbell) 1995;38:353

Editorials (continued)

- apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view (Bird) 1995;38:2
- human immunodeficiency virus encephalitis and dementia (Wiley and Achim) 1995;38:559
- is dystonia a sensory disorder? (Hallett) 1995;38:139
- kindreds of dominantly inherited Parkinson's disease: keys to the riddle (Duvoisin and Golbe) 1995;38:355
- multiple sclerosis: are HLA class I molecules involved in disease pathogenesis? (Martin and McFarland) 1995;38:137
- neurological Lyme disease: is there a true animal model? (Coyle) 1995;38:560
- neuromyotonia: a new autoimmune disease (Layzer) 1995;38:701
- plastic brain (Hallett) 1995;38:4
- selective neurodegeneration in Huntington's disease (Albin) 1995;38:835
- tumor necrosis factor: immunogenetics and disease (Hauser) 1995;38:702
- writer's cramp: a disorder of motor subroutine (Kaji) 1995;38:837

Ehlers-Danlos syndrome

- cerebrovascular complications in Ehlers-Danlos syndrome type IV (North et al) 1995;38:960

Elderly; see Aged

Electric injuries

- lightning strikes to the head (Yarnell and Cherington) 1995;38:347A

Electric stimulation

- motor effects of stimulating deep brain nuclei in awake co-operating human subjects (Ashby et al) 1995;38:330A

Electrical status epilepticus; see Status epilepticus

Electrocorticography

- significance of spikes recorded on electrocorticography in nonlesional medial temporal lobe epilepsy (Tran et al) 1995;38:763

Electrodes

- depth electrode studies and intracellular dentate granule cell recordings in temporal lobe epilepsy (Williamson et al) 1995;38:778

Electroencephalography

- barbiturate anticonvulsants: a psychometric and quantitative electroencephalographic study (Willis et al) 1995;38:515A
- computer classification of state in healthy preterm neonates (Scher et al) 1995;38:537A
- continuous electroencephalogram recording following cardiac surgery: progress in the development of a neurophysiological monitor for the pediatric intensive care unit (Rosenblatt et al) 1995;38:512A
- cyclosporin A-induced seizures: clinical, electroencephalographic, and neuroimaging findings with emphasis on seizure recurrence (Gleeson et al) 1995;38:519A
- electrographical status epilepticus in neonates (Wical and Vickers) 1995;38:506A
- localization of seizure foci in intractable epilepsy with functional magnetic resonance imaging triggered by simultaneous electroencephalogram recording of sustained but asymptomatic discharges (Warach et al) 1995;38:295A
- magnetic resonance spectroscopy in childhood focal epilepsy: correlation with electroencephalography and ^{18}F -fluorodeoxyglucose positron emission tomography (Frank et al) 1995;38:511A
- tuberous sclerosis complex: prognosis of electroencephalography, neuroimaging, and epilepsy (Foley et al) 1995;38:541A

Electromyography

- role of quantitative electromyography in inclusion body myositis (Brannagan et al) 1995;38:334A

Electronic fetal monitoring; see Fetus

Embolism

- paradoxical embolism is the most frequent cause of juvenile stroke (Klötzsch et al) 1995;38:288A

Embryo

- developmental genes link neuroembryogenesis and carcinogenesis (Joseph) 1995;38:309A

Encephalitis

- brainstem syndrome associated with cytomegalovirus encephalitis in acquired immunodeficiency syndrome (Simpson et al) 1995;38:347A

- human immunodeficiency virus encephalitis and dementia (Wiley and Achim) 1995;38:559 (Editorial)

Encephalitis virus, Japanese

- sustained-release dosage of thyrotropin-releasing hormone improves experimental Japanese encephalitis virus-induced parkinsonism in rats (Ogata et al) 1995;38:311A

Encephalitogenic basic proteins

- acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system (Seljebjerg et al) 1995;38:943

- immunoglobulins reactive with myelin basic protein promote remyelination in the central nervous system (Rodriguez et al) 1995;38:340A

- magnetic resonance imaging relaxometry of delayed myelination in the 18q- syndrome: correlation with myelin basic protein genotype (Gay et al) 1995;38:520A

- multiple sclerosis: effect of clinical disease activity and interferon beta-1b treatment on blood and cerebrospinal fluid immunological parameters and urinary myelin basic protein-like material (Baumhefner et al) 1995;38:315A

- myelin basic protein residues that contact human $\alpha\beta$ T-cell receptor and human lymphocyte antigen molecules (Hastings et al) 1995;38:313A

- urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis (Whitaker et al) 1995;38:625

Encephalomyelitis, allergic

- resistance to clinical experimental allergic encephalomyelitis during development correlates with TH2 cytokine gene expression (Smith et al) 1995;38:312A

Encephalomyelitis, autoimmune

- insulin-like growth factor-I treatment reduces demyelination, increases myelin protein synthesis, and promotes myelin regeneration in experimental autoimmune encephalomyelitis (Yao et al) 1995;38:348A

- oral administration of interferon (IFN)- α is superior to parenteral administration of IFN- α in the suppression of chronic, relapsing-remitting experimental autoimmune encephalomyelitis (Brod and Khan) 1995;38:341A

Encephalomyelitis virus, murine

- chronic myositis induced by Theiler's murine encephalomyelitis virus (Rinehart et al) 1995;38:346A

Encephalopathy, spongiform

- intracerebral distribution of infectious amyloid protein in spongiform encephalopathy (Brown et al) 1995;38:245

Endothelial cells

- enhanced endothelial cell adhesion of human cerebrospinal fluid lymphocytes (Elfont et al) 1995;38:405
- thrombomodulin expression in human brain endothelial cells (Hess et al) 1995;38:288A

Enkephalins

preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients (Richfield et al) 1995;38:852

Enzymes

distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies (Watkins et al) 1995;38:472

Ependymoma

presentation and initial neuroradiological findings in 38 infants with intracranial ependymomas (Comi et al) 1995;38:527A

prognostic factors in infants with ependymomas (Duffner et al) 1995;38:546A

Epidermal protein gene product; see Proteins

Epilepsy, absence

will a critical level of hyperventilation-induced hypocapnia always induce an absence seizure? (Wirrell et al) 1995;38:536A

Epilepsy, complex partial

hippocampal and thalamic volumes in patients with complex partial epilepsy of left temporal origin (Hatta et al) 1995;38:296A

seizure and psychosocial outcome in childhood-onset complex partial seizures: a 14-year follow-up (Szabó et al) 1995;38:529A

Epilepsy, complications

attention-deficit hyperactivity disorder in epileptic children: a new indication for methylphenidate? (Finck et al) 1995;38:520A

reversible proximal myopathy in epilepsy-related Cushing's syndrome (Herzog et al) 1995;38:305A

Epilepsy, diagnosis

predictors of childhood staring spells (Abbasi and Scheller) 1995;38:534A

Epilepsy, diet therapy

efficacy and toxicity of the ketogenic diet in children with intractable epilepsy (Vasconcelos et al) 1995;38:505A

pancreatitis, epilepsy, mitochondrial myopathy, and neuropathy: a new diet-responsive mitochondrial syndrome? (Foley et al) 1995;38:540A

successful treatment of infants with the ketogenic diet (Nordli et al) 1995;38:523A

Epilepsy, drug therapy

gabapentin increases brain gamma-aminobutyric acid levels in patients with epilepsy (Petroff et al) 1995;38:295A

open study of lamotrigine in children with intractable generalized epilepsy (Farrell et al) 1995;38:506A

safety of intravenous valproate (Devinsky et al) 1995;38:670

Epilepsy, epidemiology

in whom does status epilepticus occur: age-related differences in children (Shinnar et al) 1995;38:505A

Epilepsy, etiology

epilepsy produced by molecular knockout of neuronal, but not glial, glutamate transport (Rothstein et al) 1995;38:295A

Epilepsy, frontal lobe

frontal lobe epilepsy masquerading as a sleep disorder (Samuel et al) 1995;38:296A

Epilepsy, genetics

phenotypic spectrum related to the human epilepsy susceptibility gene "EJM1" (Sander et al) 1995;38:210

Epilepsy, myoclonic

postanoxic coma: good recovery despite myoclonus status

(Arnoldus and Lammers) (Letter); (Wijidicks et al) (Reply) 1995;38:697

use of methsuximide for juvenile myoclonic epilepsy (Hurst) 1995;38:517A

Epilepsy, partial

autosomal dominant rolandic epilepsy and speech dyspraxia: a new syndrome with anticipation (Scheffer et al) 1995;38:633

cellular activity underlying altered brain metabolism during focal epileptic activity (Bruehl and Witte) 1995;38:414

felbamate in the treatment of partial epilepsy in children (Flores et al) 1995;38:555A

ictal brain single-photon emission computed tomography using technetium 99m hexamethylpropyleneamineoxime and technetium 99m bicisate in children with medically intractable partial seizure (Park et al) 1995;38:511A

intractable partial epilepsy following low-dose scalp irradiation in infancy (Reutens et al) 1995;38:951

localization of subclinical ictal activity by functional magnetic resonance imaging: correlation with invasive monitoring (Detre et al) 1995;38:618

magnetic resonance spectroscopy in childhood focal epilepsy: correlation with electroencephalography and ¹⁸F-fluorodeoxyglucose positron emission tomography (Frank et al) 1995;38:511A

Epilepsy, pathology

localization of seizure foci in intractable epilepsy with functional magnetic resonance imaging triggered by simultaneous electroencephalogram recording of sustained but asymptomatic discharges (Warach et al) 1995;38:295A

tuberous sclerosis complex: prognosis of electroencephalography, neuroimaging, and epilepsy (Foley et al) 1995;38:541A

Epilepsy, temporal lobe

depth electrode studies and intracellular dentate granule cell recordings in temporal lobe epilepsy (Williamson et al) 1995;38:778

positron emission tomography and temporal lobe epilepsy surgical outcome (Lancman et al) 1995;38:296A

proton nuclear magnetic resonance spectroscopic imaging of human temporal lobe epilepsy at 4.1 T (Hetherington et al) 1995;38:396

significance of spikes recorded on electrocorticography in nonlesional medial temporal lobe epilepsy (Tran et al) 1995;38:763

Epistasis, genetic

epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease (Sorbi et al) 1995;38:124

Epstein-Barr virus

acute arcuate fiber demyelinating encephalopathy following Epstein-Barr virus infection (Paskavitz et al) 1995;38:127

Ethics

why do DNA testing? practical and ethical implications of new neurogenetic tests (Bird and Bennett) 1995;38:141 (Point of view)

Ethnic factors

stroke recurrence is more frequent in Blacks and Hispanics (Sheinart et al) 1995;38:289A

Etoposide

insulin-like growth factor-II prevents *cis*-platinum and etoposide-induced apoptosis in human neuroblastoma cells (Singleton et al) 1995;38:342A

Evoked potentials

- decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome and depression (Samii et al) 1995;38:284A
- electrophysiological features of the central motor tract in SCA1, SCA2, and Machado-Joseph disease (Yokota et al) 1995;38:327A

Evoked potentials, auditory

- cooling and multiple sclerosis: an auditory-evoked potential and neuropsychological analysis (Geisler et al) 1995;38:345A

Evoked potentials, auditory, brainstem

- somatosensory and brainstem auditory-evoked potentials in an experimental model of acute bilirubin neurotoxicity (Shapiro) 1995;38:553A

Evoked potentials, somatosensory

- somatosensory and brainstem auditory-evoked potentials in an experimental model of acute bilirubin neurotoxicity (Shapiro) 1995;38:553A
- somatosensory-evoked potentials in adrenomyeloneuropathy patients on Lorenzo oil (Kaplan et al) 1995;38:351A

Excitatory amino acids; *see* Amino acids

Exons

- exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy (Sivakumar et al) 1995;38:267

Experimental allergic encephalomyelitis; *see* Encephalomyelitis, allergic

Experimental autoimmune encephalomyelitis; *see* Encephalomyelitis, autoimmune

Experimental autoimmune neuritis; *see* Neuritis

Extracorporeal membrane oxygenation

- clinical antecedents of cerebral palsy, mental retardation, and hearing loss in survivors of severe, progressive respiratory failure treated with extracorporeal membrane oxygenation (Graziani et al) 1995;38:540A
- developmental outcome at early school age and clinical antecedents: a longitudinal follow-up of neonatal survivors treated with extracorporeal membrane oxygenation (Gringlas et al) 1995;38:511A

Eye movements

- cortical control of double-step saccades: implications for spatial orientation (Heide et al) 1995;38:739
- oculomotor function in amyotrophic lateral sclerosis: evidence for frontal impairment (Shaunak et al) 1995;38:38

Facial paralysis

- cerebrospinal fluid findings in children with Lyme disease-related facial nerve palsy (Belman et al) 1995;38:513A

Familial paroxysmal ataxia; *see* Ataxia

Fasciculation

- mitochondrial cytopathy manifesting as myokymia in two male siblings (McCormick and Nigro) 1995;38:304A
- periodic ataxia with myokymia syndrome (Comu et al) 1995;38:545A

Fatal familial insomnia; *see* Prion diseases

Fatigue

- fatigue in motor neuron disorders is associated with pathological motor activity during sleep (Nelson et al) 1995;38:350A

Fatigue syndrome, chronic

- decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome and depression (Samii et al) 1995;38:284A

Fatty acids

- abnormalities in fatty acid metabolism in infants with type

- 1 spinal muscular atrophy (Crawford et al) 1995;38:538A

Felbamate

- felbamate in the treatment of partial epilepsy in children (Flores et al) 1995;38:555A

Felbatol

- felbatol: benefits versus risks (Gilmartin and Rawlins) 1995;38:523A

Fetus

- bilateral fetal nigral transplantation into the postcommisural putamen in Parkinson's disease (Freeman et al) 1995;38:379
- clinical correlates of [18 F]fluorodopa uptake in five grafted parkinsonian patients (Remy et al) 1995;38:580
- intrapartum electronic fetal monitoring and cerebral palsy in a population-based study (Ting et al) 1995;38:504A
- iodine, via thyroxine, causes a metamorphosis (a fundamental developmental change) in fetal brain at the beginning of the third trimester (DeLong) 1995;38:519A
- lissencephaly: fetal pattern of glucose metabolism on positron emission tomography? (Chugani et al) 1995;38:543A
- neurological and ophthalmological findings in asymptomatic infants with prenatal cocaine exposure (Hajnal et al) 1995;38:542A
- oligodendroglial development in human fetal cerebrum (Rivkin et al) 1995;38:92
- prenatal and early postnatal abnormalities of Down syndrome brain development and maturation (Wisniewski and Kida) 1995;38:536A
- transplacental cocaine exposure: a mouse model demonstrating growth, behavioral, and signal transduction abnormalities (Kosofsky et al) 1995;38:508A

Fibroblasts

- correction of lysosomal storage in brain of canine GM1 gangliosidosis using genetically engineered fibroblasts (Kaye et al) 1995;38:499A

Fibronectin

- fibronectin expression measured by Western blot following unilateral hemidecortication and frontal decortication in developing rat brain (Shamoto et al) 1995;38:542A

Fluorodopa

- clinical correlates of [18 F]fluorodopa uptake in five grafted parkinsonian patients (Remy et al) 1995;38:580

Fluoroscopy

- noninvasive fluoroscopic measurement of NADH in vitro and in vivo (Riepe et al) 1995;38:310A

Focal epilepsy; *see* Epilepsy, partial

Food; *see* Diet

Forebrain; *see* Prosencephalon

Fragile X syndrome

- overexpression of fragile X gene (FMR-1) transcripts in neural cells results in increased levels of cyclic adenosine monophosphate production (Berry-Kravis and Ciurli-onis) 1995;38:499A

Free radicals

- identifying children at high risk for idiosyncratic anticonvulsant drug reactions: the calculated oxidative protection ratios (Glauser et al) 1995;38:543A
- increasing striatal iron content associated with normal aging: a risk factor for free-radical-mediated neuronal damage (Martin et al) 1995;38:331A

Frontal decortication; *see* Cerebral decortication

Frontal lobe

- frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease (Smith et al) 1995;38:194

- oculomotor function in amyotrophic lateral sclerosis: evidence for frontal impairment (Shaunak et al) 1995;38:38
- parcellating prefrontal functions: comparison of diagnostic efficiency of prefrontal tasks in attention-deficit hyperactivity disorder (Voeller and Edge) 1995;38:508A
- Frontal lobe epilepsy; see Epilepsy, frontal lobe**
- Functional magnetic resonance imaging; see Magnetic resonance imaging**
- Funnel chest**
- Amish "children breast disease" with unusual nemaline rod myopathy (Crawford et al) 1995;38:539A
- GABA**
- gabapentin increases brain gamma-aminobutyric acid levels in patients with epilepsy (Petroff et al) 1995;38:295A
- Gabapentin**
- gabapentin as treatment for nystagmus (Averbuch-Heller et al) 1995;38:972A
- gabapentin increases brain gamma-aminobutyric acid levels in patients with epilepsy (Petroff et al) 1995;38:295A
- Gait**
- celiac disease presenting as gait disturbance and ataxia in infancy (Sum et al) 1995;38:526A
- rhythmic facilitation in gait training of Parkinson's disease (McIntosh et al) 1995;38:331A
- Gamma-aminobutyric acid; see GABA**
- Gamma knife pallidotomy; see Globus pallidus**
- Ganglioglioma; see Neuroblastoma**
- Gangliosides**
- acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides (Illa et al) 1995;38:218
- anti-ganglioside GM₁ antibodies in Guillain-Barré syndrome and their relationship to *Campylobacter jejuni* infection (Rees et al) 1995;38:809
- spectrum of motor system disorders associated with anti-ganglioside antibodies (Bernath and Salazar-Grueso) 1995;38:307A
- Gangliosidosis**
- anti-GM₁ IgG antibodies and *Campylobacter* bacteria in Guillain-Barré syndrome: evidence of molecular mimicry (Oomes et al) 1995;38:170
- correction of lysosomal storage in brain of canine GM₁ gangliosidosis using genetically engineered fibroblasts (Kaye et al) 1995;38:499A
- Gender factors**
- effect of age, race, and gender on anti-oxidant defenses in healthy children (Glauser et al) 1995;38:543A
- Gene conversion**
- gene conversion in myotonic dystrophy (Otto et al) 1995;38:305A
- Gene expression**
- abnormal neuronal activity can alter astrocytic gene expression: spreading depression upregulates mRNA for glial fibrillary acidic protein (Bonthius et al) 1995;38:501A
- central nervous system microvasculature responds to injury and transforming growth factor- β 1 with differential immediate early gene expression (Freij et al) 1995;38:348A
- expression of unique genes in subtracted amyotrophic lateral sclerosis libraries (Rickert et al) 1995;38:293A
- gene expression within the developing rat cerebellum (Narayanan et al) 1995;38:545A
- glial fibrillary acidic protein mRNA gene expression in human astroglial cells is modulated by dexamethasone (Perlman and Nisen) 1995;38:549A
- Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites (Manley et al) 1995;38:102
- immediate early gene induction by programmed cell death in skeletal muscle (Abu-Shakra et al) 1995;38:307A
- resistance to clinical experimental allergic encephalomyelitis during development correlates with TH2 cytokine gene expression (Smith et al) 1995;38:312A
- Gene products**
- sequence heterogeneity of human T-lymphotropic virus type I (HTLV-I) proviral DNA in the central nervous system of patients with HTLV-I-associated myelopathy and the possible expression of the mutant pX gene products in vivo (Kira et al) 1995;38:347A
- Gene therapy**
- endothelial-based ex vivo gene therapy for experimental gliomas (Lattera et al) 1995;38:345A
- gene therapy in primate correlative models of Alzheimer's disease: intraparenchymal nerve growth factor gene transfer prevents cholinergic degeneration (Tuszynski et al) 1995;38:289A
- Gene transcription; see Transcription**
- Gene transfer; see Transfection**
- Genes, structural**
- developmental genes link neuroembryogenesis and carcinogenesis (Joseph) 1995;38:309A
- Genes, suppressor, tumor**
- null mutation of the p53 gene does not alter the frequency or spectrum of spontaneous mutations in the brain (Nishino et al) 1995;38:343A
- Genotype**
- apolipoprotein E genotype in diverse neurodegenerative disorders (Schneider et al) 1995;38:131
- apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives (Farrer et al) 1995;38:797
- apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease (Levy-Lahad et al) 1995;38:678
- apolipoprotein E genotyping in the diagnosis of Alzheimer's disease (Kamboh and DeKosky) (Letter); (Roses) (Reply); (Bird) (Reply) 1995;38:967
- apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view (Bird) 1995;38:2 (Editorial)
- apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view (Kakulas and van Bockxmeer) (Letter); (Bird) (Reply) 1995;38:966
- apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease (Roses) 1995;38:6 (Point of view)
- case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome (van Gool et al) 1995;38:225
- epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease (Sorbi et al) 1995;38:124
- genotype-phenotype correlation in adult-onset acid maltase deficiency (Wokke et al) 1995;38:450
- Gentamicin**
- pharmacological intervention to mitigate dystrophin deficiencies (Wade et al) 1995;38:522A
- Germinal matrix**
- germinal matrix microvascular maturation: three-dimensional in vitro studies (Ment et al) 1995;38:502
- Geste**
- geste antagonist in cervical dystonia: frequency and associated factors (Comella et al) 1995;38:328A
- Giant-cell astrocytoma; see Astrocytoma**

Glial fibrillary acidic protein

- abnormal neuronal activity can alter astrocytic gene expression: spreading depression upregulates mRNA for glial fibrillary acidic protein (Bonthius et al) 1995; 38:501A
- glial fibrillary acidic protein mRNA gene expression in human astroglial cells is modulated by dexamethasone (Perlman and Nisen) 1995;38:549A

Glial growth factor

- recombinant glial growth factor supports the proliferation of human Schwann cells in vitro (Rutkowski et al) 1995; 38:547A

Glioblastoma multiforme

- trkA receptors in a human glioblastoma multiforme cell line U-373: a new approach for therapy? (Singer et al) 1995;38:527A

Glioma

- carboplatin as a radiopotentiating agent for newly diagnosed children with brainstem gliomas (Allen et al) 1995;38:553A
- endothelial-based ex vivo gene therapy for experimental gliomas (Lattera et al) 1995;38:345A
- significance of gadolinium-pentetic acid contrast enhancement and thallium-201 chloride uptake in pediatric brainstem gliomas (Maria et al) 1995;38:514A
- survival of children with high-grade gliomas: a comparison to two sequential randomized children's cancer group trials (Packer et al) 1995;38:343A
- unexpected in vitro chemosensitivity of malignant gliomas to activated analogue of cyclophosphamide (Recht et al) 1995;38:341A

Globus pallidus

- bilateral ventral pallidotomy in patients with Parkinson's disease (Beric et al) 1995;38:332A
- comparison of physiological mapping, magnetic resonance imaging, and histologic lesion in a patient who underwent microelectrode-guided pallidotomy for Parkinson's disease (DeLong et al) 1995;38:298A
- gamma knife pallidotomy in advanced Parkinson's disease (Friedman et al) 1995;38:329A
- neuronal activity in the pallidum of a patient with hemiballismus (Vitek et al) 1995;38:296A

Glucan 1,4-alpha-glucosidase

- genotype-phenotype correlation in adult-onset acid maltase deficiency (Wokke et al) 1995;38:450

Glucose

- cerebral transport and metabolism of 1-¹¹C-D-glucose during stepped hypoglycemia (Powers et al) 1995;38:599
- Landau-Kleffner syndrome: glucose metabolism patterns in 17 children (da Silva and Chugani) 1995;38:510A
- lissencephaly: fetal pattern of glucose metabolism on positron emission tomography? (Chugani et al) 1995; 38:543A
- ontogeny of glucose metabolism in the human cerebellum (Shamoto et al) 1995;38:543A
- positron emission tomographic evaluation of glucose metabolism in childhood brain tumors (Smietana et al) 1995;38:551A
- regional cerebral glucose metabolism at rest and during audiovisual stimulation in young and older adult Down syndrome subjects (Pietrini et al) 1995;38:510A
- regional cerebral glucose metabolism at rest and during sensory stimulation in patients with Alzheimer's disease (Pietrini et al) 1995;38:324A

Glutamates

- antibodies to glutamate receptor subunit proteins in sera from patients with paraneoplastic cerebellar degenera-

tion and type I ("anti-Yo") antibody response (Greenlee et al) 1995;38:283A

antiparkinsonian action of glutamate antagonists: interaction with dopamine D1 and D2 agonists (Klockgether et al) 1995;38:329A

decreased glutamate receptor density in the basal ganglia in Rett syndrome (Blue et al) 1995;38:531A

effect of glutamate metabotropic receptor stimulation and blockade on nitric oxide production in vivo (Bhardwaj et al) 1995;38:308A

epilepsy produced by molecular knockout of neuronal, but not glial, glutamate transport (Rothstein et al) 1995; 38:295A

in vivo microdialysis study of extracellular glutamate response to temperature variance in subarachnoid hemorrhage (Shuaib et al) 1995;38:350A

regulation of glutamate transporters following selective neural pathway lesions (Ginsberg et al) 1995;38: 308A

RNA editing of non-N-methyl-D-aspartate glutamate receptors during in vitro development of clonal human neurons (Younkin et al) 1995;38:507A

selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis (Rothstein et al) 1995;38:73

studies of the high-affinity glutamate transporter cDNAs in amyotrophic lateral sclerosis (Meyer et al) 1995; 38:328A

Glutamic acid decarboxylase

- absence of glutamic acid decarboxylase autoimmunity in symptomatic palatal tremor (Davenport et al) 1995;38: 274 (Letter)

Glutathione

- reduction of excitotoxic injury in rat pups by glutathione and N-acetylcysteine (Trifiletti et al) 1995;38:503A

Glycine

- mutational analysis of familial and sporadic hyperekplexia (Shiang et al) 1995;38:85

Glycogen storage disease type VII

- novel intronic retention in M-subunit transcripts of three Ashkenazi Jews with Tarui's disease (Vasconcelos et al) 1995;38:307A

Glycoproteins

- autosomal-recessive childhood-onset muscular dystrophy associated with mutations of the 50-kDa "dystrophin-associated" glycoprotein adhalin (17q12-q21.33) (Boylan et al) 1995;38:333A
- neutrophil inhibitory factor is neuroprotective after focal ischemia in rats (Jiang et al) 1995;38:935

GM1 ganglioside; see Gangliosides

GM1b antigen; see Antigens

Guidelines

- guidelines for Data and Safety Monitoring Committees of NASCET (Hall) 1995;38:832 (Letter)

Guillain-Barré syndrome; see Polyradiculoneuritis

Hand

- manual motor blocks: characterization and quantitative assessment of a less-recognized but common feature of Parkinson's disease (Dabby et al) 1995;38:330A
- role of reading activity on the modulation of motor cortical outputs to the reading hand in Braille readers (Pascual-Leone et al) 1995;38:910

Headache

- clinical predictors of brain lesions and utility of neuroimaging in children with headache (Pinter et al) 1995;38:524A
- clinical usefulness of magnetic resonance imaging in pediatric headache (Bass et al) 1995;38:527A

- International Headache Society criteria and childhood migraines (Maytal et al) 1995;38:529A
- syndrome of low cerebrospinal fluid pressure headaches and pachymeningeal gadolinium enhancement on magnetic resonance imaging (Mokri et al) 1995;38:297A
- Hearing loss**
clinical antecedents of cerebral palsy, mental retardation, and hearing loss in survivors of severe, progressive respiratory failure treated with extracorporeal membrane oxygenation (Graziani et al) 1995;38:540A
- Heart septal defects, atrial**
occurrence of patent foramen ovale in acute stroke and transient ischemic attacks using transcranial Doppler ultrasonography (Yeung et al) 1995;38:320A
- Heart surgery**
continuous electroencephalogram recording following cardiac surgery: progress in the development of a neurophysiological monitor for the pediatric intensive care unit (Rosenblatt et al) 1995;38:512A
- Heat-shock proteins**
heat shock protein expression does not alone explain the induction of ischemic tolerance in rat brain (Simon et al) 1995;38:286A
- Heme oxygenase**
overexpression of heme oxygenase-1 in Alzheimer's disease (Schipper et al) 1995;38:323A
- Hemiballismus**
neuronal activity in the pallidum of a patient with hemiballismus (Vitek et al) 1995;38:296A
- Hemichorea**
see Chorea
- Hemidecortication**
see Cerebral decortication
- Hemiplegia**
alternating hemiplegia of childhood and beneficial effects of baclofen (Awaad et al) 1995;38:550A
familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL) (Hutchinson et al) 1995;38:817
open-label use of botulinum A in the management of children with spastic hemiplegia or diplegia (Russman et al) 1995;38:522A
skeletal muscle mitochondrial dysfunction in alternating hemiplegia of childhood (Kemp et al) 1995;38:681
- Hemolytic-uremic syndrome**
antibody responses and central nervous system involvement in the hemolytic-uremic syndrome (Gleeson et al) 1995;38:519A
- Hemophilia**
longitudinal follow-up of neurological status of a group of human immunodeficiency virus (HIV)-positive and HIV-negative hemophiliacs (Mitchell et al) 1995;38:556A
- Heparin**
treatment of pediatric sinovenous thrombosis with low molecular weight heparin (deVeber et al) 1995;38:532A
- Hepatitis**
chronic inflammatory demyelinating polyneuropathy complicating liver transplantation (Taylor et al) 1995;38:828
- Hepatitis C virus**
intracranial vasculopathy and cerebral infarction in a patient with hepatitis C virus and mixed cryoglobulinemia (Petty and Duffy) 1995;38:323A
- Hepatotoxicity**
see Liver, drug effects
- Herpes zoster**
zoster paresis and herpetic neuralgia: profile of the diseases (Kanner and Zimmermann) 1995;38:297A
- Hippocampus**
hippocampal and thalamic volumes in patients with complex partial epilepsy of left temporal origin (Hatta et al) 1995;38:296A
homosynaptic long-term depression in developing hippocampal dentate gyrus (Trommer et al) 1995;38:501A
magnetic resonance volumetric measurements of the hippocampus in the parkinsonism-dementia complex of Guam (Petersen et al) 1995;38:324A
- Hirschsprung disease**
congenital central alveolar hypoventilation syndrome, Hirschsprung's disease, and ciliary ganglia dysfunction with *RET* mutation (Leber et al) 1995;38:538A
- HIV**
AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations (Brew et al) 1995;38:563
effect of antiretroviral therapy on neurodevelopment in human immunodeficiency virus-infected children (Legido et al) 1995;38:531A
human immunodeficiency virus encephalitis and dementia (Wiley and Achim) 1995;38:559 (Editorial)
longitudinal follow-up of neurological status of a group of human immunodeficiency virus (HIV)-positive and HIV-negative hemophiliacs (Mitchell et al) 1995;38:556A
pentoxifylline: clinical application in human immunodeficiency virus-associated optic neuropathy (Sadun et al) 1995;38:483 (Letter)
- HIV-1**
effects of tumor necrosis factor- α and platelet-activating factor, human immunodeficiency virus-type 1-induced neurotoxins, on pro-apoptosis gene products in primary human neuronal cultures (Perry et al) 1995;38:551A
- HLA antigens**
acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system (Seljebjerg et al) 1995;38:943
comparative effects of interferon-consensus 1, interferon- α 2a, and interferon- β 1b on human lymphocyte antigen expression and lymphoproliferation (Jiang et al) 1995;38:315A
genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor- α by HLA-DR2⁺ T cells (Zipp et al) 1995;38:723
multiple sclerosis: are HLA class I molecules involved in disease pathogenesis? (Martin and McFarland) 1995;38:137 (Editorial)
myelin basic protein residues that contact human $\alpha\beta$ T-cell receptor and human lymphocyte antigen molecules (Hastings et al) 1995;38:313A
reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes (Li et al) 1995;38:147
- HTLV-I**
search for human T-cell leukemia virus type I in the lesions of patients with tropical spastic paraparesis and polymyositis (Tangy et al) 1995;38:454
sequence heterogeneity of human T-lymphotropic virus type I (HTLV-I) proviral DNA in the central nervous system of patients with HTLV-I-associated myelopathy and the possible expression of the mutant pX gene products in vivo (Kira et al) 1995;38:347A
- HTLV-I-associated myelopathy**
see Paraparesis, tropical spastic
- Hu antibodies**
see Antibodies
- Hu antigens**
see Antigens
- HuD**
see Oligonucleotides, antisense
- Human immunodeficiency virus**
see HIV

Human lymphocyte antigens; see HLA antigens

Huntington chorea

- identification of the Huntington's disease protein in rat, monkey, and human using antifusion protein antibodies (Hersch et al) 1995;38:298A
- juvenile Huntington's disease: unusual presentation in three children (Vuk et al) 1995;38:556A
- preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients (Richfield et al) 1995;38:852
- selective neurodegeneration in Huntington's disease (Albin) 1995;38:835 (Editorial)

Hyaluronic acid

- hyaluronic acid is increased in the skin and urine in patients with amyotrophic lateral sclerosis (Ono and Yamauchi) 1995;38:326A

Hyperekplexia

- mutational analysis of familial and sporadic hyperekplexia (Shiang et al) 1995;38:85

Hypermetria

- recovery of hypermetria after a cerebellar stroke occurs as a multistage process (Manto et al) 1995;38:437

Hyperthermia

- effect of pre-hypoxic-ischemic hypothermia and hyperthermia on brain damage in the immature rat (Yager and Asselin) 1995;38:502A
- effect of temperature on graded cerebral hypoxic-ischemic injury in immature rats (Trescher et al) 1995;38:503A
- mechanism of hypothermia and hyperthermia during sepsis (Scammell et al) 1995;38:339A

Hyperventilation

- will a critical level of hyperventilation-induced hypocapnia always induce an absence seizure? (Wirrell et al) 1995;38:536A

Hypocapnia

- will a critical level of hyperventilation-induced hypocapnia always induce an absence seizure? (Wirrell et al) 1995;38:536A

Hypoglycemia

- cerebral transport and metabolism of $1\text{-}^{11}\text{C}\text{-D-glucose}$ during stepped hypoglycemia (Powers et al) 1995;38:599

Hypokalemia

- clinical presentation of familial hypokalemic periodic paralysis at childhood (Selcen et al) 1995;38:550A

Hypomania; see Manic disorder

Hyponatremia

- re: absence of postoperative hyponatremia in young women (Ayus and Arieff) (Letter); (Wijedicks) (Reply) 1995;38:696

Hypoplasia

- clinical features of developmental disability associated with cerebellar hypoplasia (Shevell and Majnemer) 1995;38:528A
- hypoplasia of the corpus callosum and cerebral palsy (Sheth et al) 1995;38:516A

Hypotension, orthostatic

- endogenous sympatholytic activity in the plasma of a patient with sympathotonic orthostatic hypotension (Shapiro et al) 1995;38:318A

Hypothermia

- effect of pre-hypoxic-ischemic hypothermia and hyperthermia on brain damage in the immature rat (Yager and Asselin) 1995;38:502A
- effect of temperature on graded cerebral hypoxic-ischemic injury in immature rats (Trescher et al) 1995;38:503A

mechanism of hypothermia and hyperthermia during sepsis (Scammell et al) 1995;38:339A

Hypoxia; see Anoxia

Ictal activity; see Seizures entries

Idiopathic sensory neuropathy; see Neuropathies, sensory

IgG

- acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides (Illa et al) 1995;38:218
- anti-GM₁ IgG antibodies and *Campylobacter* bacteria in Guillain-Barré syndrome: evidence of molecular mimicry (Oomes et al) 1995;38:170
- antisulfatide immunoglobulin G is elevated in the serum of multiple sclerosis patients (Kolodny et al) 1995;38:340A

IgM

- high-dose intravenous immunoglobulin in patients with IgM monoclonal gammopathy and demyelinating polyneuropathy: a double-blind placebo-controlled study (Dalakas et al) 1995;38:302A

Immunogenetics

- tumor necrosis factor: immunogenetics and disease (Hauser) 1995;38:702 (Editorial)

Immunoglobulins

- immunoglobulins reactive with myelin basic protein promote remyelination in the central nervous system (Rodriguez et al) 1995;38:340A
- serum immunoglobulins and autoimmune profiles in children with autism (Zimmerman et al) 1995;38:528A

Immunoglobulins, intravenous

- comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barré syndrome (Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group) 1995;38:972A
- high-dose intravenous immunoglobulin in patients with IgM monoclonal gammopathy and demyelinating polyneuropathy: a double-blind placebo-controlled study (Dalakas et al) 1995;38:302A
- leukopenia with intravenous immunoglobulin therapy: a previously unreported complication (Mangeshkumar et al) 1995;38:337A
- rapid and continued improvement from intravenous immunoglobulin treatment of asymmetrical chronic progressive muscular atrophy after 19 years of disease progression (Engel) 1995;38:333A

Immunohistochemistry

- AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations (Brew et al) 1995;38:563
- immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia (Glass et al) 1995;38:755

Immunosuppression

- idiopathic axonal neuropathy responsive to immunosuppression (Slogosky et al) 1995;38:336A

Immunotoxins

- destruction of the cholinergic basal forebrain in rats using immunotoxin (Wiley et al) 1995;38:327A
- intraventricular injection of anti-DBH-saporin: anatomical findings (Wrenn et al) 1995;38:310A

In memoriam

- Harry M. Zimmerman, 1901-1995 (Rowland) 1995;38:834 (Obituary)

Inclusion bodies; see Cellular inclusions

Inclusion body myositis; see Myositis

Indomethacin

long-term cognitive effects of early low-dose indomethacin in very preterm neonates (Ment et al) 1995;38:521A

Inducible nitric oxide synthase; see Nitric oxide

Infantile spasms; see Spasms, infantile

Inflammatory myopathy; see Muscular diseases

Injections, intraventricular

intraventricular injection of anti-D β H-saporin: anatomical findings (Wrenn et al) 1995;38:310A

Insomnia

regional distribution of protease-resistant prion protein in fatal familial insomnia (Parchi et al) 1995;38:21

Insulin-like growth factor I

clinical trial of recombinant human insulin-like growth factor-I in myotonic dystrophy (Slonim et al) 1995;38:334A

double-blind, placebo-controlled study of myotrophin (CEP-151) in the treatment of amyotrophic lateral sclerosis (Murphy et al) 1995;38:335A

double-blind, placebo-controlled study of recombinant human insulin-like growth factor I in the treatment of amyotrophic lateral sclerosis (Lai et al) 1995;38:971A

insulin-like growth factor-I treatment reduces demyelination, increases myelin protein synthesis, and promotes myelin regeneration in experimental autoimmune encephalomyelitis (Yao et al) 1995;38:348A

insulin-like growth factor-I prevents the peripheral neuropathy induced by paclitaxel, cisplatin, and vincristine (Contreras et al) 1995;38:315A

Insulin-like growth factor II

insulin-like growth factor-II prevents *cis*-platinum and etoposide-induced apoptosis in human neuroblastoma cells (Singleton et al) 1995;38:342A

Intercostal nerves

central motor reorganization after anastomosis of the musculocutaneous and intercostal nerves following cervical root avulsion (Mano et al) 1995;38:15

Interferon-alpha

comparative effects of interferon—consensus 1, interferon- α 2a, and interferon- β 1b on human lymphocyte antigen expression and lymphoproliferation (Jiang et al) 1995;38:315A

inefficacy of interferon-alpha in acquired immunodeficiency syndrome—related progressive multifocal leukoencephalopathy (Counihan et al) 1995;38:349A

oral administration of interferon (IFN)- α is superior to parenteral administration of IFN- α in the suppression of chronic, relapsing-remitting experimental autoimmune encephalomyelitis (Brod and Khan) 1995;38:341A

Interferon-beta

comparative effects of interferon—consensus 1, interferon- α 2a, and interferon- β 1b on human lymphocyte antigen expression and lymphoproliferation (Jiang et al) 1995;38:315A

immunoassay to study the pharmacokinetics of recombinant interferon beta-1b in multiple sclerosis patients following subcutaneous administration (Khan et al) 1995;38:339A

interferon- β 1b effects on cytokine mRNA in multiple sclerosis (Byskosh and Reder) 1995;38:340A

multiple sclerosis: effect of clinical disease activity and interferon beta-1b treatment on blood and cerebrospinal fluid immunological parameters and urinary myelin basic protein—like material (Baumhefner et al) 1995;38:315A

toxicity of recombinant intramuscular recombinant interferon- β -1a in multiple sclerosis patients (Rudick et al) 1995;38:313A

Interleukin-1

adenovirus-mediated overexpression of interleukin-1 re-

ceptor antagonist in perinatal rat brain decreases susceptibility to excitotoxic injury (Hagan et al) 1995;38:501A

Interleukin-6

co-administration with interleukin-6 and soluble IL-6 receptor delays progression of Wobbler mouse motor neuron disease (Ikeda et al) 1995;38:306A

Intracerebral hemorrhage; see Cerebral hemorrhage

Intraventricular hemorrhage; see Cerebral hemorrhage

Intraventricular injections; see Injections, intraventricular

Iodine

iodine, via thyroxine, causes a metamorphosis (a fundamental developmental change) in fetal brain at the beginning of the third trimester (DeLong) 1995;38:519A

Iris

comparison of colinergic supersensitivity of the iris sphincter in patients with third nerve palsies and Adie's pupils (Jacobson) 1995;38:318A

Iron

increasing striatal iron content associated with normal aging: a risk factor for free-radical-mediated neuronal damage (Martin et al) 1995;38:331A

mechanism for pathological glial iron sequestration in Parkinson's disease (Schipper et al) 1995;38:327A

Irradiation; see Radiation therapy

Ischemic stroke; see Cerebrovascular disorders entries

Japanese encephalitis virus; see Encephalitis virus, Japanese

Joubert syndrome

"Joubert" syndrome revisited: key ocular motor signs with magnetic resonance imaging correlation (Maria et al) 1995;38:515A

Kainic acid

MK801 exacerbates kainic acid-induced seizures in neonatal rats (Stafstrom et al) 1995;38:507A

Keratinocytes

effects of skin denervation on keratinocytes and epidermal Langerhans cells (Hsieh et al) 1995;38:333A

Ketogenic diet; see Diet therapy

Kinky hair syndrome

early copper therapy in classical Menkes' disease patients with a novel splicing mutation (Kaler et al) 1995;38:921

Klinefelter's syndrome

treatable dementia of concurrent Klinefelter's and primary Sjögren's syndromes (Siller et al) 1995;38:292A

Krabbe's disease; see Leukodystrophy, globoid cell

Lac operon

adenoviral vector can transfer lacZ expression into Schwann cells in culture and in sciatic nerve (Shy et al) 1995;38:429

Lamotrigine

neuroprotective effects of lamotrigine in global ischemia in gerbils: a histological, behavioral, and microdialysis study (Shuaib et al) 1995;38:351A

open study of lamotrigine in children with intractable generalized epilepsy (Farrell et al) 1995;38:506A

Landau-Kleffner syndrome; see Aphasia, acquired

Langerhans cells

effects of skin denervation on keratinocytes and epidermal Langerhans cells (Hsieh et al) 1995;38:333A

Language disorders

childhood idiopathic language deterioration: clinical characteristics, pathophysiological correlates, and response to treatment with corticosteroids (Stefanatos et al) 1995;38:540A

Learning

mechanism of different patterns of gene transcription between seizures and learning (Feuchtwang and Mack) 1995;38:552A

Learning disorders

developmental outcome at early school age and clinical antecedents: a longitudinal follow-up of neonatal survivors treated with extracorporeal membrane oxygenation (Gringlas et al) 1995;38:511A

neuropsychological features of developmental dyscalculia (Gross-Tsur et al) 1995;38:508A

neuropsychological performance of children with attention-deficit hyperactivity disorder with and without reading disability (Reader et al) 1995;38:516A

Leber's hereditary optic neuropathy; see Optic atrophy, hereditary

Leptomeningeal neoplasms

leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications (Balmaceda et al) 1995;38:202

neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis (Freilich et al) 1995;38:51

pediatric leptomeningeal metastases: outcome following combined therapy (Chamberlain) 1995;38:517A

Leukemia

use of neuroimaging to establish etiology of seizures in children with leukemia (Kleiman et al) 1995;38:531A

Leukemia, lymphocytic, chronic

chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study (Cramer et al) 1995;38:342A

Leukemia, T-cell

search for human T-cell leukemia virus type I in the lesions of patients with tropical spastic paraparesis and polymyositis (Tangy et al) 1995;38:454

Leukocytes

CTG repeat expansion in leukocyte but not in muscle DNA correlates with muscle weakness in myotonic dystrophy (Thornton et al) 1995;38:334A

Leukocytes, mononuclear

deficient Sp3 expression in multiple sclerosis peripheral blood mononuclear cells (Grekova et al) 1995;38:312A

Leukodystrophy

ovarioleukodystrophy: a new white matter syndrome (Schiffmann et al) 1995;38:547A

Leukodystrophy, globoid cell

adult-type Krabbe's disease: clinical, radiological, and molecular analyses of four patients (Kobayashi et al) 1995;38:349A

molecular genetics of late-onset forms of Krabbe's disease (Kolodny et al) 1995;38:292A

Leukoencephalopathy

familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL) (Hutchinson et al) 1995;38:817

Italian kindred with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (Ragno et al) 1995;38:231

Leukoencephalopathy, progressive multifocal

inefficacy of interferon-alpha in acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy (Counihan et al) 1995;38:349A

progressive multifocal leukoencephalopathy: clearing of virus associated with extensive inflammation and magnetic resonance imaging gadolinium enhancement (Aksamit et al) 1995;38:346A

Leukomalacia, periventricular

neurodevelopmental outcome of infants with bilateral cystic periventricular leukomalacia is worse than outcome of infants with intraventricular hemorrhage and intraparenchymal echodensity (Perlman et al) 1995;38:548A

Leukopenia

leukopenia with intravenous immunoglobulin therapy: a previously unreported complication (Mangeshkumar et al) 1995;38:337A

Levodopa

dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion (Tuite et al) 1995;38:684

effect of deprenyl and levodopa on the progression of Parkinson's disease (Olanow et al) 1995;38:771

Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation (Markopoulou et al) 1995;38:373

late-onset parkinsonism (Singer et al) 1995;38:329A

levodopa ethylester: a novel therapeutic strategy for treatment of response fluctuations in patients with Parkinson's disease (Dialdetti et al) 1995;38:330A

liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation (Pappert et al) 1995;38:298A

new family with dopa-responsive dystonia and linkage mapping to chromosome 14q: dopa-responsive neuropsychology (Heberlein et al) 1995;38:300A

subacute levodopa test for evaluating long-duration response in Parkinson's disease (Quattrone et al) 1995;38:389

Lewy bodies

Alzheimer's disease with and without Lewy bodies: can they be distinguished at initial presentation? (Lippa et al) 1995;38:290A

Lidocaine

smoldering multiple sclerosis (MS)? lidocaine effects of unmasking silent lesions observed in an apparently inactive phase of MS patients and its implications for disease activity (Sakurai and Kanazawa) 1995;38:314A

Lightning injuries

lightning strikes to the head (Yarnell and Cherington) 1995;38:347A

Linkage

genetic susceptibility for multiple sclerosis: the impact of change of diagnosis of multiplex family members on the power to detect linkage (Rojas et al) 1995;38:319A

Lipocortin

lipocortin-1 (annexin-1) suppresses activation of autoimmune T-cell lines in the Lewis rat (Gold et al) 1995;38:313A

Lipopolysaccharides

Penner's serotype 19 *Campylobacter jejuni* lipopolysaccharide isolated from a patient with acute motor axonal neuropathy bears L2/HNK1 and GM1 epitopes (Sheikh et al) 1995;38:350A

Lissencephaly

lissencephaly: fetal pattern of glucose metabolism on positron emission tomography? (Chugani et al) 1995;38:543A

Liver, drug effects

treatment and clinical characteristics of valproate-induced hepatotoxicity (Bohan et al) 1995;38:505A

Liver transplantation

chronic inflammatory demyelinating polyneuropathy complicating liver transplantation (Taylor et al) 1995;38:828

Creutzfeldt-Jakob disease after liver transplantation (Créange et al) 1995;38:269

Locomotor training

locomotor training in paraplegic patients (Dietz) 1995;38:965 (Letter)

Lomustine

salvage chemotherapy for recurrent malignant oligodendrogliomas (Peterson et al) 1995;38:344A

Long-term depression, neural; see Neural transmission

Lorenzo oil

somatosensory-evoked potentials in adrenomyeloneuropathy patients on Lorenzo oil (Kaplan et al) 1995;38:351A

Low molecular weight heparin; see Heparin

Lumbosacral plexus

magnetic resonance imaging in lumbosacral plexopathy of cancer (Taylor et al) 1995;38:343A

Lyme disease

cerebrospinal fluid findings in children with Lyme disease-related facial nerve palsy (Belman et al) 1995;38:513A

neuroborreliosis in the nonhuman primate: *Borrelia burgdorferi* persists in the central nervous system (Pachner et al) 1995;38:667

neurological Lyme disease: is there a true animal model? (Coyle) 1995;38:560 (Editorial)

North American Lyme meningitis (Coyle et al) 1995;38:349A

post-Lyme syndrome: clinical findings (Krupp et al) 1995;38:284A

vaccination is effective in protecting against Lyme neuroborreliosis in the nonhuman primate model (Pachner et al) 1995;38:283A

Lymphocytes

enhanced endothelial cell adhesion of human cerebrospinal fluid lymphocytes (Elfont et al) 1995;38:405

lymphocyte costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture (Satoh et al) 1995;38:314A

reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes (Li et al) 1995;38:147

Lymphoma

leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications (Balmaceda et al) 1995;38:202

Lymphopenia

Pneumocystis carinii pneumonia is associated with lymphopenia in brain tumor patients (Schiff) 1995;38:343A

Lymphotoxin

genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor- α by HLA-DR2⁺ T cells (Zipp et al) 1995;38:723

Lysine

X-linked spastic paraparesis secondary to Pelizaeus-Merzbacher disease and coincidental lysinuria (Naidu and Hodes) 1995;38:295A

Lysosomal storage diseases

correction of lysosomal storage in brain of canine GM₁ gangliosidosis using genetically engineered fibroblasts (Kaye et al) 1995;38:499A

reducing laboratory costs in the workup of neurometabolic diseases: role for skin biopsy as a rapid diagnostic tool in lysosomal storage disorders (Prasad et al) 1995;38:534A

M6; see Membrane glycoproteins

Machado-Joseph disease; see Spinocerebellar degeneration

Macrophages

monocyte/macrophage differentiation in early multiple sclerosis lesions (Brück et al) 1995;38:788

Magnesium

effect of magnesium on ischemic brain lesions in the preterm infant (FineSmith et al) 1995;38:504A

Magnetic resonance angiography; see Angiography

Magnetic resonance imaging

Alzheimer's disease: role of magnetic resonance imaging in the early diagnosis and modeling of disease progression (Manfredi et al) 1995;38:325A

changes in burden of disease and lesion activity in multiple sclerosis placebo patients: a five-year study by yearly serial magnetic resonance imaging (Zhao et al) 1995;38:314A

circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging (Harrung et al) 1995;38:186

clinical predictors of brain lesions and utility of neuroimaging in children with headache (Pinter et al) 1995;38:524A

clinical usefulness of magnetic resonance imaging in pediatric headache (Bass et al) 1995;38:527A

cognitive impairment in adrenomyeloneuropathy correlates with magnetic resonance imaging abnormalities (Sacktor et al) 1995;38:547A

cognitive impairment in an adult male form of adrenoleukodystrophy correlates with magnetic resonance imaging abnormalities (Sacktor et al) 1995;38:351A

comparison of magnetic resonance angiography and magnetic resonance imaging in the evaluation of children with neurological conditions (Husain et al) 1995;38:524A

comparison of physiological mapping, magnetic resonance imaging, and histologic lesion in a patient who underwent microelectrode-guided pallidotomy for Parkinson's disease (DeLong et al) 1995;38:298A

cortical localization of the lexicon for written words by functional magnetic resonance imaging: correlation with lesion analysis and positron emission tomography (Small et al) 1995;38:284A

developmental dyslexia: cortical and subcortical anomalies by magnetic resonance imaging-based morphometry (Filipek et al) 1995;38:509A

hypoxic-ischemic injury in the neonatal rat evaluated with magnetic resonance imaging (Filloux et al) 1995;38:503A

"Joubert" syndrome revisited: key ocular motor signs with magnetic resonance imaging correlation (Maria et al) 1995;38:515A

localization of seizure foci in intractable epilepsy with functional magnetic resonance imaging triggered by simultaneous electroencephalogram recording of sustained but asymptomatic discharges (Warach et al) 1995;38:295A

localization of subclinical ictal activity by functional magnetic resonance imaging: correlation with invasive monitoring (Detre et al) 1995;38:618

magnetic resonance imaging of the central nervous system in pediatric neurofibromatosis type 1 (Taff et al) 1995;38:352A

magnetic resonance imaging lesion analysis in neurofibromatosis type-1 (DiMario et al) 1995;38:512A

magnetic resonance imaging in lumbosacral plexopathy of cancer (Taylor et al) 1995;38:343A

magnetic resonance imaging relaxometry of delayed myelination in the 18q- syndrome: correlation with myelin basic protein genotype (Gay et al) 1995;38:520A

magnetic resonance volumetric measurements of the hippocampus in the parkinsonism-dementia complex of Guam (Petersen et al) 1995;38:324A

Magnetic resonance imaging (continued)

- midbrain magnetic resonance hyperintensities, perivascular space enlargement, and substantia nigra vacuolar change (Pullicino et al) 1995;38:321A
- multifocal enhancing magnetic resonance imaging lesions following cranial irradiation (Peterson et al) 1995;38:237
- neurodevelopmental effects of X monosomy: a volumetric imaging study (Reiss et al) 1995;38:731
- neurofibromatosis type 1: correlation between volumes of T2-weighted high-intensity signals (UBOs) within neural pathways and impaired performance on judgment of line orientation (Mott et al) 1995;38:509A
- neurological sequelae of cyanide intoxication—the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings (Rosenow et al) 1995;38:825
- oral methotrexate in chronic progressive multiple sclerosis: preliminary results of magnetic resonance imaging analyses (Goodkin et al) 1995;38:349A
- perfusion magnetic resonance imaging with echo planar imaging and signal targeting with alternating radiofrequency in Alzheimer's disease (Sandson et al) 1995;38:290A
- progressive multifocal leukoencephalopathy: clearing of virus associated with extensive inflammation and magnetic resonance imaging gadolinium enhancement (Aksamit et al) 1995;38:346A
- prospective evaluation of magnetic resonance imaging lumbosacral nerve root enhancement in acute Guillain-Barré syndrome (Gorson et al) 1995;38:337A
- relapse of primary brain tumors in infants following post-operative chemotherapy: magnetic resonance imaging surveillance and salvage therapy (Fisher et al) 1995;38:517A
- resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in multiple sclerosis (Filippi et al) 1995;38:749
- serial magnetic resonance imaging in multiple sclerosis: a five-year follow-up (Thompson et al) 1995;38:294A
- significance of gadolinium-pentetic acid contrast enhancement and thallium-201 chloride uptake in pediatric brainstem gliomas (Maria et al) 1995;38:514A
- syndrome of low cerebrospinal fluid pressure headaches and pachymeningeal gadolinium enhancement on magnetic resonance imaging (Mokri et al) 1995;38:297A
- unsuspected mastoid abnormalities in pediatric brain magnetic resonance scans (Snodgrass et al) 1995;38:555A
- Magnetic resonance spectroscopy; see Nuclear magnetic resonance**
- Magnetic stimulation**
 - chronic daily left prefrontal repetitive transcranial magnetic stimulation improves mood in depression (George et al) 1995;38:284A
 - increased sensitivity to ipsilateral cutaneous stimuli following transcranial magnetic stimulation of the parietal lobe (Seyal et al) 1995;38:264
- Magnetics**
 - demonstration of tissue changes in multiple sclerosis lesions using frequent serial magnetization transfer ratio measurements (Gass et al) 1995;38:319A
- Manic disorder**
 - hemichorea/athetosis, anosognosia, and hypomania: a unique triad resulting from left thalamic infarction (Gottfried and Balish) 1995;38:285A
- Manual motor block; see Hand**
- Mastoid**
 - unsuspected mastoid abnormalities in pediatric brain magnetic resonance scans (Snodgrass et al) 1995;38:555A

Mathematics

- mathematical model of neocortical neuronogenesis (Takahashi and Caviness) 1995;38:529A
- neuropsychological features of developmental dyscalculia (Gross-Tsur et al) 1995;38:508A

Medulloblastoma

- differentiation along glial lines predicts poor outcome in primitive neuroectodermal tumors (medulloblastomas) (Janss et al) 1995;38:549A
- DNA sequences of simian virus 40 large T antigen are present in the D283 medulloblastoma cell line (Pomerooy) 1995;38:538A
- early results of reduced-dose radiotherapy plus chemotherapy for children with nondisseminated medulloblastoma: a children's cancer group study (Packer et al) 1995;38:518A

MELAS syndrome

- phenotypes of the mitochondrial encephalopathy, lactic acidosis, and stroke mutation (Damian et al) 1995;38:332A

Membrane glycoproteins

- mapping the human and murine M6 genes within the genome (Narayanan et al) 1995;38:520A

Memory disorders

- crossed-conduction aphasia with impairment of visuospatial memory: a case report (Stefanis et al) 1995;38:285A

Meningioma

- malignant meningiomas: adjuvant combined modality therapy (Chamberlain) 1995;38:344A

Meningitis, viral

- North American Lyme meningitis (Coyle et al) 1995;38:349A

Menkes' disease; see Kinky hair syndrome

Mental disorders

- prospective validation of a treatment approach for children with behavior disorders referred for pediatric neurology evaluation (Weinberg et al) 1995;38:521A
- pseudoseizures in children and adolescents: psychiatric features (Wyllie et al) 1995;38:520A

Mental retardation

- clinical antecedents of cerebral palsy, mental retardation, and hearing loss in survivors of severe, progressive respiratory failure treated with extracorporeal membrane oxygenation (Graziani et al) 1995;38:540A

Mesencephalon

- clinical correlates of [¹⁸F]fluorodopa uptake in five grafted parkinsonian patients (Remy et al) 1995;38:580

Messenger RNA; see RNA, messenger

Metalloproteinases

- matrix metalloproteinases and urokinase increase in stroke in rat (Rosenberg et al) 1995;38:322A

Metastasis; see Neoplasm metastasis

Methotrexate

- biased assessment of blinding in a randomized placebo-controlled trial of oral methotrexate in chronic progressive multiple sclerosis (Dippel et al) (Letter); (Goodkin) (Reply) 1995;38:832
- oral methotrexate in chronic progressive multiple sclerosis: preliminary results of magnetic resonance imaging analyses (Goodkin et al) 1995;38:349A

Methsuximide

- use of methsuximide for juvenile myoclonic epilepsy (Hurst) 1995;38:517A

Methylphenidate

- attention-deficit hyperactivity disorder in epileptic children: a new indication for methylphenidate? (Finck et al) 1995;38:520A

Methylprednisolone

catastrophic central nervous system dysfunction during methylprednisolone injection for refractory pain syndromes: report of 2 cases (Siller et al) 1995;38:297A

Microbodies

distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies (Watkins et al) 1995;38:472

Microdialysis

in vivo microdialysis study of extracellular glutamate response to temperature variance in subarachnoid hemorrhage (Shuaib et al) 1995;38:350A

neuroprotective effects of lamotrigine in global ischemia in gerbils: a histological, behavioral, and microdialysis study (Shuaib et al) 1995;38:351A

Microglia

lymphocyte costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture (Satoh et al) 1995;38:314A

Microtubule proteins

microtubule-associated protein 2 is abnormally expressed in the neocortex of Rett syndrome subjects and in a related animal model (Kaufmann et al) 1995;38:500A

Microtubules

TAXOL-induced accumulation of microtubules in cultured human oligodendrocytes mimics a murine myelin mutant (Kim) 1995;38:309A

Microvasculature

central nervous system microvasculature responds to injury and transforming growth factor- β 1 with differential immediate early gene expression (Freij et al) 1995;38:348A

germinal matrix microvascular maturation: three-dimensional in vitro studies (Ment et al) 1995;38:502

Migraine

familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL) (Hutchinson et al) 1995;38:817

International Headache Society criteria and childhood migraines (Maytal et al) 1995;38:529A

Mini-Mental State Examination

variability in Mini-Mental State Examination scores at one-month retest: a consortium to establish a registry for Alzheimer's disease finding (Edland and Beekly) 1995;38:325A

Mitochondria

clinical features and outcome of children with mitochondrial proliferation (Gropman et al) 1995;38:530A

mitochondrial abnormalities in neuromuscular and neuronal storage disease (Melvin et al) 1995;38:541A

mitochondrial cytopathy manifesting as myokymia in two male siblings (McCormick and Nigro) 1995;38:304A

novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis (Thyagarajan et al) 1995;38:468

pancreatitis, epilepsy, mitochondrial myopathy, and neuropathy: a new diet-responsive mitochondrial syndrome? (Foley et al) 1995;38:540A

Mitochondria, muscle

aging and muscle mitochondrial abnormalities (Grau et al) (Letter); (Karpati and Shoubridge) (Reply); (Rifai and Thornton) (Reply) 1995;38:273

skeletal muscle mitochondrial dysfunction in alternating hemiplegia of childhood (Kemp et al) 1995;38:681

Mitochondrial DNA; see DNA, mitochondrial

Mitochondrial encephalopathy, lactic acidosis and stroke syndrome; see MELAS syndrome

Mitochondrial trifunctional protein

mitochondrial trifunctional protein deficiency: clinical and biochemical findings in four patients (Dionisi-Vici et al) 1995;38:544A

MK801; see Dizocilpine maleate

Modafinil

modafinil: a mechanistically unique compound for the treatment of narcolepsy (Vaught et al) 1995;38:317A

Monoamine oxidase

striatal dopamine release following acute or chronic selective inhibition of monoamine oxidase-B TVP-1012 and deprenyl (Finberg et al) 1995;38:316A

Monoclonal gammopathies; see Paraproteinemias

Monocytes

monocyte/macrophage differentiation in early multiple sclerosis lesions (Brück et al) 1995;38:788

Mononuclear cells; see Leukocytes, mononuclear

Monosomy

neurodevelopmental effects of X monosomy: a volumetric imaging study (Reiss et al) 1995;38:731

Morphine

morphine-preferring μ opiate receptor: structure, function, and expression in the nervous system (Uhl et al) 1995;38:297A

Mosaicism

polymerase chain reaction fiber analysis and somatic mosaicism in autopsied tissue from a man with Duchenne muscular dystrophy (Uchino et al) 1995;38:336A

Motor cortex

plastic brain (Hallett) 1995;38:4 (Editorial)

role of reading activity on the modulation of motor cortical outputs to the reading hand in Braille readers (Pascual-Leone et al) 1995;38:910

Motor evoked potentials; see Evoked potentials

Motor neuron disease

co-administration with interleukin-6 and soluble IL-6 receptor delays progression of Wobbler mouse motor neuron disease (Ikeda et al) 1995;38:306A

oxidative damage to protein in sporadic motor neuron disease spinal cord (Shaw et al) 1995;38:691

Motor neurons

beta-N-oxalylamino-L-alanine toxicity on motoneuron-hybrid cells (La Bella et al) 1995;38:327A

fatigue in motor neuron disorders is associated with pathological motor activity during sleep (Nelson et al) 1995;38:350A

Motor neuropathy; see Neuropathies, motor

Motor system disorders; see Muscular diseases

Movement disorders

cerebellar outflow lesions: a comparison of movement deficits resulting from lesions at the levels of the cerebellum and thalamus (Bastian and Thach) 1995;38:881

is dystonia a sensory disorder? (Hallett) 1995;38:139 (Editorial)

paroxysmal dyskinesias: clinical features and classification (Demirkiran and Jankovic) 1995;38:571

verification of secondary cases in movement disorders (Rajput et al) 1995;38:300A

Movement-related cortical potentials

movement-related cortical potentials in writer's cramp (Deuschl et al) 1995;38:862

mRNA; see RNA, messenger

mtDNA; see DNA, mitochondrial

Multifocal motor neuropathies; see Neuropathies, motor

Multiple sclerosis, classification

useful entry criterion for multiple sclerosis clinical trials to prevent progression (Myers et al) 1995;38:339A

Multiple sclerosis, drug therapy

biased assessment of blinding in a randomized placebo-controlled trial of oral methotrexate in chronic progressive multiple sclerosis (Dippel et al) (Letter); (Goodkin) (Reply) 1995;38:832

copolymer 1: multi-center multiple sclerosis (MS) trial extension shows improved effects on relapse rate and disability (Johnson and U.S. Phase III Copolymer 1 Study Group) 1995;38:973A

effect of corticosteroid pulses on bone density in multiple sclerosis (Schwid et al) 1995;38:338A

oral methotrexate in chronic progressive multiple sclerosis: preliminary results of magnetic resonance imaging analyses (Goodkin et al) 1995;38:349A

Multiple sclerosis, genetics

DRB1 alleles share a specific common sequence associated with multiple sclerosis (Ballerini et al) 1995;38:314A

genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor- α by HLA-DR2⁺ T cells (Zipp et al) 1995;38:723

genetic susceptibility for multiple sclerosis: the impact of change of diagnosis of multiplex family members on the power to detect linkage (Rojas et al) 1995;38:319A

Multiple sclerosis, immunology

analysis of the peripheral T-cell receptor variable beta chain repertoire in patients with relapsing-remitting multiple sclerosis (Gran et al) 1995;38:340A

antisulfatide immunoglobulin G is elevated in the serum of multiple sclerosis patients (Kolodny et al) 1995;38:340A

canine distemper virus-specific antibodies in multiple sclerosis (Rohowsky-Kochan et al) 1995;38:339A

circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging (Harrung et al) 1995;38:186

reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes (Li et al) 1995;38:147

Multiple sclerosis, pathology

changes in burden of disease and lesion activity in multiple sclerosis placebo patients: a five-year study by yearly serial magnetic resonance imaging (Zhao et al) 1995;38:314A

deficient Sp3 expression in multiple sclerosis peripheral blood mononuclear cells (Grekova et al) 1995;38:312A

demonstration of tissue changes in multiple sclerosis lesions using frequent serial magnetization transfer ratio measurements (Gass et al) 1995;38:319A

influx of nonactivated T lymphocytes into the cerebrospinal fluid during relapse of multiple sclerosis (Oksaranta et al) 1995;38:465

monocyte/macrophage differentiation in early multiple sclerosis lesions (Brück et al) 1995;38:788

multiple sclerosis: are HLA class I molecules involved in disease pathogenesis? (Martin and McFarland) 1995;38:137 (Editorial)

programmed cell death in multiple sclerosis patients (Downing et al) 1995;38:341A

resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in multiple sclerosis (Filippi et al) 1995;38:749

serial magnetic resonance imaging in multiple sclerosis: a five-year follow-up (Thompson et al) 1995;38:294A

smoldering multiple sclerosis (MS)? lidocaine effects of unmasking silent lesions observed in an apparently inactive phase of MS patients and its implications for disease activity (Sakurai and Kanazawa) 1995;38:314A

urinary myelin basic protein-like material as a correlate of

the progression of multiple sclerosis (Whitaker et al) 1995;38:625

Multiple sclerosis, rehabilitation

rehabilitation service utilization in the multiple sclerosis prevalence cohort in Olmsted County, MN (Stolp-Smith et al) 1995;38:345A

Multiple sclerosis, therapy

clinical and immunological effects of cooling in multiple sclerosis (Coyle et al) 1995;38:312A

cooling and multiple sclerosis: an auditory-evoked potential and neuropsychological analysis (Geisler et al) 1995;38:345A

immunoassay to study the pharmacokinetics of recombinant interferon beta-1b in multiple sclerosis patients following subcutaneous administration (Khan et al) 1995;38:339A

interferon- β_{1b} effects on cytokine mRNA in multiple sclerosis (Byskosh and Reder) 1995;38:340A

multiple sclerosis: effect of clinical disease activity and interferon beta-1b treatment on blood and cerebrospinal fluid immunological parameters and urinary myelin basic protein-like material (Baumhefner et al) 1995;38:315A

toxicity of recombinant intramuscular recombinant interferon- β_{1a} in multiple sclerosis patients (Rudick et al) 1995;38:313A

Muscle mitochondria; see Mitochondria, muscle

Muscular atrophy

rapid and continued improvement from intravenous immunoglobulin treatment of asymmetrical chronic progressive muscular atrophy after 19 years of disease progression (Engel) 1995;38:333A

Muscular atrophy, spinal

abnormalities in fatty acid metabolism in infants with type 1 spinal muscular atrophy (Crawford et al) 1995;38:538A

deletion analysis of the survival motor neuron gene: confirmation of a powerful diagnostic tool in childhood proximal spinal muscular atrophy (Bertini et al) 1995;38:500A

function changes in patients with spinal muscular atrophy II and III (Russman et al) 1995;38:522A

lack of reinnervation in severe infantile spinal muscular atrophy (Crawford et al) 1995;38:539A

mitochondrial abnormalities in neuromuscular and neuronal storage disease (Melvin et al) 1995;38:541A

molecular characterization of five candidate genes in the spinal muscular atrophy genetic region (Wang et al) 1995;38:500A

phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy (Franz et al) 1995;38:546A

Muscular diseases; see also specific diseases

antibodies to two postsynaptic membrane cytoskeletal proteins in procainamide-induced myopathy (Agius et al) 1995;38:338A

cytokine-activated transcription proteins in muscle: implications in inflammatory myopathies (Isabel et al) 1995;38:305A

inclusion body myositis and myopathies (Griggs et al) 1995;38:705 (Neurological progress)

myopathy with myotonia in patients taking cyclosporine (Verson et al) 1995;38:303A

reversible proximal myopathy in epilepsy-related Cushing's syndrome (Herzog et al) 1995;38:305A

spectrum of motor system disorders associated with anti-ganglioside antibodies (Bernath and Salazar-Grueso) 1995;38:307A

Muscular dystrophy

adhalin gene mutations and autosomal recessive limb-girdle muscular dystrophy (Campbell) 1995;38:353 (Editorial)

autosomal-recessive childhood-onset muscular dystrophy associated with mutations of the 50-kDa "dystrophin-associated" glycoprotein adhalin (17q12-q21.33) (Boylan et al) 1995;38:333A

distribution of dystrophin and β -dystroglycan in the brains of normal controls and of patients with Duchenne muscular dystrophy (Uchino et al) 1995;38:335A

mitochondrial abnormalities in neuromuscular and neuronal storage disease (Melvin et al) 1995;38:541A

polymerase chain reaction fiber analysis and somatic mosaicism in autopsied tissue from a man with Duchenne muscular dystrophy (Uchino et al) 1995;38:336A

primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin (Ljunggren et al) 1995;38:367

quantitative Southern blot analysis in the dystrophin gene of polymerase chain reaction-negative patients with Duchenne muscular dystrophy (Kawamura et al) 1995;38:305A

Musculoskeletal nerves

central motor reorganization after anastomosis of the musculocutaneous and intercostal nerves following cervical root avulsion (Mano et al) 1995;38:15

Mutation

adhalin gene mutations and autosomal recessive limb-girdle muscular dystrophy (Campbell) 1995;38:353 (Editorial)

autosomal-recessive childhood-onset muscular dystrophy associated with mutations of the 50-kDa "dystrophin-associated" glycoprotein adhalin (17q12-q21.33) (Boylan et al) 1995;38:333A

early copper therapy in classical Menkes' disease patients with a novel splicing mutation (Kaler et al) 1995;38:921

epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease (Sorbi et al) 1995;38:124

identical inactivating mutation in three children with neurofibromatosis type 2 (MacCollin et al) 1995;38:554A

Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation (Shoffner et al) 1995;38:163

novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis (Thyagarajan et al) 1995;38:468

novel mutation in the 27-hydroxylase gene of a Pakistani family with autosomal-recessive cerebrotendinous xanthomatosis (Ahmed et al) 1995;38:293A

null mutation of the p53 gene does not alter the frequency or spectrum of spontaneous mutations in the brain (Nishino et al) 1995;38:343A

phenotypes of the mitochondrial encephalopathy, lactic acidosis, and stroke mutation (Damian et al) 1995;38:332A

primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin (Ljunggren et al) 1995;38:367

Mutational analysis; *see* DNA mutational analysis

Mutism

cerebellar mutism in children: report of seven cases and potential mechanisms (Koh et al) 1995;38:510A

Myasthenia gravis

thymectomy in children with severe myasthenia gravis (Nizam et al) 1995;38:535A

Myelin

TAXOL-induced accumulation of microtubules in cultured human oligodendrocytes mimics a murine myelin mutant (Kim) 1995;38:309A

Myelin basic proteins; *see* Encephalitogenic basic proteins

Myelin proteins

expression of PMP22 myelin protein during development of human sciatic nerve (Lee et al) 1995;38:304A

immunohistochemical study of peripheral myelin protein 22 on biopsied nerves of patients with Charcot-Marie-Tooth disease type 1A (Nishimura et al) 1995;38:334A

insulin-like growth factor-I treatment reduces demyelination, increases myelin protein synthesis, and promotes myelin regeneration in experimental autoimmune encephalomyelitis (Yao et al) 1995;38:348A

Myoclonic epilepsy; *see* Epilepsy, myoclonic

Myoclonus

effects of body temperature on myoclonus in a rat pup model (Trifiletti and Bolan) 1995;38:524A

postanoxic coma: good recovery despite myoclonus status (Arnoldus and Lammers) (Letter); (Wijdsicks et al) (Reply) 1995;38:697

Myokymia; *see* Fasciculation

Myopathy; *see* Muscular diseases

Myositis

apolipoprotein E ϵ 4 in inclusion body myositis (Garlepp et al) 1995;38:957

association of inclusion body myositis with autoimmune diseases and autoantibodies (Rugiero et al) 1995;38:333A

chronic myositis induced by Theiler's murine encephalomyelitis virus (Rinehart et al) 1995;38:346A

inclusion body myositis and myopathies (Griggs et al) 1995;38:705 (Neurological progress)

molecular mimicry between cellular phenotypes of sporadic inclusion-body myositis, hereditary inclusion-body myopathy, Alzheimer's disease, and prion diseases (Askanas and Engel) 1995;38:282A

role of quantitative electromyography in inclusion body myositis (Brannagan et al) 1995;38:334A

search for human T-cell leukemia virus type I in the lesions of patients with tropical spastic paraparesis and polymyositis (Tangy et al) 1995;38:454

Myotonia

acquired neuromyotonia: evidence for autoantibodies directed against K^+ channels of peripheral nerves (Shillito et al) 1995;38:714

myopathy with myotonia in patients taking cyclosporine (Version et al) 1995;38:303A

neuromyotonia: a new autoimmune disease (Layzer) 1995;38:701 (Editorial)

Myotonia atrophica

clinical trial of recombinant human insulin-like growth factor-I in myotonic dystrophy (Slonim et al) 1995;38:334A

CTG repeat expansion in leukocyte but not in muscle DNA correlates with muscle weakness in myotonic dystrophy (Thornton et al) 1995;38:334A

gene conversion in myotonic dystrophy (Otto et al) 1995;38:305A

PROMM syndrome (Ricker's disease) (Thornton et al) 1995;38:273 (Letter)

reduced amount of mRNA originating from the mutant MTPK allele in myotonic dystrophy (Thornton and Rifai) 1995;38:302A

- Myotonia atrophica** (*continued*)
relative stability of a minimal CTG repeat expansion in a large kindred with myotonic dystrophy (Simmons and Thornton) 1995;38:303A
- Myotonic dystrophy**; *see* **Myotonia atrophica**
- Myotrophin**; *see* **Insulin-like growth factor I**
- N-methyl-D-aspartate receptor**; *see* **Receptors, N-methyl-D-aspartate**
- NADH**
noninvasive fluoroscopic measurement of NADH in vitro and in vivo (Riepe et al) 1995;38:310A
- Naltrexone**
use of the opiate antagonist naltrexone in the treatment of dopa-induced dystonia in patients with Parkinson's disease (Sax and Kornetsky) 1995;38:332A
- Narcolepsy**
diagnostic considerations in childhood narcolepsy (Swink et al) 1995;38:548A
modafinil: a mechanistically unique compound for the treatment of narcolepsy (Vaught et al) 1995;38:317A
- Necrosis**
novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis (Thyagarajan et al) 1995;38:468
- Nemaline rods**
Amish "children breast disease" with unusual nemaline rod myopathy (Crawford et al) 1995;38:539A
- Neocortex**; *see* **Cerebral cortex**
- Neonatal seizures**; *see* **Seizures entries**
- Neoplasm metastasis**
neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis (Freilich et al) 1995;38:51
pediatric leptomeningeal metastases: outcome following combined therapy (Chamberlain) 1995;38:517A
- Neoplasms**; *see also* **specific neoplasms**
developmental genes link neuroembryogenesis and carcinogenesis (Joseph) 1995;38:309A
magnetic resonance imaging in lumbosacral plexopathy of cancer (Taylor et al) 1995;38:343A
- Neoplasms, embryonal and mixed**
differentiation along glial lines predicts poor outcome in primitive neuroectodermal tumors (medulloblastomas) (Janss et al) 1995;38:549A
- Nerve block**
tonic vibration reflex and muscle afferent block in writer's cramp (Kaji et al) 1995;38:155
- Nerve degeneration**
aging, energy, and oxidative stress in neurodegenerative diseases (Beal) 1995;38:357 (Neurological progress)
apolipoprotein E genotype in diverse neurodegenerative disorders (Schneider et al) 1995;38:131
apoptosis in inherited neurodegenerative diseases (Boustany et al) 1995;38:525A
selective neurodegeneration in Huntington's disease (Albin) 1995;38:835 (Editorial)
- Nerve growth factors**
delivery and distribution of recombinant human nerve growth factor in the brain interstitium (Krewson and Saltzman) 1995;38:294A
gene therapy in primate correlative models of Alzheimer's disease: intraparenchymal nerve growth factor gene transfer prevents cholinergic degeneration (Tuszynski et al) 1995;38:289A
intradermal recombinant human nerve growth factor induces local allodynia and lowered heat pain threshold (Dyck et al) 1995;38:335A
nerve growth factor regulates the expression of other neurotrophins, which suggests a broad spectrum of potentially treatable neuropathies (Apfel et al) 1995;38:310A
nerve growth factor-mediated resistance of neuroblastoma to chemotherapeutic-induced apoptosis: the role of the low-affinity receptor (Cortazzo et al) 1995;38:517A
overview of the clinical experience with systemic administration of nerve growth factor in treating peripheral nervous system disorders (Rask et al) 1995;38:317A
suramin in both a partial agonist and competitive inhibitor for the high-affinity nerve growth factor receptor (Gill and Windebank) 1995;38:308A
- Neural conduction**
effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial (Diabetes Control and Complications Trial Research Group) 1995;38:869
multifocal motor neuropathy: is conduction block the only manifestation? (Lange et al) 1995;38:303A
multifocal motor neuropathy human sera block distal motor nerve conduction in mice (Roberts et al) 1995;38:111
- Neural pathways**
regulation of glutamate transporters following selective neural pathway lesions (Ginsberg et al) 1995;38:308A
- Neural progenitor cells**; *see* **Stem cells**
- Neural transmission**
abnormal neuronal activity can alter astrocytic gene expression: spreading depression upregulates mRNA for glial fibrillary acidic protein (Bonthuis et al) 1995;38:501A
homosynaptic long-term depression in developing hippocampal dentate gyrus (Trommer et al) 1995;38:501A
- Neuralgia**
zoster paresis and herpetic neuralgia: profile of the diseases (Kanner and Zimmermann) 1995;38:297A
- Neuritis**
preferential T-cell receptor V α - and V β -element usage and highly conserved CDR3 region sequences among immunodominant P-2-specific T cells inducing experimental autoimmune neuritis (Giegerich et al) 1995;38:311A
- Neuroblastoma**
cytotoxic dopamine mimics as targeted therapy for neuroblastoma (Schor) 1995;38:516A
insulin-like growth factor-II prevents *cis*-platinum and etoposide-induced apoptosis in human neuroblastoma cells (Singleton et al) 1995;38:342A
nerve growth factor-mediated resistance of neuroblastoma to chemotherapeutic-induced apoptosis: the role of the low-affinity receptor (Cortazzo et al) 1995;38:517A
pediatric gangliogliomas: 103 patients over 20 years at Children's Hospital of Philadelphia (Johnson et al) 1995;38:530A
- Neuroborreliosis**; *see* **Lyme disease**
- Neuroembryogenesis**; *see* **Embryo**
- Neurofibrillary tangles**
parkinsonism associated with neurofibrillary tangles and tufted astrocytes (Handler et al) 1995;38:301A
- Neurofibromatosis 1**
brainstem lesions in children with neurofibromatosis type 1 (Weinstock et al) 1995;38:529A
magnetic resonance imaging lesion analysis in neurofibromatosis type-1 (DiMario et al) 1995;38:512A
neurofibromatosis type 1: correlation between volumes of T2-weighted high-intensity signals (UBOs) within neural pathways and impaired performance on judgment of line orientation (Mott et al) 1995;38:509A

Neurofibromatosis 2

- genotype-phenotype correlation in neurofibromatosis type 2 patients (Andermann et al) 1995;38:537A
- identical inactivating mutation in three children with neurofibromatosis type 2 (MacCollin et al) 1995;38:554A
- magnetic resonance imaging of the central nervous system in pediatric neurofibromatosis type 1 (Taff et al) 1995;38:352A

Neuroglia

- supratentorial neuroglial tumor factors and survival probability (Gilles et al) 1995;38:525A

Neuroleptics; see Tranquilizing agents, major

Neurological Progress

- aging, energy, and oxidative stress in neurodegenerative diseases (Beal) 1995;38:357
- inclusion body myositis and myopathies (Griggs et al) 1995;38:705
- neural apoptosis (Bredesen) 1995;38:839

Neuromyelitis optica

- Devic's neuromyelitis optica: a distinct neurological disorder (Miller et al) 1995;38:294A

Neuromyotonia; see Myotonia

Neuronal ceroid-lipofuscinosis

- juvenile and late infantile forms of neuronal ceroid lipofuscinosis with granular osmophilic deposits (Wisniewski et al) 1995;38:535A
- mitochondrial abnormalities in neuromuscular and neuronal storage disease (Melvin et al) 1995;38:541A

Neurons

- differential susceptibility of human central nervous system-derived oligodendrocytes and neurons to immune-mediated injury (D'Souza et al) 1995;38:312A
- experimental status epilepticus alters γ -aminobutyric acid type A receptor function in CA1 pyramidal neurons (Kapur and Coulter) 1995;38:893
- neural apoptosis (Bredesen) 1995;38:839 (Neurological progress)
- preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients (Richfield et al) 1995;38:852

Neurons, afferent

- astrocyte factors regulate substance P in sensory neurons (Adler and Skoff) 1995;38:309A
- tonic vibration reflex and muscle afferent block in writer's cramp (Kaji et al) 1995;38:155

Neurons, growth and development

- bone morphogenetic protein regulation of neural development (Mabie et al) 1995;38:310A
- mathematical model of neocortical neuronogenesis (Takahashi and Caviness) 1995;38:529A
- neuronal growth cone collapse mediated by platelet-activating factor receptors (Clark et al) 1995;38:499A
- RNA editing of non-N-methyl-D-aspartate glutamate receptors during in vitro development of clonal human neurons (Younkin et al) 1995;38:507A

Neuropathies, autonomic

- sympathetic skin response differentiates hereditary sensory and autonomic neuropathies type IV from type III (Hilz et al) 1995;38:335A

Neuropathies, motor

- mechanism of paralysis and recovery in post-*Campylobacter* acute motor axonal neuropathy (Ho et al) 1995;38:350A
- multifocal motor neuropathy: is conduction block the only manifestation? (Lange et al) 1995;38:303A
- multifocal motor neuropathy human sera block distal mo-

tor nerve conduction in mice (Roberts et al) 1995;38:111

multifocal noninflammatory progressive axonal neuropathy without conduction block (Zifko et al) 1995;38:337A

Penner's serotype 19 *Campylobacter jejuni* lipopolysaccharide isolated from a patient with acute motor axonal neuropathy bears L2/HNK1 and GM1 epitopes (Sheikh et al) 1995;38:350A

Neuropathies, sensory

clues to the pathogenesis of idiopathic sensory neuronopathy: an autopsy study (Bella et al) 1995;38:338A

electrophysiological and pathological changes in 2',3'-dideoxycytidine-induced neuropathy in an animal model (Russell et al) 1995;38:306A

increased epidermal protein gene product 9.5 mRNA levels in sensory neuropathies (Hsieh et al) 1995;38:304A

is dystonia a sensory disorder? (Hallett) 1995;38:139 (Editorial)

neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy (Gao et al) 1995;38:30

sympathetic skin response differentiates hereditary sensory and autonomic neuropathies type IV from type III (Hilz et al) 1995;38:335A

Neurotoxins

neurotoxicity of chemotherapeutic agents and immunconjugates delivered after blood-brain barrier modification: neuropathological studies (Mass et al) 1995;38:342A

Neurotrophic factor

neurotrophins brain-derived neurotrophic factors, NT-4/5, and NT-3 protect injured skeletal muscle from cell death (Alhalabi and Abu-Shakra) 1995;38:332A

Neurotrophins

nerve growth factor regulates the expression of other neurotrophins, which suggests a broad spectrum of potentially treatable neuropathies (Apfel et al) 1995;38:310A

neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy (Gao et al) 1995;38:30

neurotrophins brain-derived neurotrophic factors, NT-4/5, and NT-3 protect injured skeletal muscle from cell death (Alhalabi and Abu-Shakra) 1995;38:332A

Neutrophil inhibitory factor

neutrophil inhibitory factor is neuroprotective after focal ischemia in rats (Jiang et al) 1995;38:935

Nigeria

lack of an association between apolipoprotein E ϵ 4 and Alzheimer's disease in elderly Nigerians (Osuntokun et al) 1995;38:463

Nimodipine

double-blind, randomized, placebo-controlled trial of the calcium channel antagonist nimodipine for the neurological manifestations of acquired immunodeficiency syndrome, including dementia and painful neuropathy (Lipton et al) 1995;38:347A

Nipradilol

treatment of tremor with nipradilol (Yoshii et al) 1995;38:331A

Nitric oxide

effect of glutamate metabotropic receptor stimulation and blockade on nitric oxide production in vivo (Bhardwaj et al) 1995;38:308A

immunoreactivities of nitric oxide synthase and nitrotyrosine in neurofilamentous spheroids and conglomerates of amyotrophic lateral sclerosis (Chou et al) 1995;38:293A

inducible nitric oxide synthase (iNOS) gene expression contributes to cerebral ischemic damage: a novel ap

Nitric oxide (*continued*)

- proach to stroke treatment using an iNOS inhibitor (Iadecola et al) 1995;38:286A
- mice without perinatal nitric oxide synthase have less injury after perinatal hypoxia-ischemia (Ferriero et al) 1995;38:504A
- peptide growth factors and protein kinase C possess distinct temporal profiles of neuroprotection against nitric oxide toxicity (Maiese et al) 1995;38:316A
- protein tyrosine nitration in the developing nervous system: a marker of brain nitric oxide production (Trifiletti et al) 1995;38:523A
- role of nitric oxide during reperfusion injury in a model of transient focal cerebral ischemia in the rat pup (Ashwal et al) 1995;38:552A

Nitrotyrosine

- immunoreactivities of nitric oxide synthase and nitrotyrosine in neurofilamentous spheroids and conglomerates of amyotrophic lateral sclerosis (Chou et al) 1995;38:293A

North American Symptomatic Carotid Endarterectomy Trial

- guidelines for Data and Safety Monitoring Committees of NASCET (Hall) 1995;38:832 (Letter)

Nuclear magnetic resonance

- chemical pathology of acute demyelinating lesions and its correlation with disability (De Stefano et al) 1995;38:901
- ¹H-magnetic resonance spectroscopy obtained 3 to 5 days after acute central nervous system injury predicts outcome in children 18 months or older (Ashwal et al) 1995;38:552A
- magnetic resonance spectroscopy in childhood focal epilepsy: correlation with electroencephalography and ¹⁸F-fluorodeoxyglucose positron emission tomography (Frank et al) 1995;38:511A
- multislice proton magnetic resonance spectroscopic imaging in cerebellar degeneration (Tedeschi et al) 1995;38:328A
- predictive value of ¹H-magnetic resonance spectroscopy in perinatal central nervous system insults (Shu et al) 1995;38:551A
- proton magnetic resonance spectroscopy and imaging in adrenoleukodystrophy heterozygotes (Barker et al) 1995;38:318A
- proton magnetic resonance spectroscopy separates Alzheimer's disease and vascular dementia (Kattapong et al) 1995;38:291A
- proton nuclear magnetic resonance spectroscopic imaging of human temporal lobe epilepsy at 4.1 T (Hetherington et al) 1995;38:396

Nystagmus

- gabapentin as treatment for nystagmus (Averbuch-Heller et al) 1995;38:972A

Obituary

- Harry M. Zimmerman, 1901-1995 (Rowland) 1995;38:834

Oculomotor nerve paralysis

- comparison of colinergic supersensitivity of the iris sphincter in patients with third nerve palsies and Adie's pupils (Jacobson) 1995;38:318A

Oligodendrocytes

- oligodendrocyte death induced by cystine deprivation occurs via apoptosis (Back et al) 1995;38:502A

Oligodendroglia

- differential susceptibility of human central nervous sys-

tem-derived oligodendrocytes and neurons to immune-mediated injury (D'Souza et al) 1995;38:312A

oligodendroglial development in human fetal cerebrum (Rivkin et al) 1995;38:92

TAXOL-induced accumulation of microtubules in cultured human oligodendrocytes mimics a murine myelin mutant (Kim) 1995;38:309A

therapeutic strategies for regenerating mature oligodendrocytes for nascent neural progenitor cells (Mehler et al) 1995;38:309A

Oligodendroglioma

- salvage chemotherapy for recurrent malignant oligodendrogliomas (Peterson et al) 1995;38:344A

Oligonucleotides, antisense

- intracerebroventricular injection of antisense HuD oligonucleotides in mice results in severe motor dysfunction and seizures (Verschuuren et al) 1995;38:345A
- suppression of TNF- α by antisense oligodeoxynucleotide enhanced TGF- β_1 mRNA expression, correlating with enlarged infarct volume following cerebral ischemia in the rat (Zhai et al) 1995;38:973A

Olivopontocerebellar atrophy

- olivopontocerebellar atrophy (Coplin and Bird) (Letter); (Rinne et al) (Reply) 1995;38:965

Oncogene products

- cellular protective effect of bcl-2 against dopamine-induced apoptosis: an association with anti-oxidant pathways (Offen et al) 1995;38:328A

Ondansetron

- ondansetron for disabling cerebellar tremor (Rice et al) 1995;38:973A

Opiate receptors; *see* Receptors, endorphin

Opsoclonus-myoclonus syndrome

- autoantibodies in childhood opsoclonus-myoclonus syndrome (Connolly et al) 1995;38:505A

Optic atrophy, hereditary

- Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation (Shoffner et al) 1995;38:163

Optic nerve diseases

- pentoxifylline: clinical application in human immunodeficiency virus-associated optic neuropathy (Sadun et al) 1995;38:483 (Letter)

Optic neuritis

- acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system (Seljebjerg et al) 1995;38:943

Orthostatic hypotension; *see* Hypotension, orthostatic

Ovarian failure, premature

- ovarioleukodystrophy: a new white matter syndrome (Schiffmann et al) 1995;38:547A

Oxidants

- intracellular and extracellular oxidant injury lead to cell death by different mechanisms (Rosenbaum et al) 1995;38:287A

Oxidative stress

- aging, energy, and oxidative stress in neurodegenerative diseases (Beal) 1995;38:357 (Neurological progress)
- oxidative damage to protein in sporadic motor neuron disease spinal cord (Shaw et al) 1995;38:691

p53 gene; *see* Genes, suppressor, tumor

Paclitaxel

- insulin-like growth factor-I prevents the peripheral neuropathy induced by paclitaxel, cisplatin, and vincristine (Contreras et al) 1995;38:315A

Pain

catastrophic central nervous system dysfunction during methylprednisolone injection for refractory pain syndromes: report of 2 cases (Siller et al) 1995;38:297A

intradermal recombinant human nerve growth factor induces local allodynia and lowered heat pain threshold (Dyck et al) 1995;38:335A

Palate

absence of glutamic acid decarboxylase autoimmunity in symptomatic palatal tremor (Davenport et al) 1995;38:274 (Letter)

Pallidopyramidal disease

striatal dopaminergic denervation in pallidopyramidal disease demonstrated by positron emission tomography (Remy et al) 1995;38:954

Pallidum; see Globus pallidus

Pancreatitis

pancreatitis, epilepsy, mitochondrial myopathy, and neuropathy: a new diet-responsive mitochondrial syndrome? (Foley et al) 1995;38:540A

Papua New Guinea

neuromuscular effects of Papuan taipan snake (Connolly et al) 1995;38:916

Paradoxical embolism; see Embolism

Paralysis

clinical presentation of familial hypokalemic periodic paralysis at childhood (Selcen et al) 1995;38:550A

mechanism of paralysis and recovery in post-*Campylobacter* acute motor axonal neuropathy (Ho et al) 1995;38:350A

Paraneoplastic syndromes

antibodies to glutamate receptor subunit proteins in sera from patients with paraneoplastic cerebellar degeneration and type I ("anti-Yo") antibody response (Greenlee et al) 1995;38:283A

Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites (Manley et al) 1995;38:102

Paraparesis, tropical spastic

search for human T-cell leukemia virus type I in the lesions of patients with tropical spastic paraparesis and polymyositis (Tangy et al) 1995;38:454

sequence heterogeneity of human T-lymphotropic virus type I (HTLV-I) proviral DNA in the central nervous system of patients with HTLV-I-associated myelopathy and the possible expression of the mutant pX gene products in vivo (Kira et al) 1995;38:347A

X-linked spastic paraparesis secondary to Pelizaeus-Merzbacher disease and coincidental lysinuria (Naidu and Hodes) 1995;38:295A

Paraplegia

locomotor training in paraplegic patients (Dietz) 1995;38:965 (Letter)

Paraproteinemias

high-dose intravenous immunoglobulin in patients with IgM monoclonal gammopathy and demyelinating polyneuropathy: a double-blind placebo-controlled study (Dalakas et al) 1995;38:302A

Paresis

zoster paresis and herpetic neuralgia: profile of the diseases (Kanner and Zimmermann) 1995;38:297A

Parietal lobe

increased sensitivity to ipsilateral cutaneous stimuli following transcranial magnetic stimulation of the parietal lobe (Seyal et al) 1995;38:264

Parkinson's disease, diagnosis

accuracy of clinical diagnosis of parkinsonian disorders (Litvan et al) 1995;38:299A

diagnostic predictive values for clinical signs in autopsy-proved Parkinson's disease versus progressive supranuclear palsy and diffuse Lewy body disease (Goetz et al) 1995;38:331A

striatal dopaminergic denervation in pallidopyramidal disease demonstrated by positron emission tomography (Remy et al) 1995;38:954

Parkinson's disease, drug therapy

antiparkinsonian action of glutamate antagonists: interaction with dopamine D1 and D2 agonists (Klockgether et al) 1995;38:329A

controlled clinical trial of intranasal apomorphine as rescue therapy for "off" periods in fluctuating Parkinson's disease (Dewey et al) 1995;38:329A

effect of deprenyl and levodopa on the progression of Parkinson's disease (Olanow et al) 1995;38:771

late-onset parkinsonism (Singer et al) 1995;38:329A

levodopa ethylester: a novel therapeutic strategy for treatment of response fluctuations in patients with Parkinson's disease (Dialdetti et al) 1995;38:330A

nigral implantation differentially affects initial and long-term drug response in rodents with hemiparkinsonism (Gancher et al) 1995;38:330A

subacute levodopa test for evaluating long-duration response in Parkinson's disease (Quattrone et al) 1995;38:389

sustained-release dosage of thyrotropin-releasing hormone improves experimental Japanese encephalitis virus-induced parkinsonism in rats (Ogata et al) 1995;38:311A

use of the opiate antagonist naltrexone in the treatment of dopa-induced dystonia in patients with Parkinson's disease (Sax and Kornetsky) 1995;38:332A

Parkinson's disease, genetics

CYP 2D6 mutant alleles and sporadic Parkinson's disease in a carefully defined population (Diederich et al) 1995;38:300A

dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion (Tuite et al) 1995;38:684

Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation (Markopoulou et al) 1995;38:373

kindreds of dominantly inherited Parkinson's disease: keys to the riddle (Duvoisin and Golbe) 1995;38:355 (Editorial)

two large parkinsonian kindreds linked to *wld* locus on chromosome 17q 21-22 (Wilhelmsen et al) 1995;38:301A

Parkinson's disease, pathology

comparison of physiological mapping, magnetic resonance imaging, and histologic lesion in a patient who underwent microelectrode-guided pallidotomy for Parkinson's disease (DeLong et al) 1995;38:298A

decreased single-photon emission computed tomographic [¹²³I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease (Seibyl et al) 1995;38:589

magnetic resonance volumetric measurements of the hippocampus in the parkinsonism-dementia complex of Guam (Petersen et al) 1995;38:324A

mechanism for pathological glial iron sequestration in Parkinson's disease (Schipper et al) 1995;38:327A

parkinsonism associated with neurofibrillary tangles and tufted astrocytes (Handler et al) 1995;38:301A

Parkinson's disease, physiopathology

- late-onset parkinsonism (Singer et al) 1995;38:329A
- longitudinal stability in asymmetry of motor symptom onset and its influence on cognition in Parkinson's disease (Levin et al) 1995;38:301A
- manual motor blocks: characterization and quantitative assessment of a less-recognized but common feature of Parkinson's disease (Dabby et al) 1995;38:330A

Parkinson's disease, rehabilitation

- rhythmic facilitation in gait training of Parkinson's disease (McIntosh et al) 1995;38:331A

Parkinson's disease, surgery

- bilateral fetal nigral transplantation into the postcommisural putamen in Parkinson's disease (Freeman et al) 1995;38:379
- bilateral ventral pallidotomy in patients with Parkinson's disease (Beric et al) 1995;38:332A
- clinical correlates of [^{18}F]fluorodopa uptake in five grafted parkinsonian patients (Remy et al) 1995;38:580
- gamma knife pallidotomy in advanced Parkinson's disease (Friedman et al) 1995;38:329A

Paroxysmal dyskinesia; see Dyskinesia**Partial epilepsy; see Epilepsy, partial****Patent foramen ovale; see Heart septal defects, atrial****Patient-controlled analgesia; see Analgesia, patient-controlled****Pelizaeus-Merzbacher disease; see Cerebral sclerosis, diffuse****Pentoxifylline**

- pentoxifylline: clinical application in human immunodeficiency virus-associated optic neuropathy (Sadun et al) 1995;38:483 (Letter)

Peptide growth factors

- peptide growth factors and protein kinase C possess distinct temporal profiles of neuroprotection against nitric oxide toxicity (Maiese et al) 1995;38:316A

Peptides

- reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes (Li et al) 1995;38:147

Peripheral blood mononuclear cells; see Leukocytes, mononuclear**Peripheral nerve diseases**

- insulin-like growth factor-I prevents the peripheral neuropathy induced by paclitaxel, cisplatin, and vincristine (Contreras et al) 1995;38:315A
- neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy (Gao et al) 1995;38:30
- overview of the clinical experience with systemic administration of nerve growth factor in treating peripheral nervous system disorders (Rask et al) 1995;38:317A
- potential neurotoxicity of dolastatin 10: a new chemotherapeutic agent (Schumacher and Windebank) 1995;38:316A
- suramin-induced peripheral neuropathy—clinical and electrophysiological features (Chaudhry et al) 1995;38:337A

Peripheral Nerve Society

- diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society (Peripheral Nerve Society) 1995;38:478 (Special report)

Peripheral nerves

- acquired neuromyotonia: evidence for autoantibodies directed against K^+ channels of peripheral nerves (Shillito et al) 1995;38:714

Periventricular leukomalacia; see Leukomalacia, periventricular**Peroxisomes; see Microbodies****Pertussis; see Whooping cough****Pervasive development disorders; see Child development disorders, pervasive****Phenobarbital**

- phenobarbital inhibits dendritic development induced by osteogenic protein-1 in cultures of sympathetic neurons (Loegering et al) 1995;38:507A

Phenotype

- dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion (Tuite et al) 1995;38:684
- genotype-phenotype correlation in adult-onset acid maltase deficiency (Wokke et al) 1995;38:450
- phenotypic spectrum related to the human epilepsy susceptibility gene "EJM1" (Sander et al) 1995;38:210

Phosphorus

- frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease (Smith et al) 1995;38:194

Photoc stimulation

- regional cerebral glucose metabolism at rest and during audiovisual stimulation in young and older adult Down syndrome subjects (Pietrini et al) 1995;38:510A

Pineal body

- nonneoplastic pineal cysts in children (Ugokwe et al) 1995;38:546A

Placenta

- placental abnormalities in neonates with electrically confirmed seizures (Scher et al) 1995;38:537A

Plasma exchange

- comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barré syndrome (Plasma Exchange/Sandoglobulin Guillain Barré Syndrome Trial Group) 1995;38:972A
- plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled crossover study (Hahn et al) 1995;38:303A

Plasmapheresis

- left hemispherectomy after successful plasmapheresis for Rasmussen's syndrome: report of operation on three preteenagers (Freeman et al) 1995;38:514A

Platelet-activating factor

- effects of tumor necrosis factor- α and platelet-activating factor, human immunodeficiency virus-type 1—induced neurotoxins, on pro-apoptosis gene products in primary human neuronal cultures (Perry et al) 1995;38:551A
- neuronal growth cone collapse mediated by platelet-activating factor receptors (Clark et al) 1995;38:499A

Platinum

- insulin-like growth factor-II prevents *cis*-platinum and etoposide-induced apoptosis in human neuroblastoma cells (Singleton et al) 1995;38:342A

Pneumonia, *Pneumocystis carinii*

- Pneumocystis carinii* pneumonia is associated with lymphopenia in brain tumor patients (Schiff) 1995;38:343A

Polyclonal antibodies; see Antibodies**Polymerase chain reaction**

- polymerase chain reaction fiber analysis and somatic mosaicism in autopsied tissue from a man with Duchenne muscular dystrophy (Uchino et al) 1995;38:336A

Polymyositis; see Myositis

Polyradiculoneuritis

acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides (Illa et al) 1995;38:218

acute Guillain-Barré syndrome as the initial presentation of relapsing chronic inflammatory demyelinating polyneuropathy (Muriello et al) 1995;38:302A

annual costs of Guillain-Barré syndrome in the United States (Buzby et al) 1995;38:348A

anti-ganglioside GM₁ antibodies in Guillain-Barré syndrome and their relationship to *Campylobacter jejuni* infection (Rees et al) 1995;38:809

anti-GM₁ IgG antibodies and *Campylobacter* bacteria in Guillain-Barré syndrome: evidence of molecular mimicry (Oomes et al) 1995;38:170

comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barré syndrome (Plasma Exchange/Sandoglobulin Guillain Barré Syndrome Trial Group) 1995;38:972A

GM1b is a new member of antigen specifically recognized by serum antibody in Guillain-Barré syndrome (Kusunoki et al) 1995;38:338A

patterns of recovery in different forms of the Guillain-Barré syndrome associated with *Campylobacter jejuni* (Ho et al) 1995;38:336A

prospective evaluation of magnetic resonance imaging lumbosacral nerve root enhancement in acute Guillain-Barré syndrome (Gorson et al) 1995;38:337A

Positron emission tomography; see Tomography, emission-computed

Post-Lyme syndrome; see Lyme disease

Posterior communicating artery

detection of flow velocity and flow direction in the posterior communicating artery by transcranial color-coded duplex sonography (Popescu et al) 1995;38:321A

Posterior fossa; see Cranial fossa, posterior

Postoperative complications

re: absence of postoperative hyponatremia in young women (Ayus and Arief) (Letter); (Wijidicks) (Reply) 1995;38:696

Potassium channels

acquired neuromyotonia: evidence for autoantibodies directed against K⁺ channels of peripheral nerves (Shillito et al) 1995;38:714

Prednisone

high-dose adrenocorticotrophic hormone or prednisone for infantile spasms? a prospective, randomized, blinded study (Baram et al) 1995;38:506A

Prefrontal region; see Frontal lobe

Preproenkephalin; see Enkephalins

Preprotachykinin; see Tachykinins

Primitive neuroectodermal tumors; see Neoplasms, embryonal and mixed

Prion diseases

molecular mimicry between cellular phenotypes of sporadic inclusion-body myositis, hereditary inclusion-body myopathy, Alzheimer's disease, and prion diseases (Askanas and Engel) 1995;38:282A

regional distribution of protease-resistant prion protein in fatal familial insomnia (Parchi et al) 1995;38:21

Procainamide

antibodies to two postsynaptic membrane cytoskeletal proteins in procainamide-induced myopathy (Agius et al) 1995;38:338A

Procarbazine

salvage chemotherapy for recurrent malignant oligodendrogliomas (Peterson et al) 1995;38:344A

Procollagen

increased concentrations of procollagen propeptides in the cerebrospinal fluid after subarachnoid hemorrhage suggest a meningeal fibrotic reaction (Sajanti et al) 1995;38:319A

Progenitor cells; see Stem cells

Programmed cell death; see Cell death

Progressive multifocal leukoencephalopathy; see Leukoencephalopathy, progressive multifocal

Progressive supranuclear palsy; see Supranuclear palsy, progressive

PROMM syndrome

PROMM syndrome (Ricker's disease) (Thornton et al) 1995;38:273 (Letter)

Prosencephalon

destruction of the cholinergic basal forebrain in rats using immunotoxin (Wiley et al) 1995;38:327A

Proteases

regional distribution of protease-resistant prion protein in fatal familial insomnia (Parchi et al) 1995;38:21

Protein C

protein S and protein C deficiency in children with ischemic cerebral vascular accident (Koh et al) 1995;38:556A

Protein kinase C

peptide growth factors and protein kinase C possess distinct temporal profiles of neuroprotection against nitric oxide toxicity (Maiese et al) 1995;38:316A

Protein S

protein S and protein C deficiency in children with ischemic cerebral vascular accident (Koh et al) 1995;38:556A

Protein-tyrosine kinase

congenital central alveolar hypoventilation syndrome, Hirschsprung's disease, and ciliary ganglia dysfunction with *RET* mutation (Leber et al) 1995;38:538A

Proteins

immunoexpression of a polyclonal antibody directed against the S182 and E5-1 proteins (Lippa et al) 1995;38:972A

increased epidermal protein gene product 9.5 mRNA levels in sensory neuropathies (Hsieh et al) 1995;38:304A

oxidative damage to protein in sporadic motor neuron disease spinal cord (Shaw et al) 1995;38:691

Proteolipids

acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system (Seljelberg et al) 1995;38:943

Prothrombin

prothrombin fragment 1+2: a risk factor for ischemic stroke (Kargman et al) 1995;38:320A

Protirelin

sustained-release dosage of thyrotropin-releasing hormone improves experimental Japanese encephalitis virus-induced parkinsonism in rats (Ogata et al) 1995;38:311A

Proto-oncogenes

trkA receptors in a human glioblastoma multiforme cell line U-373: a new approach for therapy? (Singer et al) 1995;38:527A

Proton magnetic resonance spectroscopy; see Nuclear magnetic resonance

Pseudoseizures; see Seizures entries

Putamen

bilateral fetal nigral transplantation into the postcommis-
sural putamen in Parkinson's disease (Freeman et al)
1995;38:379

Pyramidal neurons; see Neurons

Pyruvate carboxylase

molecular genetics of human pyruvate carboxylase defi-
ciency (O'Driscoll et al) 1995;38:545A

18q- syndrome

magnetic resonance imaging relaxometry of delayed my-
elination in the 18q- syndrome: correlation with myelin
basic protein genotype (Gay et al) 1995;38:520A

Quality of life

change in quality of life in cerebral palsy children after
botulinum toxin type A injection (Awaad et al) 1995;
38:550A

measuring quality of life in brain tumor patients: method-
ological issues and priorities for research (Perry) 1995;
38:344A

quality of life after ischemic stroke: the Northern Manhat-
tan Stroke Study (Sacco et al) 1995;38:322A

Racial factors

effect of age, race, and gender on anti-oxidant defenses in
healthy children (Glauser et al) 1995;38:543A

Radiation therapy

early results of reduced-dose radiotherapy plus chemother-
apy for children with nondisseminated medulloblas-
toma: a children's cancer group study (Packer et al)
1995;38:518A

intractable partial epilepsy following low-dose scalp irradi-
ation in infancy (Reutens et al) 1995;38:951

multifocal enhancing magnetic resonance imaging lesions
following cranial irradiation (Peterson et al) 1995;
38:237

Rasagiline

neuroprotective and neurorescue activities of rasagiline
(TVP 1012,N-propargyl-1 [R] amino-indan) (Youdim
et al) 1995;38:317A

Rasmussen's syndrome

left hemispherectomy after successful plasmapheresis for
Rasmussen's syndrome: report of operation on three
preteenagers (Freeman et al) 1995;38:514A

Reading

neuropsychological performance of children with atten-
tion-deficit hyperactivity disorder with and without read-
ing disability (Reader et al) 1995;38:516A

role of reading activity on the modulation of motor cortical
outputs to the reading hand in Braille readers (Pascual-
Leone et al) 1995;38:910

Receptors, antigen, T-cell

analysis of the peripheral T-cell receptor variable beta
chain repertoire in patients with relapsing-remitting
multiple sclerosis (Gran et al) 1995;38:340A

preferential T-cell receptor V α - and V β -element usage and
highly conserved CDR3 region sequences among immu-
nodominant P-2-specific T cells inducing experimental
autoimmune neuritis (Giegerich et al) 1995;38:311A

Receptors, antigen, T-cell, alpha-beta

myelin basic protein residues that contact human $\alpha\beta$ T-cell
receptor and human lymphocyte antigen molecules
(Hastings et al) 1995;38:313A

Receptors, endorphin

morphine-preferring μ opiate receptor: structure, func-

tion, and expression in the nervous system (Uhl et al)
1995;38:297A

Receptors, GABA-benzodiazepine

benzodiazepine receptor binding in cerebellar degenera-
tions studied with positron emission tomography (Gil-
man et al) 1995;38:176

experimental status epilepticus alters γ -aminobutyric acid
type A receptor function in CA1 pyramidal neurons
(Kapur and Coulter) 1995;38:893

Receptors, N-methyl-D-aspartate

neuroprotective agent MK-801 increases expression of the
N-methyl-D-aspartate receptor subunits NR2A and
NR2B in neonatal rats (Kinsman et al) 1995;38:530A

Recombinant glial growth factor; see Glial growth factor

Recombinant human ciliary neurotrophic factor; see Cili- ary neurotrophic factor

Recombinant human nerve growth factor; see Nerve growth factors

Reflex

tonic vibration reflex and muscle afferent block in writer's
cramp (Kaji et al) 1995;38:155

Refractory pain syndromes; see Pain

Reperfusion injury

role of nitric oxide during reperfusion injury in a model
of transient focal cerebral ischemia in the rat pup (Ash-
wal et al) 1995;38:552A

Reproducibility of results

variability in Mini-Mental State Examination scores at one-
month retest: a consortium to establish a registry for
Alzheimer's disease finding (Edland and Beekly) 1995;
38:325A

Respiratory insufficiency

clinical antecedents of cerebral palsy, mental retardation,
and hearing loss in survivors of severe, progressive respi-
ratory failure treated with extracorporeal membrane ox-
ygenation (Graziani et al) 1995;38:540A

RET; see Protein-tyrosine kinase

Rett syndrome

decreased glutamate receptor density in the basal ganglia
in Rett syndrome (Blue et al) 1995;38:531A

microtubule-associated protein 2 is abnormally expressed
in the neocortex of Rett syndrome subjects and in a
related animal model (Kaufmann et al) 1995;38:500A

single-strand conformational polymorphism analysis of
mtDNA in Rett syndrome (Lewis et al) 1995;38:532A

Reviewers

thanks to reviewers 1995;38:1

Rhythmic auditory stimulation; see Acoustic stimulation

Ricker's disease

PROMM syndrome (Ricker's disease) (Thornton et al)
1995;38:273 (Letter)

RNA

RNA editing of non-N-methyl-D-aspartate glutamate re-
ceptors during in vitro development of clonal human
neurons (Younkin et al) 1995;38:507A

RNA, messenger

abnormal neuronal activity can alter astrocytic gene expres-
sion: spreading depression upregulates mRNA for glial
fibrillary acidic protein (Bonthius et al) 1995;38:501A

glial fibrillary acidic protein mRNA gene expression in
human astroglial cells is modulated by dexamethasone
(Perlman and Nisen) 1995;38:549A

increased epidermal protein gene product 9.5 mRNA lev-
els in sensory neuropathies (Hsieh et al) 1995;38:304A

interferon- β_{15} effects on cytokine mRNA in multiple scler-
osis (Byskosh and Reder) 1995;38:340A

- overexpression of DM20 messenger RNA in two brothers with Pelizaeus-Merzbacher disease (Carango et al) 1995; 38:610
- overexpression of DM20 mRNA in two brothers with Pelizaeus-Merzbacher disease (Marks et al) 1995;38:514A
- reduced amount of mRNA originating from the mutant MTPK allele in myotonic dystrophy (Thornton and Rifai) 1995;38:302A
- suppression of TNF- α by antisense oligodeoxynucleotide enhanced TGF- β_1 mRNA expression, correlating with enlarged infarct volume following cerebral ischemia in the rat (Zhai et al) 1995;38:973A
- Rolandic epilepsy; see Epilepsy, partial**
- Saccades**
- cortical control of double-step saccades: implications for spatial orientation (Heide et al) 1995;38:739
- oculomotor function in amyotrophic lateral sclerosis: evidence for frontal impairment (Shaunak et al) 1995;38:38
- Scalp, radiotherapy**
- intractable partial epilepsy following low-dose scalp irradiation in infancy (Reutens et al) 1995;38:951
- Schwann cells**
- adenoviral vector can transfer lacZ expression into Schwann cells in culture and in sciatic nerve (Shy et al) 1995;38:429
- recombinant glial growth factor supports the proliferation of human Schwann cells in vitro (Rutkowski et al) 1995; 38:547A
- selective expansion and long-term culture of human Schwann cells from sural nerve biopsies (Van den Berg et al) 1995;38:674
- Sciatic nerve**
- adenoviral vector can transfer lacZ expression into Schwann cells in culture and in sciatic nerve (Shy et al) 1995;38:429
- expression of PMP22 myelin protein during development of human sciatic nerve (Lee et al) 1995;38:304A
- Seizures, diagnosis**
- predictors of childhood staring spells (Abbasi and Scheller) 1995;38:534A
- Seizures, diet therapy**
- seizure frequency, behavioral, and performance effects of the ketogenic diet (Nigro et al) 1995;38:549A
- Seizures, drug therapy**
- felbatol: benefits versus risks (Gilmartin and Rawlins) 1995;38:523A
- Seizures, epidemiology**
- epidemiology of clinical neonatal seizures in Newfoundland, Canada: a five-year cohort (Ronen and Penney) 1995;38:518A
- Seizures, etiology**
- breath-holding spells and prolonged seizures (Moorjani et al) 1995;38:512A
- cyclosporin A-induced seizures: clinical, electroencephalographic, and neuroimaging findings with emphasis on seizure recurrence (Gleeson et al) 1995;38:519A
- etiology of neonatal seizures (Wells et al) 1995;38:521A
- intracerebroventricular injection of antisense HuD oligonucleotides in mice results in severe motor dysfunction and seizures (Verschuuren et al) 1995;38:345A
- MK801 exacerbates kainic acid-induced seizures in neonatal rats (Stafstrom et al) 1995;38:507A
- use of neuroimaging to establish etiology of seizures in children with leukemia (Kleiman et al) 1995;38:531A
- Seizures, genetics**
- mechanism of different patterns of gene transcription between seizures and learning (Feuchtwang and Mack) 1995;38:552A
- Seizures, imaging**
- localization of subclinical ictal activity by functional magnetic resonance imaging: correlation with invasive monitoring (Detre et al) 1995;38:618
- Seizures, pathology**
- comparison of ictal-single-photon emission computed tomographic and positron emission tomographic scans for localization of seizure foci in children with intractable seizures (Bhatia et al) 1995;38:542A
- emergency room brain computed tomography in children with seizures: which children are most likely to benefit? (Garvey et al) 1995;38:535A
- Seizures, physiopathology**
- early factors predictive of outcome in newborns with seizures (Koh and Libenson) 1995;38:534A
- placental abnormalities in neonates with electrically confirmed seizures (Scher et al) 1995;38:537A
- seizure and psychosocial outcome in childhood-onset complex partial seizures: a 14-year follow-up (Szabó et al) 1995;38:529A
- Seizures, psychiatry**
- pseudoseizures in children and adolescents: psychiatric features (Wyllie et al) 1995;38:520A
- Selegiline**
- effect of deprenyl and levodopa on the progression of Parkinson's disease (Olanow et al) 1995;38:771
- striatal dopamine release following acute or chronic selective inhibition of monoamine oxidase-B TVP-1012 and deprenyl (Finberg et al) 1995;38:316A
- Selenium**
- superoxide dismutase over activity, excessive selenium, and low copper in acquired epileptic aphasia (the Landau-Kleffner syndrome) (Chez et al) 1995;38:544A
- Sensory neurons; see Neurons, afferent**
- Sensory neuropathy; see Neuropathies, sensory**
- Septicemia**
- mechanism of hypothermia and hyperthermia during sepsis (Scammell et al) 1995;38:339A
- Sickness impact profile**
- Tuft's quantitative neuromuscular examination: high correlation with the sickness impact profile in measuring progression of amyotrophic lateral sclerosis (McGuire et al) 1995;38:336A
- Simian virus 40; see SV40 virus**
- Single-photon emission-computed tomography; see Tomography, emission-computed, single-photon**
- Sinus arrhythmia; see Arrhythmia, sinus**
- Sinus thrombosis**
- treatment of dural sinus thrombosis using selective catheterization and urokinase (Horowitz et al) 1995;38:58
- treatment of pediatric sinovenous thrombosis with low molecular weight heparin (deVeber et al) 1995;38: 532A
- Sjögren's syndrome**
- treatable dementia of concurrent Klinefelter's and primary Sjögren's syndromes (Siller et al) 1995;38:292A
- Skin biopsy; see Biopsy**
- Skin denervation; see Denervation**
- Skull**
- multifocal enhancing magnetic resonance imaging lesions following cranial irradiation (Peterson et al) 1995; 38:237

Sleep apnea syndromes

congenital central alveolar hypoventilation syndrome, Hirschsprung's disease, and ciliary ganglia dysfunction with *RET* mutation (Leber et al) 1995;38:538A

Sleep disorders

diagnostic considerations in childhood narcolepsy (Swink et al) 1995;38:548A

¹⁸F-fluorodeoxyglucose-positron emission tomography in electrical status epilepticus of sleep (Gaillard et al) 1995;38:534A

frontal lobe epilepsy masquerading as a sleep disorder (Samuel et al) 1995;38:296A

Small cell lung cancer; see Carcinoma, oat cell

Smoking

smoking and Alzheimer's disease: a case-control study (Rocca et al) 1995;38:326A

Smooth pursuit

oculomotor function in amyotrophic lateral sclerosis: evidence for frontal impairment (Shaunak et al) 1995;38:38

Snake venoms

neuromuscular effects of Papuan taipan snake (Connolly et al) 1995;38:916

Somatosensory evoked potentials; see Evoked potentials, somatosensory

Spasms, infantile

high-dose adrenocorticotrophic hormone or prednisone for infantile spasms? a prospective, randomized, blinded study (Baram et al) 1995;38:506A

which and how many infants with massive infantile spasms may benefit from positron emission tomographic scans? (Le et al) 1995;38:556A

Spastic paraparesis; see Paraparesis, tropical spastic

Specialties, medical

impact of consulting with stroke specialists in ambulatory clinical practice (Gomez et al) 1995;38:320A

Speech disorders

autosomal dominant rolandic epilepsy and speech dyspraxia: a new syndrome with anticipation (Scheffer et al) 1995;38:633

motor processes underlying incipient and chronic stuttering (Joullian et al) 1995;38:285A

Spinal cord

oxidative damage to protein in sporadic motor neuron disease spinal cord (Shaw et al) 1995;38:691

Spinal muscular atrophy; see Muscular atrophy, spinal

Spindle coma; see Coma

Spinocerebellar degeneration

correlation between the CAG triplet repeat number and phenotypic variability of spinocerebellar ataxia type 1 in the Yakut people of Siberia (Goldfarb et al) 1995;38:326A

dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion (Tuite et al) 1995;38:684

electrophysiological features of the central motor tract in SCA1, SCA2, and Machado-Joseph disease (Yokota et al) 1995;38:327A

interrupted repeat configuration in expanded alleles from Machado-Joseph disease patients (Matsumura) 1995;38:292A

molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease (Matilla et al) 1995;38:68

Spongiform encephalopathy; see Encephalopathy, spongiform

Spreading depression, neural; see Neural transmission

Staring spells

predictors of childhood staring spells (Abbasi and Scheller) 1995;38:534A

Status epilepticus

electrographical status epilepticus in neonates (Wical and Vickers) 1995;38:506A

experimental status epilepticus alters γ -aminobutyric acid type A receptor function in CA1 pyramidal neurons (Kapur and Coulter) 1995;38:893

¹⁸F-fluorodeoxyglucose-positron emission tomography in electrical status epilepticus of sleep (Gaillard et al) 1995;38:534A

status epilepticus and anti-epileptic medication levels in children (Maytal et al) 1995;38:513A

susceptibility to and stages of status epilepticus in immature and prepubescent rats (Mikati et al) 1995;38:513A in whom does status epilepticus occur: age-related differences in children (Shinnar et al) 1995;38:505A

Stem cells

therapeutic strategies for regenerating mature oligodendrocytes for nascent neural progenitor cells (Mehler et al) 1995;38:309A

Stress

neuroendocrine effects of chronic stress: abnormal hormonal stress response in an infant rat model (Gilles et al) 1995;38:526A

Striatum; see Corpus striatum

Stroke; see Cerebrovascular disorders entries

Stuttering

motor processes underlying incipient and chronic stuttering (Joullian et al) 1995;38:285A

Subarachnoid hemorrhage

familial subarachnoid hemorrhage: distinctive features and patterns of inheritance (Bromberg et al) 1995;38:929

in vivo microdialysis study of extracellular glutamate response to temperature variance in subarachnoid hemorrhage (Shuaib et al) 1995;38:350A

increased concentrations of procollagen propeptides in the cerebrospinal fluid after subarachnoid hemorrhage suggest a meningeal fibrotic reaction (Sajanti et al) 1995;38:319A

Submersion injury; see Drowning

Substance P

astrocyte factors regulate substance P in sensory neurons (Adler and Skoff) 1995;38:309A

Substantia nigra

bilateral fetal nigral transplantation into the postcommisural putamen in Parkinson's disease (Freeman et al) 1995;38:379

midbrain magnetic resonance hyperintensities, perivascular space enlargement, and substantia nigra vacuolar change (Pulicino et al) 1995;38:321A

Superoxide dismutase

superoxide dismutase over activity, excessive selenium, and low copper in acquired epileptic aphasia (the Landau-Kleffner syndrome) (Chez et al) 1995;38:544A

Supranuclear palsy, progressive

axial and limb apraxia in progressive supranuclear palsy (Lindholm et al) 1995;38:301A

diagnostic predictive values for clinical signs in autopsy-proved Parkinson's disease versus progressive supranuclear palsy and diffuse Lewy body disease (Goetz et al) 1995;38:331A

Supratentorial neoplasms

supratentorial neuroglial tumor factors and survival probability (Gilles et al) 1995;38:525A

Sural nerve

selective expansion and long-term culture of human Schwann cells from sural nerve biopsies (Van den Berg et al) 1995;38:674

Suramin

suramin in both a partial agonist and competitive inhibitor for the high-affinity nerve growth factor receptor (Gill and Windebank) 1995;38:308A

suramin-induced peripheral neuropathy—clinical and electrophysiological features (Chaudhry et al) 1995;38:337A

SV40 virus

DNA sequences of simian virus 40 large T antigen are present in the D283 medulloblastoma cell line (Pomeroy) 1995;38:538A

Sympatholytics

endogenous sympatholytic activity in the plasma of a patient with sympathotonic orthostatic hypotension (Shapiro et al) 1995;38:318A

Synapses

CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease (Chen et al) 1995;38:653
deficiency of brain synaptic dystrophin in human Duchenne muscular dystrophy (Kim et al) 1995;38:446 (Expedited publication)

T-cell leukemia; see Leukemia, T-cell

T-cell receptors; see Receptors, antigen, T-cell

T-lymphocytes

genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor- α by HLA-DR2⁺ T cells (Zipp et al) 1995;38:723
influx of nonactivated T lymphocytes into the cerebrospinal fluid during relapse of multiple sclerosis (Oksaranta et al) 1995;38:465
lipocortin-1 (annexin-1) suppresses activation of autoimmune T-cell lines in the Lewis rat (Gold et al) 1995;38:313A

T2-weighted high-intensity signals; see Magnetic resonance imaging

Tachykinins

preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients (Richfield et al) 1995;38:852

Tacrine

long-term treatment effects of tacrine in Alzheimer's disease patients (Pendlebury et al) 1995;38:291A

Tardive dyskinesia; see Dyskinesia, drug-induced

Tarui's disease; see Glycogen storage disease type VII

Tau proteins

evolutionary analysis of tau-encoding transcripts: implications for Alzheimer's disease (Nelson et al) 1995;38:972A

tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease (Arai et al) 1995;38:649

TAXOL

TAXOL-induced accumulation of microtubules in cultured human oligodendrocytes mimics a murine myelin mutant (Kim) 1995;38:309A

Technetium 99m hexamethylpropyleneamine SPECT; see Tomography, emission-computed, single-photon

Temporal lobe epilepsy; see Epilepsy, temporal lobe

Tenascin

desmin, vimentin, tenascin, and N-CAM expression in developmental myopathies (Roig and Gratacòs) 1995;38:554A

Teratoma

childhood atypical teratoid tumors: an expanding clinical spectrum in older children (Packer and Rorke) 1995;38:518A

Thalamus

acute hypoxic-ischemic basal ganglia/thalamic injury in the term newborn: computed tomography and clinical syndrome (Rodriguez et al) 1995;38:544A

cerebellar outflow lesions: a comparison of movement deficits resulting from lesions at the levels of the cerebellum and thalamus (Bastian and Thach) 1995;38:881

hemichorea/athetosis, anosognosia, and hypomania: a unique triad resulting from left thalamic infarction (Gottfried and Balish) 1995;38:285A

hippocampal and thalamic volumes in patients with complex partial epilepsy of left temporal origin (Harta et al) 1995;38:296A

Theiler's murine encephalomyelitis virus; see Encephalomyelitis virus, murine

Third nerve palsy; see Oculomotor nerve paralysis

Thrombomodulin

thrombomodulin expression in human brain endothelial cells (Hess et al) 1995;38:288A

Thrombophlebitis

treatment of pediatric sinovenous thrombosis with low molecular weight heparin (deVeber et al) 1995;38:532A

Thrombosis

recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome (Levine et al) 1995;38:119

Thymectomy

thymectomy in children with severe myasthenia gravis (Nizam et al) 1995;38:535A

Thyrotropin-releasing hormone; see Protirelin

Thyroxine

iodine, via thyroxine, causes a metamorphosis (a fundamental developmental change) in fetal brain at the beginning of the third trimester (DeLong) 1995;38:519A

Tic

tics/Tourette's syndrome and new treatment options (Awaad and Michon) 1995;38:549A

Tomography, emission-computed

benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography (Gilman et al) 1995;38:176

clinical correlates of [¹⁸F]fluorodopa uptake in five grafted parkinsonian patients (Remy et al) 1995;38:580

comparison of ictal—single-photon emission computed tomographic and positron emission tomographic scans for localization of seizure foci in children with intractable seizures (Bhatia et al) 1995;38:542A

cortical localization of the lexicon for written words by functional magnetic resonance imaging: correlation with lesion analysis and positron emission tomography (Small et al) 1995;38:284A

¹⁸F-fluorodeoxyglucose—positron emission tomography in electrical status epilepticus of sleep (Gaillard et al) 1995;38:534A

lissencephaly: fetal pattern of glucose metabolism on positron emission tomography? (Chugani et al) 1995;38:543A

magnetic resonance spectroscopy in childhood focal epilepsy: correlation with electroencephalography and ¹⁸F-fluorodeoxyglucose positron emission tomography (Frank et al) 1995;38:511A

neurological sequelae of cyanide intoxication—the patterns of clinical, magnetic resonance imaging, and posi

Tomography, emission-computed (continued)

- tron emission tomography findings (Rosenow et al) 1995; 38:825
- positron emission tomographic evaluation of glucose metabolism in childhood brain tumors (Smietana et al) 1995;38:551A
- positron emission tomography hypermetabolism in radiotherapy-induced brain injury (O'Neill et al) 1995; 38:344A
- positron emission tomography and temporal lobe epilepsy surgical outcome (Lancman et al) 1995;38:296A
- striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? (Kish et al) 1995;38:260
- striatal dopaminergic denervation in pallidopyramidal disease demonstrated by positron emission tomography (Remy et al) 1995;38:954
- which and how many infants with massive infantile spasms may benefit from positron emission tomographic scans? (Le et al) 1995;38:556A

Tomography, emission-computed, single-photon

- absolute versus semiquantitative technetium 99m hexamethylpropyleneamine oxime evaluation of regional cerebral blood flow pattern in Alzheimer's disease (Falcini et al) 1995;38:292A
- comparison of ictal-single-photon emission computed tomographic and positron emission tomographic scans for localization of seizure foci in children with intractable seizures (Bhatia et al) 1995;38:542A
- decreased single-photon emission computed tomographic [¹²³I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease (Seibyl et al) 1995;38:589
- effect of intraventricular blood on global cortical perfusion in acute intracerebral hemorrhage: a single-photon emission computed tomographic study (Mayer et al) 1995; 38:288A
- ictal brain single-photon emission computed tomography using technetium 99m hexamethylpropyleneamineoxime and technetium 99m bicisate in children with medically intractable partial seizure (Park et al) 1995; 38:511A
- significance of gadolinium-pentetic acid contrast enhancement and thallium-201 chloride uptake in pediatric brainstem gliomas (Maria et al) 1995;38:514A

Tomography, x-ray computed

- acute hypoxic-ischemic basal ganglia/thalamic injury in the term newborn: computed tomography and clinical syndrome (Rodriguez et al) 1995;38:544A
- computed tomographic criteria for early fatal outcome in acute stroke (Pulicino et al) 1995;38:319A
- emergency room brain computed tomography in children with seizures: which children are most likely to benefit? (Garvey et al) 1995;38:535A

Tongue

- botulinum toxin injection for tongue protrusion (Charles et al) 1995;38:299A

Tonic vibration reflex; see Reflex

Topiramate

- topiramate: a new anti-epileptic drug with success in children (Rosenfeld) 1995;38:555A

Tourette syndrome

- family study and segregation analysis of Tourette's syndrome: evidence for a major additive locus and multifactorial background (Singer et al) 1995;38:527A
- morphology of the corpus callosum in children with Tourette's syndrome and attention-deficit hyperactivity disorder (Singer et al) 1995;38:509A

neuropsychological status of children with Tourette's syndrome with and without attention-deficit hyperactivity disorder (Schuerholz et al) 1995;38:515A

speed of coordination in children with Tourette's syndrome (TS), attention-deficit hyperactivity disorder (ADHD), and TS plus ADHD (Denckla et al) 1995; 38:515A

tics/Tourette's syndrome and new treatment options (Awaad and Michon) 1995;38:549A

Tranquilizing agents, major

diurnal variation in acute neuroleptic-induced dystonia (Mazurek and Rosebush) 1995;38:299A

Transcranial Doppler ultrasonography; see Ultrasonography

Transcranial magnetic stimulation; see Magnetic stimulation

Transcription

- cytokine-activated transcription proteins in muscle: implications in inflammatory myopathies (Isabel et al) 1995; 38:305A
- mechanism of different patterns of gene transcription between seizures and learning (Feuchtwang and Mack) 1995;38:552A
- novel intronic retention in M-subunit transcripts of three Ashkenazi Jews with Tarui's disease (Vasconcelos et al) 1995;38:307A

Transfection

recombinant adeno-associated virus-mediated gene transfer into the central nervous system (Lo et al) 1995; 38:546A

Transforming growth factor beta

- central nervous system microvasculature responds to injury and transforming growth factor-β1 with differential immediate early gene expression (Freij et al) 1995; 38:348A
- suppression of TNF-α by antisense oligodeoxynucleotide enhanced TGF-β1 mRNA expression, correlating with enlarged infarct volume following cerebral ischemia in the rat (Zhai et al) 1995;38:973A

Transient cerebral ischemia; see Cerebral ischemia, transient

Tremor

- absence of glutamic acid decarboxylase autoimmunity in symptomatic palatal tremor (Davenport et al) 1995;38: 274 (Letter)
- ondansetron for disabling cerebellar tremor (Rice et al) 1995;38:973A
- treatment of tremor with nupradilol (Yoshii et al) 1995; 38:331A

Trinucleotide repeats

- correlation between the CAG triplet repeat number and phenotypic variability of spinocerebellar ataxia type 1 in the Yakut people of Siberia (Goldfarb et al) 1995; 38:326A
- CTG repeat expansion in leukocyte but not in muscle DNA correlates with muscle weakness in myotonic dystrophy (Thornton et al) 1995;38:334A
- dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion (Tuite et al) 1995;38:684
- molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease (Matilla et al) 1995; 38:68
- relative stability of a minimal CTG repeat expansion in a large kindred with myotonic dystrophy (Simmons and Thornton) 1995;38:303A

trkA; see Proto-oncogenes

Tuberous sclerosis

- early diagnosis of giant-cell astrocytoma in patients with tuberous sclerosis complex (Torres et al) 1995;38:528A
- molecular pathology of tuberous sclerosis complex (Kandt et al) 1995;38:537A
- tuberous sclerosis complex: prognosis of electroencephalography, neuroimaging, and epilepsy (Foley et al) 1995;38:541A

Tuft's quantitative neuromuscular examination

- Tuft's quantitative neuromuscular examination: high correlation with the sickness impact profile in measuring progression of amyotrophic lateral sclerosis (McGuire et al) 1995;38:336A

Tumor necrosis factor

- circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging (Harrung et al) 1995;38:186
- effects of tumor necrosis factor- α and platelet-activating factor, human immunodeficiency virus-type 1-induced neurotoxins, on pro-apoptosis gene products in primary human neuronal cultures (Perry et al) 1995;38:551A
- genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor- α by HLA-DR2⁺ T cells (Zipp et al) 1995;38:723
- suppression of TNF- α by antisense oligodeoxynucleotide enhanced TGF- β_1 mRNA expression, correlating with enlarged infarct volume following cerebral ischemia in the rat (Zhai et al) 1995;38:973A
- tumor necrosis factor: immunogenetics and disease (Hauser) 1995;38:702 (Editorial)

Turner's syndrome

- neurodevelopmental effects of X monosomy: a volumetric imaging study (Reiss et al) 1995;38:731

Tyrosine

- protein tyrosine nitration in the developing nervous system: a marker of brain nitric oxide production (Trifiletti et al) 1995;38:523A

Ultrasonography

- detection of flow velocity and flow direction in the posterior communicating artery by transcranial color-coded duplex sonography (Popescu et al) 1995;38:321A
- occurrence of patent foramen ovale in acute stroke and transient ischemic attacks using transcranial Doppler ultrasonography (Yeung et al) 1995;38:320A
- source of transcranial Doppler signals during cerebral and coronary angiography and its significance (Khan et al) 1995;38:288A

Urine

- urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis (Whitaker et al) 1995;38:625

Urokinase

- matrix metalloproteinases and urokinase increase in stroke in rat (Rosenberg et al) 1995;38:322A
- treatment of dural sinus thrombosis using selective catheterization and urokinase (Horowitz et al) 1995;38:58

Vaccination

- vaccination is effective in protecting against Lyme neuroborreliosis in the nonhuman primate model (Pachner et al) 1995;38:283A

Valproic acid

- reversible dementia and apparent brain atrophy during valproate therapy (Papazian et al) 1995;38:687
- safety of intravenous valproate (Devinsky et al) 1995;38:670

- treatment and clinical characteristics of valproate-induced hepatotoxicity (Bohan et al) 1995;38:505A

Varicella

- varicella with delayed cerebral infarction: a series of six cases (Sutton et al) 1995;38:548A

Vascular dementia; see Dementia, vascular

Venoms

- neuromuscular effects of Papuan taipan snake (Connolly et al) 1995;38:916

Vertebral artery

- carotid and vertebral artery angioplasty and stenting (Yadav et al) 1995;38:283A

Vimentin

- desmin, vimentin, tenascin, and N-CAM expression in developmental myopathies (Roig and Gratacòs) 1995;38:554A

Vincristine

- insulin-like growth factor-I prevents the peripheral neuropathy induced by paclitaxel, cisplatin, and vincristine (Contreras et al) 1995;38:315A
- salvage chemotherapy for recurrent malignant oligodendrogliomas (Peterson et al) 1995;38:344A

Vitamin E deficiency

- isolation and chromosome localization of the gene for human α -tocopherol transfer protein and identification of mutations in patients with familial vitamin E deficiency (Hentati et al) 1995;38:282A

Volumetric imaging; see Magnetic resonance imaging

White matter

- evidence for a sequential involvement of subcortical frontal white matter lesions in progressive vascular encephalopathy (Hennerici et al) 1995;38:286A
- ovarioleukodystrophy: a new white matter syndrome (Schiffmann et al) 1995;38:547A

Whooping cough

- pertussis and neurological complications: a fifteen-year Sicilian experience (Incorpora et al) 1995;38:524A

Wrist

- recovery of hypermetria after a cerebellar stroke occurs as a multistage process (Manto et al) 1995;38:437

Writer's cramp

- movement-related cortical potentials in writer's cramp (Deuschl et al) 1995;38:862
- tonic vibration reflex and muscle afferent block in writer's cramp (Kaji et al) 1995;38:155
- writer's cramp: a disorder of motor subroutine? (Kaji et al) 1995;38:837 (Editorial)

Written word recognition

- cortical localization of the lexicon for written words by functional magnetic resonance imaging: correlation with lesion analysis and positron emission tomography (Small et al) 1995;38:284A

X chromosome

- neurodevelopmental effects of X monosomy: a volumetric imaging study (Reiss et al) 1995;38:731

Xanthomatosis

- novel mutation in the 27-hydroxylase gene of a Pakistani family with autosomal-recessive cerebrotendinous xanthomatosis (Ahmed et al) 1995;38:293A

Zimmerman, Harry M.

- Harry M. Zimmerman, 1901-1995 (Rowland) 1995;38:834 (Obituary)

Zoster; see Herpes zoster